#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder
#Text=The response to drugs of abuse is affected by expectation, which is modulated in part by dopamine (DA), which encodes for a reward prediction error.
1-1	0-11	Expectation	_	
1-2	12-19	effects	_	
1-3	20-22	on	_	
1-4	23-28	brain	_	
1-5	29-37	dopamine	_	
1-6	38-47	responses	_	
1-7	48-50	to	_	
1-8	51-66	methylphenidate	_	
1-9	67-69	in	_	
1-10	70-77	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-11	78-81	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-12	82-90	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-13	91-94	The	_	
1-14	95-103	response	_	
1-15	104-106	to	_	
1-16	107-112	drugs	_	
1-17	113-115	of	_	
1-18	116-121	abuse	_	
1-19	122-124	is	_	
1-20	125-133	affected	_	
1-21	134-136	by	_	
1-22	137-148	expectation	_	
1-23	148-149	,	_	
1-24	150-155	which	_	
1-25	156-158	is	_	
1-26	159-168	modulated	_	
1-27	169-171	in	_	
1-28	172-176	part	_	
1-29	177-179	by	_	
1-30	180-188	dopamine	_	
1-31	189-190	(	_	
1-32	190-192	DA	_	
1-33	192-193	)	_	
1-34	193-194	,	_	
1-35	195-200	which	_	
1-36	201-208	encodes	_	
1-37	209-212	for	_	
1-38	213-214	a	_	
1-39	215-221	reward	_	
1-40	222-232	prediction	_	
1-41	233-238	error	_	
1-42	238-239	.	_	

#Text=Here we assessed the effect of expectation on methylphenidate (MP)-induced striatal DA changes in 23 participants with an active cocaine use disorder (CUD) and 23 healthy controls (HC) using [11C]raclopride and PET both after placebo (PL) and after MP (0.5 mg/kg, i.v.).
2-1	240-244	Here	_	
2-2	245-247	we	_	
2-3	248-256	assessed	_	
2-4	257-260	the	_	
2-5	261-267	effect	_	
2-6	268-270	of	_	
2-7	271-282	expectation	_	
2-8	283-285	on	_	
2-9	286-301	methylphenidate	_	
2-10	302-303	(	_	
2-11	303-305	MP	_	
2-12	305-306	)	_	
2-13	306-307	-	_	
2-14	307-314	induced	_	
2-15	315-323	striatal	_	
2-16	324-326	DA	_	
2-17	327-334	changes	_	
2-18	335-337	in	_	
2-19	338-340	23	_	
2-20	341-353	participants	_	
2-21	354-358	with	_	
2-22	359-361	an	_	
2-23	362-368	active	_	
2-24	369-376	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
2-25	377-380	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
2-26	381-389	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
2-27	390-391	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
2-28	391-394	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
2-29	394-395	)	_	
2-30	396-399	and	_	
2-31	400-402	23	_	
2-32	403-410	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-33	411-419	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-34	420-421	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-35	421-423	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-36	423-424	)	_	
2-37	425-430	using	_	
2-38	431-432	[	_	
2-39	432-435	11C	_	
2-40	435-436	]	_	
2-41	436-446	raclopride	_	
2-42	447-450	and	_	
2-43	451-454	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
2-44	455-459	both	_	
2-45	460-465	after	_	
2-46	466-473	placebo	_	
2-47	474-475	(	_	
2-48	475-477	PL	_	
2-49	477-478	)	_	
2-50	479-482	and	_	
2-51	483-488	after	_	
2-52	489-491	MP	_	
2-53	492-493	(	_	
2-54	493-496	0.5	_	
2-55	497-499	mg	_	
2-56	499-500	/	_	
2-57	500-502	kg	_	
2-58	502-503	,	_	
2-59	504-507	i.v	_	
2-60	507-508	.	_	
2-61	508-509	)	_	
2-62	509-510	.	_	

#Text=Brain dopamine D2 and D3 receptor availability (D2R: non-displaceable binding potential (BPND)) was measured under four conditions in randomized order: (1) expecting PL/receiving PL, (2) expecting PL/receiving MP, (3) expecting MP/receiving PL, and (4) expecting MP/receiving MP.
3-1	511-516	Brain	_	
3-2	517-525	dopamine	_	
3-3	526-528	D2	_	
3-4	529-532	and	_	
3-5	533-535	D3	_	
3-6	536-544	receptor	_	
3-7	545-557	availability	_	
3-8	558-559	(	_	
3-9	559-562	D2R	_	
3-10	562-563	:	_	
3-11	564-580	non-displaceable	_	
3-12	581-588	binding	_	
3-13	589-598	potential	_	
3-14	599-600	(	_	
3-15	600-604	BPND	_	
3-16	604-605	)	_	
3-17	605-606	)	_	
3-18	607-610	was	_	
3-19	611-619	measured	_	
3-20	620-625	under	_	
3-21	626-630	four	_	
3-22	631-641	conditions	_	
3-23	642-644	in	_	
3-24	645-655	randomized	_	
3-25	656-661	order	_	
3-26	661-662	:	_	
3-27	663-664	(	_	
3-28	664-665	1	_	
3-29	665-666	)	_	
3-30	667-676	expecting	_	
3-31	677-679	PL	_	
3-32	679-680	/	_	
3-33	680-689	receiving	_	
3-34	690-692	PL	_	
3-35	692-693	,	_	
3-36	694-695	(	_	
3-37	695-696	2	_	
3-38	696-697	)	_	
3-39	698-707	expecting	_	
3-40	708-710	PL	_	
3-41	710-711	/	_	
3-42	711-720	receiving	_	
3-43	721-723	MP	_	
3-44	723-724	,	_	
3-45	725-726	(	_	
3-46	726-727	3	_	
3-47	727-728	)	_	
3-48	729-738	expecting	_	
3-49	739-741	MP	_	
3-50	741-742	/	_	
3-51	742-751	receiving	_	
3-52	752-754	PL	_	
3-53	754-755	,	_	
3-54	756-759	and	_	
3-55	760-761	(	_	
3-56	761-762	4	_	
3-57	762-763	)	_	
3-58	764-773	expecting	_	
3-59	774-776	MP	_	
3-60	776-777	/	_	
3-61	777-786	receiving	_	
3-62	787-789	MP	_	
3-63	789-790	.	_	

#Text=Expecting MP increased pulse rate compared to expecting PL.
4-1	791-800	Expecting	_	
4-2	801-803	MP	_	
4-3	804-813	increased	_	
4-4	814-819	pulse	_	
4-5	820-824	rate	_	
4-6	825-833	compared	_	
4-7	834-836	to	_	
4-8	837-846	expecting	_	
4-9	847-849	PL	_	
4-10	849-850	.	_	

#Text=Receiving MP decreased D2R in striatum compared to PL, indicating MP-induced striatal DA release, and this effect was significantly blunted in CUD versus HC consistent with prior findings of decreased striatal dopamine responses both in active and detoxified CUD.
5-1	851-860	Receiving	_	
5-2	861-863	MP	_	
5-3	864-873	decreased	_	
5-4	874-877	D2R	_	
5-5	878-880	in	_	
5-6	881-889	striatum	_	
5-7	890-898	compared	_	
5-8	899-901	to	_	
5-9	902-904	PL	_	
5-10	904-905	,	_	
5-11	906-916	indicating	_	
5-12	917-927	MP-induced	_	
5-13	928-936	striatal	_	
5-14	937-939	DA	_	
5-15	940-947	release	_	
5-16	947-948	,	_	
5-17	949-952	and	_	
5-18	953-957	this	_	
5-19	958-964	effect	_	
5-20	965-968	was	_	
5-21	969-982	significantly	_	
5-22	983-990	blunted	_	
5-23	991-993	in	_	
5-24	994-997	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
5-25	998-1004	versus	_	
5-26	1005-1007	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-27	1008-1018	consistent	_	
5-28	1019-1023	with	_	
5-29	1024-1029	prior	_	
5-30	1030-1038	findings	_	
5-31	1039-1041	of	_	
5-32	1042-1051	decreased	_	
5-33	1052-1060	striatal	_	
5-34	1061-1069	dopamine	_	
5-35	1070-1079	responses	_	
5-36	1080-1084	both	_	
5-37	1085-1087	in	_	
5-38	1088-1094	active	_	
5-39	1095-1098	and	_	
5-40	1099-1109	detoxified	_	
5-41	1110-1113	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
5-42	1113-1114	.	_	

#Text=There was a group × challenge × expectation effect in caudate and midbrain, with expectation of MP increasing MP-induced DA release in HC but not in CUD, and expectation of PL showing a trend to increase MP-induced DA release in CUD but not in HC.
6-1	1115-1120	There	_	
6-2	1121-1124	was	_	
6-3	1125-1126	a	_	
6-4	1127-1132	group	_	
6-5	1133-1134	×	_	
6-6	1135-1144	challenge	_	
6-7	1145-1146	×	_	
6-8	1147-1158	expectation	_	
6-9	1159-1165	effect	_	
6-10	1166-1168	in	_	
6-11	1169-1176	caudate	_	
6-12	1177-1180	and	_	
6-13	1181-1189	midbrain	_	
6-14	1189-1190	,	_	
6-15	1191-1195	with	_	
6-16	1196-1207	expectation	_	
6-17	1208-1210	of	_	
6-18	1211-1213	MP	_	
6-19	1214-1224	increasing	_	
6-20	1225-1235	MP-induced	_	
6-21	1236-1238	DA	_	
6-22	1239-1246	release	_	
6-23	1247-1249	in	_	
6-24	1250-1252	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-25	1253-1256	but	_	
6-26	1257-1260	not	_	
6-27	1261-1263	in	_	
6-28	1264-1267	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
6-29	1267-1268	,	_	
6-30	1269-1272	and	_	
6-31	1273-1284	expectation	_	
6-32	1285-1287	of	_	
6-33	1288-1290	PL	_	
6-34	1291-1298	showing	_	
6-35	1299-1300	a	_	
6-36	1301-1306	trend	_	
6-37	1307-1309	to	_	
6-38	1310-1318	increase	_	
6-39	1319-1329	MP-induced	_	
6-40	1330-1332	DA	_	
6-41	1333-1340	release	_	
6-42	1341-1343	in	_	
6-43	1344-1347	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
6-44	1348-1351	but	_	
6-45	1352-1355	not	_	
6-46	1356-1358	in	_	
6-47	1359-1361	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-48	1361-1362	.	_	

#Text=These results are consistent with the role of DA in reward prediction error in the human brain: decreasing DA signaling when rewards are less than expected (blunted DA increases to MP in CUD) and increasing them when greater than expected (for PL in CUD reflecting conditioned responses to injection).
7-1	1363-1368	These	_	
7-2	1369-1376	results	_	
7-3	1377-1380	are	_	
7-4	1381-1391	consistent	_	
7-5	1392-1396	with	_	
7-6	1397-1400	the	_	
7-7	1401-1405	role	_	
7-8	1406-1408	of	_	
7-9	1409-1411	DA	_	
7-10	1412-1414	in	_	
7-11	1415-1421	reward	_	
7-12	1422-1432	prediction	_	
7-13	1433-1438	error	_	
7-14	1439-1441	in	_	
7-15	1442-1445	the	_	
7-16	1446-1451	human	_	
7-17	1452-1457	brain	_	
7-18	1457-1458	:	_	
7-19	1459-1469	decreasing	_	
7-20	1470-1472	DA	_	
7-21	1473-1482	signaling	_	
7-22	1483-1487	when	_	
7-23	1488-1495	rewards	_	
7-24	1496-1499	are	_	
7-25	1500-1504	less	_	
7-26	1505-1509	than	_	
7-27	1510-1518	expected	_	
7-28	1519-1520	(	_	
7-29	1520-1527	blunted	_	
7-30	1528-1530	DA	_	
7-31	1531-1540	increases	_	
7-32	1541-1543	to	_	
7-33	1544-1546	MP	_	
7-34	1547-1549	in	_	
7-35	1550-1553	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
7-36	1553-1554	)	_	
7-37	1555-1558	and	_	
7-38	1559-1569	increasing	_	
7-39	1570-1574	them	_	
7-40	1575-1579	when	_	
7-41	1580-1587	greater	_	
7-42	1588-1592	than	_	
7-43	1593-1601	expected	_	
7-44	1602-1603	(	_	
7-45	1603-1606	for	_	
7-46	1607-1609	PL	_	
7-47	1610-1612	in	_	
7-48	1613-1616	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
7-49	1617-1627	reflecting	_	
7-50	1628-1639	conditioned	_	
7-51	1640-1649	responses	_	
7-52	1650-1652	to	_	
7-53	1653-1662	injection	_	
7-54	1662-1663	)	_	
7-55	1663-1664	.	_	

#Text=Our findings also document disruption of the expectation of drug effects in dopamine signaling in participants with CUD compared to non-addicted individuals.
8-1	1665-1668	Our	_	
8-2	1669-1677	findings	_	
8-3	1678-1682	also	_	
8-4	1683-1691	document	_	
8-5	1692-1702	disruption	_	
8-6	1703-1705	of	_	
8-7	1706-1709	the	_	
8-8	1710-1721	expectation	_	
8-9	1722-1724	of	_	
8-10	1725-1729	drug	_	
8-11	1730-1737	effects	_	
8-12	1738-1740	in	_	
8-13	1741-1749	dopamine	_	
8-14	1750-1759	signaling	_	
8-15	1760-1762	in	_	
8-16	1763-1775	participants	_	
8-17	1776-1780	with	_	
8-18	1781-1784	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
8-19	1785-1793	compared	_	
8-20	1794-1796	to	_	
8-21	1797-1809	non-addicted	_	
8-22	1810-1821	individuals	_	
8-23	1821-1822	.	_	

#Text=Introduction
#Text=There is growing evidence that the context under which a drug is administered can affect the behavioral, physiological, and the neurochemical response to the drug.
9-1	1823-1835	Introduction	_	
9-2	1836-1841	There	_	
9-3	1842-1844	is	_	
9-4	1845-1852	growing	_	
9-5	1853-1861	evidence	_	
9-6	1862-1866	that	_	
9-7	1867-1870	the	_	
9-8	1871-1878	context	_	
9-9	1879-1884	under	_	
9-10	1885-1890	which	_	
9-11	1891-1892	a	_	
9-12	1893-1897	drug	_	
9-13	1898-1900	is	_	
9-14	1901-1913	administered	_	
9-15	1914-1917	can	_	
9-16	1918-1924	affect	_	
9-17	1925-1928	the	_	
9-18	1929-1939	behavioral	_	
9-19	1939-1940	,	_	
9-20	1941-1954	physiological	_	
9-21	1954-1955	,	_	
9-22	1956-1959	and	_	
9-23	1960-1963	the	_	
9-24	1964-1977	neurochemical	_	
9-25	1978-1986	response	_	
9-26	1987-1989	to	_	
9-27	1990-1993	the	_	
9-28	1994-1998	drug	_	
9-29	1998-1999	.	_	

#Text=For example, the response to drugs of abuse is affected by expectation, which in turn is sensitive to prior drug experiences.
10-1	2000-2003	For	_	
10-2	2004-2011	example	_	
10-3	2011-2012	,	_	
10-4	2013-2016	the	_	
10-5	2017-2025	response	_	
10-6	2026-2028	to	_	
10-7	2029-2034	drugs	_	
10-8	2035-2037	of	_	
10-9	2038-2043	abuse	_	
10-10	2044-2046	is	_	
10-11	2047-2055	affected	_	
10-12	2056-2058	by	_	
10-13	2059-2070	expectation	_	
10-14	2070-2071	,	_	
10-15	2072-2077	which	_	
10-16	2078-2080	in	_	
10-17	2081-2085	turn	_	
10-18	2086-2088	is	_	
10-19	2089-2098	sensitive	_	
10-20	2099-2101	to	_	
10-21	2102-2107	prior	_	
10-22	2108-2112	drug	_	
10-23	2113-2124	experiences	_	
10-24	2124-2125	.	_	

#Text=This is modulated in part by dopamine (DA), which is a neurotransmitter involved with reward and expectation of reward.
11-1	2126-2130	This	_	
11-2	2131-2133	is	_	
11-3	2134-2143	modulated	_	
11-4	2144-2146	in	_	
11-5	2147-2151	part	_	
11-6	2152-2154	by	_	
11-7	2155-2163	dopamine	_	
11-8	2164-2165	(	_	
11-9	2165-2167	DA	_	
11-10	2167-2168	)	_	
11-11	2168-2169	,	_	
11-12	2170-2175	which	_	
11-13	2176-2178	is	_	
11-14	2179-2180	a	_	
11-15	2181-2197	neurotransmitter	_	
11-16	2198-2206	involved	_	
11-17	2207-2211	with	_	
11-18	2212-2218	reward	_	
11-19	2219-2222	and	_	
11-20	2223-2234	expectation	_	
11-21	2235-2237	of	_	
11-22	2238-2244	reward	_	
11-23	2244-2245	.	_	

#Text=Animal studies have shown that expectation affects the responses to drugs of abuse.
12-1	2246-2252	Animal	_	
12-2	2253-2260	studies	_	
12-3	2261-2265	have	_	
12-4	2266-2271	shown	_	
12-5	2272-2276	that	_	
12-6	2277-2288	expectation	_	
12-7	2289-2296	affects	_	
12-8	2297-2300	the	_	
12-9	2301-2310	responses	_	
12-10	2311-2313	to	_	
12-11	2314-2319	drugs	_	
12-12	2320-2322	of	_	
12-13	2323-2328	abuse	_	
12-14	2328-2329	.	_	

#Text=For example, cocaine-induced increases in DA and its behavioral effects are greater when animals receive the drug in an environment where they expect it than when they do not or when they self-administer it than when it is administered by the investigator.
13-1	2330-2333	For	_	
13-2	2334-2341	example	_	
13-3	2341-2342	,	_	
13-4	2343-2358	cocaine-induced	_	
13-5	2359-2368	increases	_	
13-6	2369-2371	in	_	
13-7	2372-2374	DA	_	
13-8	2375-2378	and	_	
13-9	2379-2382	its	_	
13-10	2383-2393	behavioral	_	
13-11	2394-2401	effects	_	
13-12	2402-2405	are	_	
13-13	2406-2413	greater	_	
13-14	2414-2418	when	_	
13-15	2419-2426	animals	_	
13-16	2427-2434	receive	_	
13-17	2435-2438	the	_	
13-18	2439-2443	drug	_	
13-19	2444-2446	in	_	
13-20	2447-2449	an	_	
13-21	2450-2461	environment	_	
13-22	2462-2467	where	_	
13-23	2468-2472	they	_	
13-24	2473-2479	expect	_	
13-25	2480-2482	it	_	
13-26	2483-2487	than	_	
13-27	2488-2492	when	_	
13-28	2493-2497	they	_	
13-29	2498-2500	do	_	
13-30	2501-2504	not	_	
13-31	2505-2507	or	_	
13-32	2508-2512	when	_	
13-33	2513-2517	they	_	
13-34	2518-2533	self-administer	_	
13-35	2534-2536	it	_	
13-36	2537-2541	than	_	
13-37	2542-2546	when	_	
13-38	2547-2549	it	_	
13-39	2550-2552	is	_	
13-40	2553-2565	administered	_	
13-41	2566-2568	by	_	
13-42	2569-2572	the	_	
13-43	2573-2585	investigator	_	
13-44	2585-2586	.	_	

#Text=Similarly, in human cocaine abusers the behavioral and regional brain metabolic responses to stimulants have been shown to be stronger when stimulants are expected versus when placebo (PL) is expected.
14-1	2587-2596	Similarly	_	
14-2	2596-2597	,	_	
14-3	2598-2600	in	_	
14-4	2601-2606	human	_	
14-5	2607-2614	cocaine	_	
14-6	2615-2622	abusers	_	
14-7	2623-2626	the	_	
14-8	2627-2637	behavioral	_	
14-9	2638-2641	and	_	
14-10	2642-2650	regional	_	
14-11	2651-2656	brain	_	
14-12	2657-2666	metabolic	_	
14-13	2667-2676	responses	_	
14-14	2677-2679	to	_	
14-15	2680-2690	stimulants	_	
14-16	2691-2695	have	_	
14-17	2696-2700	been	_	
14-18	2701-2706	shown	_	
14-19	2707-2709	to	_	
14-20	2710-2712	be	_	
14-21	2713-2721	stronger	_	
14-22	2722-2726	when	_	
14-23	2727-2737	stimulants	_	
14-24	2738-2741	are	_	
14-25	2742-2750	expected	_	
14-26	2751-2757	versus	_	
14-27	2758-2762	when	_	
14-28	2763-2770	placebo	_	
14-29	2771-2772	(	_	
14-30	2772-2774	PL	_	
14-31	2774-2775	)	_	
14-32	2776-2778	is	_	
14-33	2779-2787	expected	_	
14-34	2787-2788	.	_	

#Text=The dopaminergic system has also been shown to be involved in the PL-induced expectation of therapeutic benefit including analgesia.
15-1	2789-2792	The	_	
15-2	2793-2805	dopaminergic	_	
15-3	2806-2812	system	_	
15-4	2813-2816	has	_	
15-5	2817-2821	also	_	
15-6	2822-2826	been	_	
15-7	2827-2832	shown	_	
15-8	2833-2835	to	_	
15-9	2836-2838	be	_	
15-10	2839-2847	involved	_	
15-11	2848-2850	in	_	
15-12	2851-2854	the	_	
15-13	2855-2865	PL-induced	_	
15-14	2866-2877	expectation	_	
15-15	2878-2880	of	_	
15-16	2881-2892	therapeutic	_	
15-17	2893-2900	benefit	_	
15-18	2901-2910	including	_	
15-19	2911-2920	analgesia	_	
15-20	2920-2921	.	_	

#Text=Similarly, the involvement of the dopaminergic response has been documented for PL responses in Parkinson’s disease: both to medications and to repetitive transcranial magnetic stimulation.
16-1	2922-2931	Similarly	_	
16-2	2931-2932	,	_	
16-3	2933-2936	the	_	
16-4	2937-2948	involvement	_	
16-5	2949-2951	of	_	
16-6	2952-2955	the	_	
16-7	2956-2968	dopaminergic	_	
16-8	2969-2977	response	_	
16-9	2978-2981	has	_	
16-10	2982-2986	been	_	
16-11	2987-2997	documented	_	
16-12	2998-3001	for	_	
16-13	3002-3004	PL	_	
16-14	3005-3014	responses	_	
16-15	3015-3017	in	_	
16-16	3018-3027	Parkinson	_	
16-17	3027-3028	’	_	
16-18	3028-3029	s	_	
16-19	3030-3037	disease	_	
16-20	3037-3038	:	_	
16-21	3039-3043	both	_	
16-22	3044-3046	to	_	
16-23	3047-3058	medications	_	
16-24	3059-3062	and	_	
16-25	3063-3065	to	_	
16-26	3066-3076	repetitive	_	
16-27	3077-3089	transcranial	_	
16-28	3090-3098	magnetic	_	
16-29	3099-3110	stimulation	_	
16-30	3110-3111	.	_	

#Text=That is, patients who responded to PL (reporting clinical improvement) had greater DA release in the striatum than those who did not.
17-1	3112-3116	That	_	
17-2	3117-3119	is	_	
17-3	3119-3120	,	_	
17-4	3121-3129	patients	_	
17-5	3130-3133	who	_	
17-6	3134-3143	responded	_	
17-7	3144-3146	to	_	
17-8	3147-3149	PL	_	
17-9	3150-3151	(	_	
17-10	3151-3160	reporting	_	
17-11	3161-3169	clinical	_	
17-12	3170-3181	improvement	_	
17-13	3181-3182	)	_	
17-14	3183-3186	had	_	
17-15	3187-3194	greater	_	
17-16	3195-3197	DA	_	
17-17	3198-3205	release	_	
17-18	3206-3208	in	_	
17-19	3209-3212	the	_	
17-20	3213-3221	striatum	_	
17-21	3222-3226	than	_	
17-22	3227-3232	those	_	
17-23	3233-3236	who	_	
17-24	3237-3240	did	_	
17-25	3241-3244	not	_	
17-26	3244-3245	.	_	

#Text=We have studied the effects of expectation on the effects of the stimulant drug methylphenidate (MP) on regional brain glucose metabolism and on behavior.
18-1	3246-3248	We	_	
18-2	3249-3253	have	_	
18-3	3254-3261	studied	_	
18-4	3262-3265	the	_	
18-5	3266-3273	effects	_	
18-6	3274-3276	of	_	
18-7	3277-3288	expectation	_	
18-8	3289-3291	on	_	
18-9	3292-3295	the	_	
18-10	3296-3303	effects	_	
18-11	3304-3306	of	_	
18-12	3307-3310	the	_	
18-13	3311-3320	stimulant	_	
18-14	3321-3325	drug	_	
18-15	3326-3341	methylphenidate	_	
18-16	3342-3343	(	_	
18-17	3343-3345	MP	_	
18-18	3345-3346	)	_	
18-19	3347-3349	on	_	
18-20	3350-3358	regional	_	
18-21	3359-3364	brain	_	
18-22	3365-3372	glucose	_	
18-23	3373-3383	metabolism	_	
18-24	3384-3387	and	_	
18-25	3388-3390	on	_	
18-26	3391-3399	behavior	_	
18-27	3399-3400	.	_	

#Text=MP, like cocaine, increases DA by blocking DA transporters (DATs); hence, its effects are a function of the level of DAT blockade and the rate of DA release (reflects DA cell activity).
19-1	3401-3403	MP	_	
19-2	3403-3404	,	_	
19-3	3405-3409	like	_	
19-4	3410-3417	cocaine	_	
19-5	3417-3418	,	_	
19-6	3419-3428	increases	_	
19-7	3429-3431	DA	_	
19-8	3432-3434	by	_	
19-9	3435-3443	blocking	_	
19-10	3444-3446	DA	_	
19-11	3447-3459	transporters	_	
19-12	3460-3461	(	_	
19-13	3461-3465	DATs	_	
19-14	3465-3466	)	_	
19-15	3466-3467	;	_	
19-16	3468-3473	hence	_	
19-17	3473-3474	,	_	
19-18	3475-3478	its	_	
19-19	3479-3486	effects	_	
19-20	3487-3490	are	_	
19-21	3491-3492	a	_	
19-22	3493-3501	function	_	
19-23	3502-3504	of	_	
19-24	3505-3508	the	_	
19-25	3509-3514	level	_	
19-26	3515-3517	of	_	
19-27	3518-3521	DAT	_	
19-28	3522-3530	blockade	_	
19-29	3531-3534	and	_	
19-30	3535-3538	the	_	
19-31	3539-3543	rate	_	
19-32	3544-3546	of	_	
19-33	3547-3549	DA	_	
19-34	3550-3557	release	_	
19-35	3558-3559	(	_	
19-36	3559-3567	reflects	_	
19-37	3568-3570	DA	_	
19-38	3571-3575	cell	_	
19-39	3576-3584	activity	_	
19-40	3584-3585	)	_	
19-41	3585-3586	.	_	

#Text=In healthy volunteers, we showed that the expectation of receiving MP while receiving PL significantly activated brain glucose metabolism in the nucleus accumbens (NAc) and ventral cingulate cortex (Brodmann area 25), and effects were strongest in subjects who, because of experimental randomization, had not experienced MP before.
20-1	3587-3589	In	_	
20-2	3590-3597	healthy	_	
20-3	3598-3608	volunteers	_	
20-4	3608-3609	,	_	
20-5	3610-3612	we	_	
20-6	3613-3619	showed	_	
20-7	3620-3624	that	_	
20-8	3625-3628	the	_	
20-9	3629-3640	expectation	_	
20-10	3641-3643	of	_	
20-11	3644-3653	receiving	_	
20-12	3654-3656	MP	_	
20-13	3657-3662	while	_	
20-14	3663-3672	receiving	_	
20-15	3673-3675	PL	_	
20-16	3676-3689	significantly	_	
20-17	3690-3699	activated	_	
20-18	3700-3705	brain	_	
20-19	3706-3713	glucose	_	
20-20	3714-3724	metabolism	_	
20-21	3725-3727	in	_	
20-22	3728-3731	the	_	
20-23	3732-3739	nucleus	_	
20-24	3740-3749	accumbens	_	
20-25	3750-3751	(	_	
20-26	3751-3754	NAc	_	
20-27	3754-3755	)	_	
20-28	3756-3759	and	_	
20-29	3760-3767	ventral	_	
20-30	3768-3777	cingulate	_	
20-31	3778-3784	cortex	_	
20-32	3785-3786	(	_	
20-33	3786-3794	Brodmann	_	
20-34	3795-3799	area	_	
20-35	3800-3802	25	_	
20-36	3802-3803	)	_	
20-37	3803-3804	,	_	
20-38	3805-3808	and	_	
20-39	3809-3816	effects	_	
20-40	3817-3821	were	_	
20-41	3822-3831	strongest	_	
20-42	3832-3834	in	_	
20-43	3835-3843	subjects	_	
20-44	3844-3847	who	_	
20-45	3847-3848	,	_	
20-46	3849-3856	because	_	
20-47	3857-3859	of	_	
20-48	3860-3872	experimental	_	
20-49	3873-3886	randomization	_	
20-50	3886-3887	,	_	
20-51	3888-3891	had	_	
20-52	3892-3895	not	_	
20-53	3896-3907	experienced	_	
20-54	3908-3910	MP	_	
20-55	3911-3917	before	_	
20-56	3917-3918	.	_	

#Text=These results corroborated the involvement of the NAc and the ventral cingulate in processing expectation for “uncertain drug effects.”
21-1	3919-3924	These	_	
21-2	3925-3932	results	_	
21-3	3933-3945	corroborated	_	
21-4	3946-3949	the	_	
21-5	3950-3961	involvement	_	
21-6	3962-3964	of	_	
21-7	3965-3968	the	_	
21-8	3969-3972	NAc	_	
21-9	3973-3976	and	_	
21-10	3977-3980	the	_	
21-11	3981-3988	ventral	_	
21-12	3989-3998	cingulate	_	
21-13	3999-4001	in	_	
21-14	4002-4012	processing	_	
21-15	4013-4024	expectation	_	
21-16	4025-4028	for	_	
21-17	4029-4030	“	_	
21-18	4030-4039	uncertain	_	
21-19	4040-4044	drug	_	
21-20	4045-4052	effects	_	
21-21	4052-4053	.	_	
21-22	4053-4054	”	_	

#Text=However, the extent to which these regional changes reflect the involvement of DA in processing expectation of drug effects rather than non dopaminergic signaling (i.e glutamatergic signaling) needs further investigation.
22-1	4055-4062	However	_	
22-2	4062-4063	,	_	
22-3	4064-4067	the	_	
22-4	4068-4074	extent	_	
22-5	4075-4077	to	_	
22-6	4078-4083	which	_	
22-7	4084-4089	these	_	
22-8	4090-4098	regional	_	
22-9	4099-4106	changes	_	
22-10	4107-4114	reflect	_	
22-11	4115-4118	the	_	
22-12	4119-4130	involvement	_	
22-13	4131-4133	of	_	
22-14	4134-4136	DA	_	
22-15	4137-4139	in	_	
22-16	4140-4150	processing	_	
22-17	4151-4162	expectation	_	
22-18	4163-4165	of	_	
22-19	4166-4170	drug	_	
22-20	4171-4178	effects	_	
22-21	4179-4185	rather	_	
22-22	4186-4190	than	_	
22-23	4191-4194	non	_	
22-24	4195-4207	dopaminergic	_	
22-25	4208-4217	signaling	_	
22-26	4218-4219	(	_	
22-27	4219-4222	i.e	_	
22-28	4223-4236	glutamatergic	_	
22-29	4237-4246	signaling	_	
22-30	4246-4247	)	_	
22-31	4248-4253	needs	_	
22-32	4254-4261	further	_	
22-33	4262-4275	investigation	_	
22-34	4275-4276	.	_	

#Text=Understanding the neuronal signals underlying expectation responses in addiction and specifically that of DA could help guide development of targeted pharmacotherapeutic interventions.
23-1	4277-4290	Understanding	_	
23-2	4291-4294	the	_	
23-3	4295-4303	neuronal	_	
23-4	4304-4311	signals	_	
23-5	4312-4322	underlying	_	
23-6	4323-4334	expectation	_	
23-7	4335-4344	responses	_	
23-8	4345-4347	in	_	
23-9	4348-4357	addiction	_	
23-10	4358-4361	and	_	
23-11	4362-4374	specifically	_	
23-12	4375-4379	that	_	
23-13	4380-4382	of	_	
23-14	4383-4385	DA	_	
23-15	4386-4391	could	_	
23-16	4392-4396	help	_	
23-17	4397-4402	guide	_	
23-18	4403-4414	development	_	
23-19	4415-4417	of	_	
23-20	4418-4426	targeted	_	
23-21	4427-4446	pharmacotherapeutic	_	
23-22	4447-4460	interventions	_	
23-23	4460-4461	.	_	

#Text=Further, the characterization of how expectation influences drug responses in non-addicted and addicted individuals might also help guide prevention interventions.
24-1	4462-4469	Further	_	
24-2	4469-4470	,	_	
24-3	4471-4474	the	_	
24-4	4475-4491	characterization	_	
24-5	4492-4494	of	_	
24-6	4495-4498	how	_	
24-7	4499-4510	expectation	_	
24-8	4511-4521	influences	_	
24-9	4522-4526	drug	_	
24-10	4527-4536	responses	_	
24-11	4537-4539	in	_	
24-12	4540-4552	non-addicted	_	
24-13	4553-4556	and	_	
24-14	4557-4565	addicted	_	
24-15	4566-4577	individuals	_	
24-16	4578-4583	might	_	
24-17	4584-4588	also	_	
24-18	4589-4593	help	_	
24-19	4594-4599	guide	_	
24-20	4600-4610	prevention	_	
24-21	4611-4624	interventions	_	
24-22	4624-4625	.	_	

#Text=Indeed, while expectations might differently impact the effects of drugs of abuse in controls and in addicted individuals due to conditioning, there is also evidence that they might be influenced by genetics.
25-1	4626-4632	Indeed	_	
25-2	4632-4633	,	_	
25-3	4634-4639	while	_	
25-4	4640-4652	expectations	_	
25-5	4653-4658	might	_	
25-6	4659-4670	differently	_	
25-7	4671-4677	impact	_	
25-8	4678-4681	the	_	
25-9	4682-4689	effects	_	
25-10	4690-4692	of	_	
25-11	4693-4698	drugs	_	
25-12	4699-4701	of	_	
25-13	4702-4707	abuse	_	
25-14	4708-4710	in	_	
25-15	4711-4719	controls	_	
25-16	4720-4723	and	_	
25-17	4724-4726	in	_	
25-18	4727-4735	addicted	_	
25-19	4736-4747	individuals	_	
25-20	4748-4751	due	_	
25-21	4752-4754	to	_	
25-22	4755-4767	conditioning	_	
25-23	4767-4768	,	_	
25-24	4769-4774	there	_	
25-25	4775-4777	is	_	
25-26	4778-4782	also	_	
25-27	4783-4791	evidence	_	
25-28	4792-4796	that	_	
25-29	4797-4801	they	_	
25-30	4802-4807	might	_	
25-31	4808-4810	be	_	
25-32	4811-4821	influenced	_	
25-33	4822-4824	by	_	
25-34	4825-4833	genetics	_	
25-35	4833-4834	.	_	

#Text=For example, a recent study showed that individuals with family history of alcoholism showed stronger striatal DA release when expecting to receive alcohol, suggesting that genetics influence the sensitivity to expectation; although surprisingly these responses did not differ between controls and alcohol use disorder (AUD) participants.
26-1	4835-4838	For	_	
26-2	4839-4846	example	_	
26-3	4846-4847	,	_	
26-4	4848-4849	a	_	
26-5	4850-4856	recent	_	
26-6	4857-4862	study	_	
26-7	4863-4869	showed	_	
26-8	4870-4874	that	_	
26-9	4875-4886	individuals	_	
26-10	4887-4891	with	_	
26-11	4892-4898	family	_	
26-12	4899-4906	history	_	
26-13	4907-4909	of	_	
26-14	4910-4920	alcoholism	_	
26-15	4921-4927	showed	_	
26-16	4928-4936	stronger	_	
26-17	4937-4945	striatal	_	
26-18	4946-4948	DA	_	
26-19	4949-4956	release	_	
26-20	4957-4961	when	_	
26-21	4962-4971	expecting	_	
26-22	4972-4974	to	_	
26-23	4975-4982	receive	_	
26-24	4983-4990	alcohol	_	
26-25	4990-4991	,	_	
26-26	4992-5002	suggesting	_	
26-27	5003-5007	that	_	
26-28	5008-5016	genetics	_	
26-29	5017-5026	influence	_	
26-30	5027-5030	the	_	
26-31	5031-5042	sensitivity	_	
26-32	5043-5045	to	_	
26-33	5046-5057	expectation	_	
26-34	5057-5058	;	_	
26-35	5059-5067	although	_	
26-36	5068-5080	surprisingly	_	
26-37	5081-5086	these	_	
26-38	5087-5096	responses	_	
26-39	5097-5100	did	_	
26-40	5101-5104	not	_	
26-41	5105-5111	differ	_	
26-42	5112-5119	between	_	
26-43	5120-5128	controls	_	
26-44	5129-5132	and	_	
26-45	5133-5140	alcohol	_	
26-46	5141-5144	use	_	
26-47	5145-5153	disorder	_	
26-48	5154-5155	(	_	
26-49	5155-5158	AUD	_	
26-50	5158-5159	)	_	
26-51	5160-5172	participants	_	
26-52	5172-5173	.	_	

#Text=Inasmuch as drug-induced DA increases trigger conditioning to the drug and its cues, one would have predicted that in addicted individuals the expectation effects on DA signaling would be stronger than in controls.
27-1	5174-5182	Inasmuch	_	
27-2	5183-5185	as	_	
27-3	5186-5198	drug-induced	_	
27-4	5199-5201	DA	_	
27-5	5202-5211	increases	_	
27-6	5212-5219	trigger	_	
27-7	5220-5232	conditioning	_	
27-8	5233-5235	to	_	
27-9	5236-5239	the	_	
27-10	5240-5244	drug	_	
27-11	5245-5248	and	_	
27-12	5249-5252	its	_	
27-13	5253-5257	cues	_	
27-14	5257-5258	,	_	
27-15	5259-5262	one	_	
27-16	5263-5268	would	_	
27-17	5269-5273	have	_	
27-18	5274-5283	predicted	_	
27-19	5284-5288	that	_	
27-20	5289-5291	in	_	
27-21	5292-5300	addicted	_	
27-22	5301-5312	individuals	_	
27-23	5313-5316	the	_	
27-24	5317-5328	expectation	_	
27-25	5329-5336	effects	_	
27-26	5337-5339	on	_	
27-27	5340-5342	DA	_	
27-28	5343-5352	signaling	_	
27-29	5353-5358	would	_	
27-30	5359-5361	be	_	
27-31	5362-5370	stronger	_	
27-32	5371-5375	than	_	
27-33	5376-5378	in	_	
27-34	5379-5387	controls	_	
27-35	5387-5388	.	_	

#Text=However, once conditioning occurs, DA neurons stop firing upon receipt of the reward and instead fire when exposed to the conditioned cues (that predict the reward) or to an unexpected larger reward, whereas they inhibit their firing when the experience of the reward does not materialize or is less than expected.
28-1	5389-5396	However	_	
28-2	5396-5397	,	_	
28-3	5398-5402	once	_	
28-4	5403-5415	conditioning	_	
28-5	5416-5422	occurs	_	
28-6	5422-5423	,	_	
28-7	5424-5426	DA	_	
28-8	5427-5434	neurons	_	
28-9	5435-5439	stop	_	
28-10	5440-5446	firing	_	
28-11	5447-5451	upon	_	
28-12	5452-5459	receipt	_	
28-13	5460-5462	of	_	
28-14	5463-5466	the	_	
28-15	5467-5473	reward	_	
28-16	5474-5477	and	_	
28-17	5478-5485	instead	_	
28-18	5486-5490	fire	_	
28-19	5491-5495	when	_	
28-20	5496-5503	exposed	_	
28-21	5504-5506	to	_	
28-22	5507-5510	the	_	
28-23	5511-5522	conditioned	_	
28-24	5523-5527	cues	_	
28-25	5528-5529	(	_	
28-26	5529-5533	that	_	
28-27	5534-5541	predict	_	
28-28	5542-5545	the	_	
28-29	5546-5552	reward	_	
28-30	5552-5553	)	_	
28-31	5554-5556	or	_	
28-32	5557-5559	to	_	
28-33	5560-5562	an	_	
28-34	5563-5573	unexpected	_	
28-35	5574-5580	larger	_	
28-36	5581-5587	reward	_	
28-37	5587-5588	,	_	
28-38	5589-5596	whereas	_	
28-39	5597-5601	they	_	
28-40	5602-5609	inhibit	_	
28-41	5610-5615	their	_	
28-42	5616-5622	firing	_	
28-43	5623-5627	when	_	
28-44	5628-5631	the	_	
28-45	5632-5642	experience	_	
28-46	5643-5645	of	_	
28-47	5646-5649	the	_	
28-48	5650-5656	reward	_	
28-49	5657-5661	does	_	
28-50	5662-5665	not	_	
28-51	5666-5677	materialize	_	
28-52	5678-5680	or	_	
28-53	5681-5683	is	_	
28-54	5684-5688	less	_	
28-55	5689-5693	than	_	
28-56	5694-5702	expected	_	
28-57	5702-5703	.	_	

#Text=Therefore, it is likely that the differences in DA responses between addicted and non-addicted individuals will depend on whether the expectation is for PL versus stimulant drugs.
29-1	5704-5713	Therefore	_	
29-2	5713-5714	,	_	
29-3	5715-5717	it	_	
29-4	5718-5720	is	_	
29-5	5721-5727	likely	_	
29-6	5728-5732	that	_	
29-7	5733-5736	the	_	
29-8	5737-5748	differences	_	
29-9	5749-5751	in	_	
29-10	5752-5754	DA	_	
29-11	5755-5764	responses	_	
29-12	5765-5772	between	_	
29-13	5773-5781	addicted	_	
29-14	5782-5785	and	_	
29-15	5786-5798	non-addicted	_	
29-16	5799-5810	individuals	_	
29-17	5811-5815	will	_	
29-18	5816-5822	depend	_	
29-19	5823-5825	on	_	
29-20	5826-5833	whether	_	
29-21	5834-5837	the	_	
29-22	5838-5849	expectation	_	
29-23	5850-5852	is	_	
29-24	5853-5856	for	_	
29-25	5857-5859	PL	_	
29-26	5860-5866	versus	_	
29-27	5867-5876	stimulant	_	
29-28	5877-5882	drugs	_	
29-29	5882-5883	.	_	

#Text=To test this possibility, we studied 23 subjects with active cocaine use disorder (CUD) and 23 healthy non-drug- dependent control subjects (HC) with Positron Emission Tomography (PET) and [11C]raclopride, a DA D2/D3 receptor (D2R) ligand that is sensitive to competition with endogenous DA.
30-1	5884-5886	To	_	
30-2	5887-5891	test	_	
30-3	5892-5896	this	_	
30-4	5897-5908	possibility	_	
30-5	5908-5909	,	_	
30-6	5910-5912	we	_	
30-7	5913-5920	studied	_	
30-8	5921-5923	23	_	
30-9	5924-5932	subjects	_	
30-10	5933-5937	with	_	
30-11	5938-5944	active	_	
30-12	5945-5952	cocaine	_	
30-13	5953-5956	use	_	
30-14	5957-5965	disorder	_	
30-15	5966-5967	(	_	
30-16	5967-5970	CUD	_	
30-17	5970-5971	)	_	
30-18	5972-5975	and	_	
30-19	5976-5978	23	_	
30-20	5979-5986	healthy	_	
30-21	5987-5995	non-drug	_	
30-22	5995-5996	-	_	
30-23	5997-6006	dependent	_	
30-24	6007-6014	control	_	
30-25	6015-6023	subjects	_	
30-26	6024-6025	(	_	
30-27	6025-6027	HC	_	
30-28	6027-6028	)	_	
30-29	6029-6033	with	_	
30-30	6034-6042	Positron	_	
30-31	6043-6051	Emission	_	
30-32	6052-6062	Tomography	_	
30-33	6063-6064	(	_	
30-34	6064-6067	PET	_	
30-35	6067-6068	)	_	
30-36	6069-6072	and	_	
30-37	6073-6074	[	_	
30-38	6074-6077	11C	_	
30-39	6077-6078	]	_	
30-40	6078-6088	raclopride	_	
30-41	6088-6089	,	_	
30-42	6090-6091	a	_	
30-43	6092-6094	DA	_	
30-44	6095-6097	D2	_	
30-45	6097-6098	/	_	
30-46	6098-6100	D3	_	
30-47	6101-6109	receptor	_	
30-48	6110-6111	(	_	
30-49	6111-6114	D2R	_	
30-50	6114-6115	)	_	
30-51	6116-6122	ligand	_	
30-52	6123-6127	that	_	
30-53	6128-6130	is	_	
30-54	6131-6140	sensitive	_	
30-55	6141-6143	to	_	
30-56	6144-6155	competition	_	
30-57	6156-6160	with	_	
30-58	6161-6171	endogenous	_	
30-59	6172-6174	DA	_	
30-60	6174-6175	.	_	

#Text=Each subject underwent 4 [11C]raclopride scans: (1) PL/PL: expecting PL and receiving PL; (2) PL/MP: expecting PL and receiving MP; (3) MP/PL: expecting MP and receiving PL; and (4) MP/MP: expecting MP and receiving MP.
31-1	6176-6180	Each	_	
31-2	6181-6188	subject	_	
31-3	6189-6198	underwent	_	
31-4	6199-6200	4	_	
31-5	6201-6202	[	_	
31-6	6202-6205	11C	_	
31-7	6205-6206	]	_	
31-8	6206-6216	raclopride	_	
31-9	6217-6222	scans	_	
31-10	6222-6223	:	_	
31-11	6224-6225	(	_	
31-12	6225-6226	1	_	
31-13	6226-6227	)	_	
31-14	6228-6230	PL	_	
31-15	6230-6231	/	_	
31-16	6231-6233	PL	_	
31-17	6233-6234	:	_	
31-18	6235-6244	expecting	_	
31-19	6245-6247	PL	_	
31-20	6248-6251	and	_	
31-21	6252-6261	receiving	_	
31-22	6262-6264	PL	_	
31-23	6264-6265	;	_	
31-24	6266-6267	(	_	
31-25	6267-6268	2	_	
31-26	6268-6269	)	_	
31-27	6270-6272	PL	_	
31-28	6272-6273	/	_	
31-29	6273-6275	MP	_	
31-30	6275-6276	:	_	
31-31	6277-6286	expecting	_	
31-32	6287-6289	PL	_	
31-33	6290-6293	and	_	
31-34	6294-6303	receiving	_	
31-35	6304-6306	MP	_	
31-36	6306-6307	;	_	
31-37	6308-6309	(	_	
31-38	6309-6310	3	_	
31-39	6310-6311	)	_	
31-40	6312-6314	MP	_	
31-41	6314-6315	/	_	
31-42	6315-6317	PL	_	
31-43	6317-6318	:	_	
31-44	6319-6328	expecting	_	
31-45	6329-6331	MP	_	
31-46	6332-6335	and	_	
31-47	6336-6345	receiving	_	
31-48	6346-6348	PL	_	
31-49	6348-6349	;	_	
31-50	6350-6353	and	_	
31-51	6354-6355	(	_	
31-52	6355-6356	4	_	
31-53	6356-6357	)	_	
31-54	6358-6360	MP	_	
31-55	6360-6361	/	_	
31-56	6361-6363	MP	_	
31-57	6363-6364	:	_	
31-58	6365-6374	expecting	_	
31-59	6375-6377	MP	_	
31-60	6378-6381	and	_	
31-61	6382-6391	receiving	_	
31-62	6392-6394	MP	_	
31-63	6394-6395	.	_	

#Text=We hypothesized that expectation of receiving the drug would increase DA release in striatum (i.e., lower D2R availability) when compared with unexpected and that because of conditioning in CUD we hypothesized that the difference from expectation (expected MP versus unexpected MP) would be greater in CUD than in HC in line with our previous findings that expectation of MP increased brain glucose metabolism in CUD versus HC, even though the overall dopaminergic effects of MP would be greater in HC than in CUD regardless of condition.
32-1	6396-6398	We	_	
32-2	6399-6411	hypothesized	_	
32-3	6412-6416	that	_	
32-4	6417-6428	expectation	_	
32-5	6429-6431	of	_	
32-6	6432-6441	receiving	_	
32-7	6442-6445	the	_	
32-8	6446-6450	drug	_	
32-9	6451-6456	would	_	
32-10	6457-6465	increase	_	
32-11	6466-6468	DA	_	
32-12	6469-6476	release	_	
32-13	6477-6479	in	_	
32-14	6480-6488	striatum	_	
32-15	6489-6490	(	_	
32-16	6490-6493	i.e	_	
32-17	6493-6494	.	_	
32-18	6494-6495	,	_	
32-19	6496-6501	lower	_	
32-20	6502-6505	D2R	_	
32-21	6506-6518	availability	_	
32-22	6518-6519	)	_	
32-23	6520-6524	when	_	
32-24	6525-6533	compared	_	
32-25	6534-6538	with	_	
32-26	6539-6549	unexpected	_	
32-27	6550-6553	and	_	
32-28	6554-6558	that	_	
32-29	6559-6566	because	_	
32-30	6567-6569	of	_	
32-31	6570-6582	conditioning	_	
32-32	6583-6585	in	_	
32-33	6586-6589	CUD	_	
32-34	6590-6592	we	_	
32-35	6593-6605	hypothesized	_	
32-36	6606-6610	that	_	
32-37	6611-6614	the	_	
32-38	6615-6625	difference	_	
32-39	6626-6630	from	_	
32-40	6631-6642	expectation	_	
32-41	6643-6644	(	_	
32-42	6644-6652	expected	_	
32-43	6653-6655	MP	_	
32-44	6656-6662	versus	_	
32-45	6663-6673	unexpected	_	
32-46	6674-6676	MP	_	
32-47	6676-6677	)	_	
32-48	6678-6683	would	_	
32-49	6684-6686	be	_	
32-50	6687-6694	greater	_	
32-51	6695-6697	in	_	
32-52	6698-6701	CUD	_	
32-53	6702-6706	than	_	
32-54	6707-6709	in	_	
32-55	6710-6712	HC	_	
32-56	6713-6715	in	_	
32-57	6716-6720	line	_	
32-58	6721-6725	with	_	
32-59	6726-6729	our	_	
32-60	6730-6738	previous	_	
32-61	6739-6747	findings	_	
32-62	6748-6752	that	_	
32-63	6753-6764	expectation	_	
32-64	6765-6767	of	_	
32-65	6768-6770	MP	_	
32-66	6771-6780	increased	_	
32-67	6781-6786	brain	_	
32-68	6787-6794	glucose	_	
32-69	6795-6805	metabolism	_	
32-70	6806-6808	in	_	
32-71	6809-6812	CUD	_	
32-72	6813-6819	versus	_	
32-73	6820-6822	HC	_	
32-74	6822-6823	,	_	
32-75	6824-6828	even	_	
32-76	6829-6835	though	_	
32-77	6836-6839	the	_	
32-78	6840-6847	overall	_	
32-79	6848-6860	dopaminergic	_	
32-80	6861-6868	effects	_	
32-81	6869-6871	of	_	
32-82	6872-6874	MP	_	
32-83	6875-6880	would	_	
32-84	6881-6883	be	_	
32-85	6884-6891	greater	_	
32-86	6892-6894	in	_	
32-87	6895-6897	HC	_	
32-88	6898-6902	than	_	
32-89	6903-6905	in	_	
32-90	6906-6909	CUD	_	
32-91	6910-6920	regardless	_	
32-92	6921-6923	of	_	
32-93	6924-6933	condition	_	
32-94	6933-6934	.	_	

#Text=However, we also considered the possibility that, because participants with a CUD would have attenuated DA increases when given MP, they would show a lower than expected reward resulting in inhibition of DA neuronal firing, whereas the expectation of receiving PL and instead receiving MP in CUD would lead to a greater than expected reward signal and hence greater DA neuronal firing than in controls.
33-1	6935-6942	However	_	
33-2	6942-6943	,	_	
33-3	6944-6946	we	_	
33-4	6947-6951	also	_	
33-5	6952-6962	considered	_	
33-6	6963-6966	the	_	
33-7	6967-6978	possibility	_	
33-8	6979-6983	that	_	
33-9	6983-6984	,	_	
33-10	6985-6992	because	_	
33-11	6993-7005	participants	_	
33-12	7006-7010	with	_	
33-13	7011-7012	a	_	
33-14	7013-7016	CUD	_	
33-15	7017-7022	would	_	
33-16	7023-7027	have	_	
33-17	7028-7038	attenuated	_	
33-18	7039-7041	DA	_	
33-19	7042-7051	increases	_	
33-20	7052-7056	when	_	
33-21	7057-7062	given	_	
33-22	7063-7065	MP	_	
33-23	7065-7066	,	_	
33-24	7067-7071	they	_	
33-25	7072-7077	would	_	
33-26	7078-7082	show	_	
33-27	7083-7084	a	_	
33-28	7085-7090	lower	_	
33-29	7091-7095	than	_	
33-30	7096-7104	expected	_	
33-31	7105-7111	reward	_	
33-32	7112-7121	resulting	_	
33-33	7122-7124	in	_	
33-34	7125-7135	inhibition	_	
33-35	7136-7138	of	_	
33-36	7139-7141	DA	_	
33-37	7142-7150	neuronal	_	
33-38	7151-7157	firing	_	
33-39	7157-7158	,	_	
33-40	7159-7166	whereas	_	
33-41	7167-7170	the	_	
33-42	7171-7182	expectation	_	
33-43	7183-7185	of	_	
33-44	7186-7195	receiving	_	
33-45	7196-7198	PL	_	
33-46	7199-7202	and	_	
33-47	7203-7210	instead	_	
33-48	7211-7220	receiving	_	
33-49	7221-7223	MP	_	
33-50	7224-7226	in	_	
33-51	7227-7230	CUD	_	
33-52	7231-7236	would	_	
33-53	7237-7241	lead	_	
33-54	7242-7244	to	_	
33-55	7245-7246	a	_	
33-56	7247-7254	greater	_	
33-57	7255-7259	than	_	
33-58	7260-7268	expected	_	
33-59	7269-7275	reward	_	
33-60	7276-7282	signal	_	
33-61	7283-7286	and	_	
33-62	7287-7292	hence	_	
33-63	7293-7300	greater	_	
33-64	7301-7303	DA	_	
33-65	7304-7312	neuronal	_	
33-66	7313-7319	firing	_	
33-67	7320-7324	than	_	
33-68	7325-7327	in	_	
33-69	7328-7336	controls	_	
33-70	7336-7337	.	_	

#Text=Methods
#Text=Subjects
#Text=Characteristics of the study participants
#Text=\tCUD (n = 23)\tHC (n = 23)\tp Value\t \tAge (years)\t44.1 (3.6)\t42.1 (4.1)\tns\t \tYears of education\t13.2 (5.7)\t14.7 (2.8)\tns\t \tVerbal IQ Barona\t97.0 (11.9)\t97.8 (13.6)\tns\t \tBMI\t26.4 (5.0)\t26.4 (2.3)\tns\t \tCigarette (pack years)\t8.8 (5.6)\t0.5 (1.9)\t<0.0001\t \tCocaine age\t21.9 (5.8)\tNA\tNA\t \tCocaine use (g/day)\t3.5 (2.8)\t0\t<0.0001\t \tCocaine use (years)\t18.4 (7.2)\t0\t<0.0001\t \tBDI\t10.4 (11.3)\t2.1 (2.6)a\t0.002\t \tMPQ PEM\t44.2 (9.3)\t51.9 (9.9)\t0.010\t \tMPQ NEM\t19.5 (11.5)\t8.4 (7.0)\t<0.0001\t \tMPQ constraint\t49.1 (7.9)\t55.6 (8.4)\t0.010\t \t
#Text=BDI Beck’s depression inventory, BMI body mass index, cigarette (pack years) (number of cigarettes per day × years of smoking)/20, with 20 being the size of a common pack of cigarettes, CUD cocaine use disorder, HC healthy controls, MPQ multidimensional personality questionnaire, PEM positive emotionality, NEM negative emotionality, NA not applicable, ns not significant
#Text=an = 21
#Text=The Institutional Review Boards at the Stony Brook University/Brookhaven National Laboratory approved the protocol.
34-1	7338-7345	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
34-2	7346-7354	Subjects	_	
34-3	7355-7370	Characteristics	_	
34-4	7371-7373	of	_	
34-5	7374-7377	the	_	
34-6	7378-7383	study	_	
34-7	7384-7396	participants	_	
34-8	7398-7401	CUD	_	
34-9	7402-7403	(	_	
34-10	7403-7404	n	_	
34-11	7405-7406	=	_	
34-12	7407-7409	23	_	
34-13	7409-7410	)	_	
34-14	7411-7413	HC	_	
34-15	7414-7415	(	_	
34-16	7415-7416	n	_	
34-17	7417-7418	=	_	
34-18	7419-7421	23	_	
34-19	7421-7422	)	_	
34-20	7423-7424	p	_	
34-21	7425-7430	Value	_	
34-22	7433-7436	Age	_	
34-23	7437-7438	(	_	
34-24	7438-7443	years	_	
34-25	7443-7444	)	_	
34-26	7445-7449	44.1	_	
34-27	7450-7451	(	_	
34-28	7451-7454	3.6	_	
34-29	7454-7455	)	_	
34-30	7456-7460	42.1	_	
34-31	7461-7462	(	_	
34-32	7462-7465	4.1	_	
34-33	7465-7466	)	_	
34-34	7467-7469	ns	_	
34-35	7472-7477	Years	_	
34-36	7478-7480	of	_	
34-37	7481-7490	education	_	
34-38	7491-7495	13.2	_	
34-39	7496-7497	(	_	
34-40	7497-7500	5.7	_	
34-41	7500-7501	)	_	
34-42	7502-7506	14.7	_	
34-43	7507-7508	(	_	
34-44	7508-7511	2.8	_	
34-45	7511-7512	)	_	
34-46	7513-7515	ns	_	
34-47	7518-7524	Verbal	_	
34-48	7525-7527	IQ	_	
34-49	7528-7534	Barona	_	
34-50	7535-7539	97.0	_	
34-51	7540-7541	(	_	
34-52	7541-7545	11.9	_	
34-53	7545-7546	)	_	
34-54	7547-7551	97.8	_	
34-55	7552-7553	(	_	
34-56	7553-7557	13.6	_	
34-57	7557-7558	)	_	
34-58	7559-7561	ns	_	
34-59	7564-7567	BMI	_	
34-60	7568-7572	26.4	_	
34-61	7573-7574	(	_	
34-62	7574-7577	5.0	_	
34-63	7577-7578	)	_	
34-64	7579-7583	26.4	_	
34-65	7584-7585	(	_	
34-66	7585-7588	2.3	_	
34-67	7588-7589	)	_	
34-68	7590-7592	ns	_	
34-69	7595-7604	Cigarette	_	
34-70	7605-7606	(	_	
34-71	7606-7610	pack	_	
34-72	7611-7616	years	_	
34-73	7616-7617	)	_	
34-74	7618-7621	8.8	_	
34-75	7622-7623	(	_	
34-76	7623-7626	5.6	_	
34-77	7626-7627	)	_	
34-78	7628-7631	0.5	_	
34-79	7632-7633	(	_	
34-80	7633-7636	1.9	_	
34-81	7636-7637	)	_	
34-82	7638-7639	<	_	
34-83	7639-7645	0.0001	_	
34-84	7648-7655	Cocaine	_	
34-85	7656-7659	age	_	
34-86	7660-7664	21.9	_	
34-87	7665-7666	(	_	
34-88	7666-7669	5.8	_	
34-89	7669-7670	)	_	
34-90	7671-7673	NA	_	
34-91	7674-7676	NA	_	
34-92	7679-7686	Cocaine	_	
34-93	7687-7690	use	_	
34-94	7691-7692	(	_	
34-95	7692-7693	g	_	
34-96	7693-7694	/	_	
34-97	7694-7697	day	_	
34-98	7697-7698	)	_	
34-99	7699-7702	3.5	_	
34-100	7703-7704	(	_	
34-101	7704-7707	2.8	_	
34-102	7707-7708	)	_	
34-103	7709-7710	0	_	
34-104	7711-7712	<	_	
34-105	7712-7718	0.0001	_	
34-106	7721-7728	Cocaine	_	
34-107	7729-7732	use	_	
34-108	7733-7734	(	_	
34-109	7734-7739	years	_	
34-110	7739-7740	)	_	
34-111	7741-7745	18.4	_	
34-112	7746-7747	(	_	
34-113	7747-7750	7.2	_	
34-114	7750-7751	)	_	
34-115	7752-7753	0	_	
34-116	7754-7755	<	_	
34-117	7755-7761	0.0001	_	
34-118	7764-7767	BDI	_	
34-119	7768-7772	10.4	_	
34-120	7773-7774	(	_	
34-121	7774-7778	11.3	_	
34-122	7778-7779	)	_	
34-123	7780-7783	2.1	_	
34-124	7784-7785	(	_	
34-125	7785-7788	2.6	_	
34-126	7788-7789	)	_	
34-127	7789-7790	a	_	
34-128	7791-7796	0.002	_	
34-129	7799-7802	MPQ	_	
34-130	7803-7806	PEM	_	
34-131	7807-7811	44.2	_	
34-132	7812-7813	(	_	
34-133	7813-7816	9.3	_	
34-134	7816-7817	)	_	
34-135	7818-7822	51.9	_	
34-136	7823-7824	(	_	
34-137	7824-7827	9.9	_	
34-138	7827-7828	)	_	
34-139	7829-7834	0.010	_	
34-140	7837-7840	MPQ	_	
34-141	7841-7844	NEM	_	
34-142	7845-7849	19.5	_	
34-143	7850-7851	(	_	
34-144	7851-7855	11.5	_	
34-145	7855-7856	)	_	
34-146	7857-7860	8.4	_	
34-147	7861-7862	(	_	
34-148	7862-7865	7.0	_	
34-149	7865-7866	)	_	
34-150	7867-7868	<	_	
34-151	7868-7874	0.0001	_	
34-152	7877-7880	MPQ	_	
34-153	7881-7891	constraint	_	
34-154	7892-7896	49.1	_	
34-155	7897-7898	(	_	
34-156	7898-7901	7.9	_	
34-157	7901-7902	)	_	
34-158	7903-7907	55.6	_	
34-159	7908-7909	(	_	
34-160	7909-7912	8.4	_	
34-161	7912-7913	)	_	
34-162	7914-7919	0.010	_	
34-163	7923-7926	BDI	_	
34-164	7927-7931	Beck	_	
34-165	7931-7932	’	_	
34-166	7932-7933	s	_	
34-167	7934-7944	depression	_	
34-168	7945-7954	inventory	_	
34-169	7954-7955	,	_	
34-170	7956-7959	BMI	_	
34-171	7960-7964	body	_	
34-172	7965-7969	mass	_	
34-173	7970-7975	index	_	
34-174	7975-7976	,	_	
34-175	7977-7986	cigarette	_	
34-176	7987-7988	(	_	
34-177	7988-7992	pack	_	
34-178	7993-7998	years	_	
34-179	7998-7999	)	_	
34-180	8000-8001	(	_	
34-181	8001-8007	number	_	
34-182	8008-8010	of	_	
34-183	8011-8021	cigarettes	_	
34-184	8022-8025	per	_	
34-185	8026-8029	day	_	
34-186	8030-8031	×	_	
34-187	8032-8037	years	_	
34-188	8038-8040	of	_	
34-189	8041-8048	smoking	_	
34-190	8048-8049	)	_	
34-191	8049-8050	/	_	
34-192	8050-8052	20	_	
34-193	8052-8053	,	_	
34-194	8054-8058	with	_	
34-195	8059-8061	20	_	
34-196	8062-8067	being	_	
34-197	8068-8071	the	_	
34-198	8072-8076	size	_	
34-199	8077-8079	of	_	
34-200	8080-8081	a	_	
34-201	8082-8088	common	_	
34-202	8089-8093	pack	_	
34-203	8094-8096	of	_	
34-204	8097-8107	cigarettes	_	
34-205	8107-8108	,	_	
34-206	8109-8112	CUD	_	
34-207	8113-8120	cocaine	_	
34-208	8121-8124	use	_	
34-209	8125-8133	disorder	_	
34-210	8133-8134	,	_	
34-211	8135-8137	HC	_	
34-212	8138-8145	healthy	_	
34-213	8146-8154	controls	_	
34-214	8154-8155	,	_	
34-215	8156-8159	MPQ	_	
34-216	8160-8176	multidimensional	_	
34-217	8177-8188	personality	_	
34-218	8189-8202	questionnaire	_	
34-219	8202-8203	,	_	
34-220	8204-8207	PEM	_	
34-221	8208-8216	positive	_	
34-222	8217-8229	emotionality	_	
34-223	8229-8230	,	_	
34-224	8231-8234	NEM	_	
34-225	8235-8243	negative	_	
34-226	8244-8256	emotionality	_	
34-227	8256-8257	,	_	
34-228	8258-8260	NA	_	
34-229	8261-8264	not	_	
34-230	8265-8275	applicable	_	
34-231	8275-8276	,	_	
34-232	8277-8279	ns	_	
34-233	8280-8283	not	_	
34-234	8284-8295	significant	_	
34-235	8296-8298	an	_	
34-236	8299-8300	=	_	
34-237	8301-8303	21	_	
34-238	8304-8307	The	_	
34-239	8308-8321	Institutional	_	
34-240	8322-8328	Review	_	
34-241	8329-8335	Boards	_	
34-242	8336-8338	at	_	
34-243	8339-8342	the	_	
34-244	8343-8348	Stony	_	
34-245	8349-8354	Brook	_	
34-246	8355-8365	University	_	
34-247	8365-8366	/	_	
34-248	8366-8376	Brookhaven	_	
34-249	8377-8385	National	_	
34-250	8386-8396	Laboratory	_	
34-251	8397-8405	approved	_	
34-252	8406-8409	the	_	
34-253	8410-8418	protocol	_	
34-254	8418-8419	.	_	

#Text=Written informed consent was obtained after the experimental procedure was explained to the participants.
35-1	8420-8427	Written	_	
35-2	8428-8436	informed	_	
35-3	8437-8444	consent	_	
35-4	8445-8448	was	_	
35-5	8449-8457	obtained	_	
35-6	8458-8463	after	_	
35-7	8464-8467	the	_	
35-8	8468-8480	experimental	_	
35-9	8481-8490	procedure	_	
35-10	8491-8494	was	_	
35-11	8495-8504	explained	_	
35-12	8505-8507	to	_	
35-13	8508-8511	the	_	
35-14	8512-8524	participants	_	
35-15	8524-8525	.	_	

#Text=A total of n = 23 CUD and n = 23 HC participants were recruited from the New York metropolitan area and were matched for age (range: 34–50), gender (4 females in each group), body mass index, education years, and intelligence quotient (IQ) (see Table 1 for demographic details of each group).
36-1	8526-8527	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-2	8528-8533	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-3	8534-8536	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-4	8537-8538	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-5	8539-8540	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-6	8541-8543	23	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-7	8544-8547	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[5]	
36-8	8548-8551	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-9	8552-8553	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-10	8554-8555	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-11	8556-8558	23	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-12	8559-8561	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
36-13	8562-8574	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-14	8575-8579	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-15	8580-8589	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-16	8590-8594	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-17	8595-8598	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-18	8599-8602	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-19	8603-8607	York	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-20	8608-8620	metropolitan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-21	8621-8625	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-22	8626-8629	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-23	8630-8634	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-24	8635-8642	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-25	8643-8646	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-26	8647-8650	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-27	8651-8652	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-28	8652-8657	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-29	8657-8658	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-30	8659-8661	34	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-31	8661-8662	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-32	8662-8664	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-33	8664-8665	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-34	8665-8666	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-35	8667-8673	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-36	8674-8675	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-37	8675-8676	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-38	8677-8684	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-39	8685-8687	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-40	8688-8692	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-41	8693-8698	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-42	8698-8699	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-43	8699-8700	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-44	8701-8705	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-45	8706-8710	mass	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-46	8711-8716	index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-47	8716-8717	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-48	8718-8727	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-49	8728-8733	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-50	8733-8734	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-51	8735-8738	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-52	8739-8751	intelligence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-53	8752-8760	quotient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-54	8761-8762	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-55	8762-8764	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-56	8764-8765	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-57	8766-8767	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-58	8767-8770	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-59	8771-8776	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-60	8777-8778	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-61	8779-8782	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-62	8783-8794	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-63	8795-8802	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-64	8803-8805	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-65	8806-8810	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-66	8811-8816	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-67	8816-8817	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
36-68	8817-8818	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants completed the Full-Scale IQ from the Wechsler Adult Intelligence Scale, and Barona estimates were computed by incorporating race, region of the country in which the person is living, and whether they live in an urban or rural environment.
37-1	8819-8831	Participants	_	
37-2	8832-8841	completed	_	
37-3	8842-8845	the	_	
37-4	8846-8856	Full-Scale	_	
37-5	8857-8859	IQ	_	
37-6	8860-8864	from	_	
37-7	8865-8868	the	_	
37-8	8869-8877	Wechsler	_	
37-9	8878-8883	Adult	_	
37-10	8884-8896	Intelligence	_	
37-11	8897-8902	Scale	_	
37-12	8902-8903	,	_	
37-13	8904-8907	and	_	
37-14	8908-8914	Barona	_	
37-15	8915-8924	estimates	_	
37-16	8925-8929	were	_	
37-17	8930-8938	computed	_	
37-18	8939-8941	by	_	
37-19	8942-8955	incorporating	_	
37-20	8956-8960	race	_	
37-21	8960-8961	,	_	
37-22	8962-8968	region	_	
37-23	8969-8971	of	_	
37-24	8972-8975	the	_	
37-25	8976-8983	country	_	
37-26	8984-8986	in	_	
37-27	8987-8992	which	_	
37-28	8993-8996	the	_	
37-29	8997-9003	person	_	
37-30	9004-9006	is	_	
37-31	9007-9013	living	_	
37-32	9013-9014	,	_	
37-33	9015-9018	and	_	
37-34	9019-9026	whether	_	
37-35	9027-9031	they	_	
37-36	9032-9036	live	_	
37-37	9037-9039	in	_	
37-38	9040-9042	an	_	
37-39	9043-9048	urban	_	
37-40	9049-9051	or	_	
37-41	9052-9057	rural	_	
37-42	9058-9069	environment	_	
37-43	9069-9070	.	_	

#Text=There were also no differences in ethnicity between the CUD (African American: n = 18, Caucasian: n = 4, mixed ancestry: n = 1) and HC group (African American: n = 18, Caucasian: n = 3, mixed ancestry: n = 2; χ246,2 = 0.5, p = 0.8), which has been shown to be associated with D2R.
38-1	9071-9076	There	_	
38-2	9077-9081	were	_	
38-3	9082-9086	also	_	
38-4	9087-9089	no	_	
38-5	9090-9101	differences	_	
38-6	9102-9104	in	_	
38-7	9105-9114	ethnicity	_	
38-8	9115-9122	between	_	
38-9	9123-9126	the	_	
38-10	9127-9130	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
38-11	9131-9132	(	_	
38-12	9132-9139	African	_	
38-13	9140-9148	American	_	
38-14	9148-9149	:	_	
38-15	9150-9151	n	_	
38-16	9152-9153	=	_	
38-17	9154-9156	18	_	
38-18	9156-9157	,	_	
38-19	9158-9167	Caucasian	_	
38-20	9167-9168	:	_	
38-21	9169-9170	n	_	
38-22	9171-9172	=	_	
38-23	9173-9174	4	_	
38-24	9174-9175	,	_	
38-25	9176-9181	mixed	_	
38-26	9182-9190	ancestry	_	
38-27	9190-9191	:	_	
38-28	9192-9193	n	_	
38-29	9194-9195	=	_	
38-30	9196-9197	1	_	
38-31	9197-9198	)	_	
38-32	9199-9202	and	_	
38-33	9203-9205	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
38-34	9206-9211	group	_	
38-35	9212-9213	(	_	
38-36	9213-9220	African	_	
38-37	9221-9229	American	_	
38-38	9229-9230	:	_	
38-39	9231-9232	n	_	
38-40	9233-9234	=	_	
38-41	9235-9237	18	_	
38-42	9237-9238	,	_	
38-43	9239-9248	Caucasian	_	
38-44	9248-9249	:	_	
38-45	9250-9251	n	_	
38-46	9252-9253	=	_	
38-47	9254-9255	3	_	
38-48	9255-9256	,	_	
38-49	9257-9262	mixed	_	
38-50	9263-9271	ancestry	_	
38-51	9271-9272	:	_	
38-52	9273-9274	n	_	
38-53	9275-9276	=	_	
38-54	9277-9278	2	_	
38-55	9278-9279	;	_	
38-56	9280-9286	χ246,2	_	
38-57	9287-9288	=	_	
38-58	9289-9292	0.5	_	
38-59	9292-9293	,	_	
38-60	9294-9295	p	_	
38-61	9296-9297	=	_	
38-62	9298-9301	0.8	_	
38-63	9301-9302	)	_	
38-64	9302-9303	,	_	
38-65	9304-9309	which	_	
38-66	9310-9313	has	_	
38-67	9314-9318	been	_	
38-68	9319-9324	shown	_	
38-69	9325-9327	to	_	
38-70	9328-9330	be	_	
38-71	9331-9341	associated	_	
38-72	9342-9346	with	_	
38-73	9347-9350	D2R	_	
38-74	9350-9351	.	_	

#Text=There were, however, more smokers in the CUD (current smokers: n = 20, ex-smokers: n = 1, never-smokers: n = 2) compared to the HC group (current smokers: n = 3, ex-smokers: n = 1, never-smokers: n = 19; χ246,2 = 26.3, p < 0.001).
39-1	9352-9357	There	_	
39-2	9358-9362	were	_	
39-3	9362-9363	,	_	
39-4	9364-9371	however	_	
39-5	9371-9372	,	_	
39-6	9373-9377	more	_	
39-7	9378-9385	smokers	_	
39-8	9386-9388	in	_	
39-9	9389-9392	the	_	
39-10	9393-9396	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
39-11	9397-9398	(	_	
39-12	9398-9405	current	_	
39-13	9406-9413	smokers	_	
39-14	9413-9414	:	_	
39-15	9415-9416	n	_	
39-16	9417-9418	=	_	
39-17	9419-9421	20	_	
39-18	9421-9422	,	_	
39-19	9423-9433	ex-smokers	_	
39-20	9433-9434	:	_	
39-21	9435-9436	n	_	
39-22	9437-9438	=	_	
39-23	9439-9440	1	_	
39-24	9440-9441	,	_	
39-25	9442-9455	never-smokers	_	
39-26	9455-9456	:	_	
39-27	9457-9458	n	_	
39-28	9459-9460	=	_	
39-29	9461-9462	2	_	
39-30	9462-9463	)	_	
39-31	9464-9472	compared	_	
39-32	9473-9475	to	_	
39-33	9476-9479	the	_	
39-34	9480-9482	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
39-35	9483-9488	group	_	
39-36	9489-9490	(	_	
39-37	9490-9497	current	_	
39-38	9498-9505	smokers	_	
39-39	9505-9506	:	_	
39-40	9507-9508	n	_	
39-41	9509-9510	=	_	
39-42	9511-9512	3	_	
39-43	9512-9513	,	_	
39-44	9514-9524	ex-smokers	_	
39-45	9524-9525	:	_	
39-46	9526-9527	n	_	
39-47	9528-9529	=	_	
39-48	9530-9531	1	_	
39-49	9531-9532	,	_	
39-50	9533-9546	never-smokers	_	
39-51	9546-9547	:	_	
39-52	9548-9549	n	_	
39-53	9550-9551	=	_	
39-54	9552-9554	19	_	
39-55	9554-9555	;	_	
39-56	9556-9562	χ246,2	_	
39-57	9563-9564	=	_	
39-58	9565-9569	26.3	_	
39-59	9569-9570	,	_	
39-60	9571-9572	p	_	
39-61	9573-9574	<	_	
39-62	9575-9580	0.001	_	
39-63	9580-9581	)	_	
39-64	9581-9582	.	_	

#Text=Result on the effects of MP when it was not expected were previously published as part of a larger study that compared the effects of MP between CUD and HC.
40-1	9583-9589	Result	_	
40-2	9590-9592	on	_	
40-3	9593-9596	the	_	
40-4	9597-9604	effects	_	
40-5	9605-9607	of	_	
40-6	9608-9610	MP	_	
40-7	9611-9615	when	_	
40-8	9616-9618	it	_	
40-9	9619-9622	was	_	
40-10	9623-9626	not	_	
40-11	9627-9635	expected	_	
40-12	9636-9640	were	_	
40-13	9641-9651	previously	_	
40-14	9652-9661	published	_	
40-15	9662-9664	as	_	
40-16	9665-9669	part	_	
40-17	9670-9672	of	_	
40-18	9673-9674	a	_	
40-19	9675-9681	larger	_	
40-20	9682-9687	study	_	
40-21	9688-9692	that	_	
40-22	9693-9701	compared	_	
40-23	9702-9705	the	_	
40-24	9706-9713	effects	_	
40-25	9714-9716	of	_	
40-26	9717-9719	MP	_	
40-27	9720-9727	between	_	
40-28	9728-9731	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
40-29	9732-9735	and	_	
40-30	9736-9738	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
40-31	9738-9739	.	_	

#Text=However, this study is the first in reporting the effect of Expectation on D2R availability in CUD after PL and after MP and in comparing the Expectation responses to PL and to MP between controls and CUD.
41-1	9740-9747	However	_	
41-2	9747-9748	,	_	
41-3	9749-9753	this	_	
41-4	9754-9759	study	_	
41-5	9760-9762	is	_	
41-6	9763-9766	the	_	
41-7	9767-9772	first	_	
41-8	9773-9775	in	_	
41-9	9776-9785	reporting	_	
41-10	9786-9789	the	_	
41-11	9790-9796	effect	_	
41-12	9797-9799	of	_	
41-13	9800-9811	Expectation	_	
41-14	9812-9814	on	_	
41-15	9815-9818	D2R	_	
41-16	9819-9831	availability	_	
41-17	9832-9834	in	_	
41-18	9835-9838	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
41-19	9839-9844	after	_	
41-20	9845-9847	PL	_	
41-21	9848-9851	and	_	
41-22	9852-9857	after	_	
41-23	9858-9860	MP	_	
41-24	9861-9864	and	_	
41-25	9865-9867	in	_	
41-26	9868-9877	comparing	_	
41-27	9878-9881	the	_	
41-28	9882-9893	Expectation	_	
41-29	9894-9903	responses	_	
41-30	9904-9906	to	_	
41-31	9907-9909	PL	_	
41-32	9910-9913	and	_	
41-33	9914-9916	to	_	
41-34	9917-9919	MP	_	
41-35	9920-9927	between	_	
41-36	9928-9936	controls	_	
41-37	9937-9940	and	_	
41-38	9941-9944	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
41-39	9944-9945	.	_	

#Text=CUD subjects were included if they met Diagnostic and Statistical Manual of Mental Disorders IV diagnosis for current cocaine dependence with at least a 2-year history of cocaine abuse (at least 3 g/week), use cocaine predominantly by smoked or intravenous (iv) route, and presently intended to continue using cocaine.
42-1	9946-9949	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[8]	
42-2	9950-9958	subjects	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-3	9959-9963	were	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-4	9964-9972	included	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-5	9973-9975	if	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-6	9976-9980	they	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-7	9981-9984	met	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-8	9985-9995	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-9	9996-9999	and	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-10	10000-10011	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-11	10012-10018	Manual	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-12	10019-10021	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-13	10022-10028	Mental	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-14	10029-10038	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-15	10039-10041	IV	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-16	10042-10051	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-17	10052-10055	for	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-18	10056-10063	current	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-19	10064-10071	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-20	10072-10082	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-21	10083-10087	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-22	10088-10090	at	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-23	10091-10096	least	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-24	10097-10098	a	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-25	10099-10100	2	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-26	10100-10101	-	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-27	10101-10105	year	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-28	10106-10113	history	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-29	10114-10116	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-30	10117-10124	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-31	10125-10130	abuse	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-32	10131-10132	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-33	10132-10134	at	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-34	10135-10140	least	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-35	10141-10142	3	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-36	10143-10144	g	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-37	10144-10145	/	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-38	10145-10149	week	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-39	10149-10150	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-40	10150-10151	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-41	10152-10155	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-42	10156-10163	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-43	10164-10177	predominantly	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-44	10178-10180	by	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-45	10181-10187	smoked	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-46	10188-10190	or	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-47	10191-10202	intravenous	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-48	10203-10204	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-49	10204-10206	iv	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-50	10206-10207	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-51	10208-10213	route	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-52	10213-10214	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-53	10215-10218	and	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-54	10219-10228	presently	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-55	10229-10237	intended	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-56	10238-10240	to	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-57	10241-10249	continue	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-58	10250-10255	using	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-59	10256-10263	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	
42-60	10263-10264	.	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]	

#Text=The inclusion criteria for the HC subjects were a prior experience of using stimulant (i.e., cocaine, methamphetamine, MP) at least once but no presence or history of other substance use disorders than nicotine.
43-1	10265-10268	The	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-2	10269-10278	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-3	10279-10287	criteria	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-4	10288-10291	for	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-5	10292-10295	the	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-6	10296-10298	HC	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
43-7	10299-10307	subjects	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-8	10308-10312	were	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-9	10313-10314	a	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-10	10315-10320	prior	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-11	10321-10331	experience	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-12	10332-10334	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-13	10335-10340	using	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-14	10341-10350	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-15	10351-10352	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-16	10352-10355	i.e	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-17	10355-10356	.	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-18	10356-10357	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-19	10358-10365	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-20	10365-10366	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-21	10367-10382	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-22	10382-10383	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-23	10384-10386	MP	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-24	10386-10387	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-25	10388-10390	at	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-26	10391-10396	least	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-27	10397-10401	once	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-28	10402-10405	but	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-29	10406-10408	no	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-30	10409-10417	presence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-31	10418-10420	or	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-32	10421-10428	history	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-33	10429-10431	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-34	10432-10437	other	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-35	10438-10447	substance	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-36	10448-10451	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-37	10452-10461	disorders	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-38	10462-10466	than	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-39	10467-10475	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
43-40	10475-10476	.	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	

#Text=CUD and HC were excluded if they had current or a history of neurological disease of central origin or psychiatric disease including seizures, high levels of anxiety, panic attacks, psychosis; current medical illness that may affect brain function; current or history of cardiovascular disease; head trauma with loss of consciousness >30 min; urine positive for psychoactive drugs; and history of vascular headaches.
44-1	10477-10480	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[11]	
44-2	10481-10484	and	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-3	10485-10487	HC	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
44-4	10488-10492	were	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-5	10493-10501	excluded	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-6	10502-10504	if	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-7	10505-10509	they	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-8	10510-10513	had	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-9	10514-10521	current	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-10	10522-10524	or	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-11	10525-10526	a	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-12	10527-10534	history	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-13	10535-10537	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-14	10538-10550	neurological	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-15	10551-10558	disease	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-16	10559-10561	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-17	10562-10569	central	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-18	10570-10576	origin	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-19	10577-10579	or	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-20	10580-10591	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-21	10592-10599	disease	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-22	10600-10609	including	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-23	10610-10618	seizures	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-24	10618-10619	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-25	10620-10624	high	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-26	10625-10631	levels	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-27	10632-10634	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-28	10635-10642	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-29	10642-10643	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-30	10644-10649	panic	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-31	10650-10657	attacks	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-32	10657-10658	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-33	10659-10668	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-34	10668-10669	;	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-35	10670-10677	current	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-36	10678-10685	medical	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-37	10686-10693	illness	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-38	10694-10698	that	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-39	10699-10702	may	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-40	10703-10709	affect	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-41	10710-10715	brain	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-42	10716-10724	function	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-43	10724-10725	;	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-44	10726-10733	current	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-45	10734-10736	or	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-46	10737-10744	history	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-47	10745-10747	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-48	10748-10762	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-49	10763-10770	disease	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-50	10770-10771	;	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-51	10772-10776	head	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-52	10777-10783	trauma	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-53	10784-10788	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-54	10789-10793	loss	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-55	10794-10796	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-56	10797-10810	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-57	10811-10812	>	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-58	10812-10814	30	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-59	10815-10818	min	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-60	10818-10819	;	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-61	10820-10825	urine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-62	10826-10834	positive	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-63	10835-10838	for	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-64	10839-10851	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-65	10852-10857	drugs	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-66	10857-10858	;	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-67	10859-10862	and	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-68	10863-10870	history	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-69	10871-10873	of	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-70	10874-10882	vascular	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-71	10883-10892	headaches	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
44-72	10892-10893	.	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	

#Text=Study design
#Text=Participants were scanned with 4 PET scans and [11C]raclopride after MP (0.5 mg/kg iv) or PL.
45-1	10894-10899	Study	_	
45-2	10900-10906	design	_	
45-3	10907-10919	Participants	_	
45-4	10920-10924	were	_	
45-5	10925-10932	scanned	_	
45-6	10933-10937	with	_	
45-7	10938-10939	4	_	
45-8	10940-10943	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
45-9	10944-10949	scans	_	
45-10	10950-10953	and	_	
45-11	10954-10955	[	_	
45-12	10955-10958	11C	_	
45-13	10958-10959	]	_	
45-14	10959-10969	raclopride	_	
45-15	10970-10975	after	_	
45-16	10976-10978	MP	_	
45-17	10979-10980	(	_	
45-18	10980-10983	0.5	_	
45-19	10984-10986	mg	_	
45-20	10986-10987	/	_	
45-21	10987-10989	kg	_	
45-22	10990-10992	iv	_	
45-23	10992-10993	)	_	
45-24	10994-10996	or	_	
45-25	10997-10999	PL	_	
45-26	10999-11000	.	_	

#Text=Brain DA D2R availability was measured in 2 days under 4 conditions on two different days: (1) PL/PL: expecting PL and receiving PL, (2) PL/MP: expecting PL and receiving MP, (3) MP/PL: expecting MP and receiving PL, (4) MP/MP: expecting MP and receiving MP.
46-1	11001-11006	Brain	_	
46-2	11007-11009	DA	_	
46-3	11010-11013	D2R	_	
46-4	11014-11026	availability	_	
46-5	11027-11030	was	_	
46-6	11031-11039	measured	_	
46-7	11040-11042	in	_	
46-8	11043-11044	2	_	
46-9	11045-11049	days	_	
46-10	11050-11055	under	_	
46-11	11056-11057	4	_	
46-12	11058-11068	conditions	_	
46-13	11069-11071	on	_	
46-14	11072-11075	two	_	
46-15	11076-11085	different	_	
46-16	11086-11090	days	_	
46-17	11090-11091	:	_	
46-18	11092-11093	(	_	
46-19	11093-11094	1	_	
46-20	11094-11095	)	_	
46-21	11096-11098	PL	_	
46-22	11098-11099	/	_	
46-23	11099-11101	PL	_	
46-24	11101-11102	:	_	
46-25	11103-11112	expecting	_	
46-26	11113-11115	PL	_	
46-27	11116-11119	and	_	
46-28	11120-11129	receiving	_	
46-29	11130-11132	PL	_	
46-30	11132-11133	,	_	
46-31	11134-11135	(	_	
46-32	11135-11136	2	_	
46-33	11136-11137	)	_	
46-34	11138-11140	PL	_	
46-35	11140-11141	/	_	
46-36	11141-11143	MP	_	
46-37	11143-11144	:	_	
46-38	11145-11154	expecting	_	
46-39	11155-11157	PL	_	
46-40	11158-11161	and	_	
46-41	11162-11171	receiving	_	
46-42	11172-11174	MP	_	
46-43	11174-11175	,	_	
46-44	11176-11177	(	_	
46-45	11177-11178	3	_	
46-46	11178-11179	)	_	
46-47	11180-11182	MP	_	
46-48	11182-11183	/	_	
46-49	11183-11185	PL	_	
46-50	11185-11186	:	_	
46-51	11187-11196	expecting	_	
46-52	11197-11199	MP	_	
46-53	11200-11203	and	_	
46-54	11204-11213	receiving	_	
46-55	11214-11216	PL	_	
46-56	11216-11217	,	_	
46-57	11218-11219	(	_	
46-58	11219-11220	4	_	
46-59	11220-11221	)	_	
46-60	11222-11224	MP	_	
46-61	11224-11225	/	_	
46-62	11225-11227	MP	_	
46-63	11227-11228	:	_	
46-64	11229-11238	expecting	_	
46-65	11239-11241	MP	_	
46-66	11242-11245	and	_	
46-67	11246-11255	receiving	_	
46-68	11256-11258	MP	_	
46-69	11258-11259	.	_	

#Text=The order of sessions was pseudo-randomized over 2 days and equally distributed over diagnostic groups.
47-1	11260-11263	The	_	
47-2	11264-11269	order	_	
47-3	11270-11272	of	_	
47-4	11273-11281	sessions	_	
47-5	11282-11285	was	_	
47-6	11286-11303	pseudo-randomized	_	
47-7	11304-11308	over	_	
47-8	11309-11310	2	_	
47-9	11311-11315	days	_	
47-10	11316-11319	and	_	
47-11	11320-11327	equally	_	
47-12	11328-11339	distributed	_	
47-13	11340-11344	over	_	
47-14	11345-11355	diagnostic	_	
47-15	11356-11362	groups	_	
47-16	11362-11363	.	_	

#Text=For practical reasons, receiving MP was always provided after receiving PL (always the second scan on a given day) to avoid the pharmacological effects of MP that would otherwise affect the following scan, providing the following combinations: day A: PL/PL following PL/MP and day B: MP/PL following MP/MP; or day A: PL/PL following MP/MP and day B: MP/PL following PL/MP.
48-1	11364-11367	For	_	
48-2	11368-11377	practical	_	
48-3	11378-11385	reasons	_	
48-4	11385-11386	,	_	
48-5	11387-11396	receiving	_	
48-6	11397-11399	MP	_	
48-7	11400-11403	was	_	
48-8	11404-11410	always	_	
48-9	11411-11419	provided	_	
48-10	11420-11425	after	_	
48-11	11426-11435	receiving	_	
48-12	11436-11438	PL	_	
48-13	11439-11440	(	_	
48-14	11440-11446	always	_	
48-15	11447-11450	the	_	
48-16	11451-11457	second	_	
48-17	11458-11462	scan	_	
48-18	11463-11465	on	_	
48-19	11466-11467	a	_	
48-20	11468-11473	given	_	
48-21	11474-11477	day	_	
48-22	11477-11478	)	_	
48-23	11479-11481	to	_	
48-24	11482-11487	avoid	_	
48-25	11488-11491	the	_	
48-26	11492-11507	pharmacological	_	
48-27	11508-11515	effects	_	
48-28	11516-11518	of	_	
48-29	11519-11521	MP	_	
48-30	11522-11526	that	_	
48-31	11527-11532	would	_	
48-32	11533-11542	otherwise	_	
48-33	11543-11549	affect	_	
48-34	11550-11553	the	_	
48-35	11554-11563	following	_	
48-36	11564-11568	scan	_	
48-37	11568-11569	,	_	
48-38	11570-11579	providing	_	
48-39	11580-11583	the	_	
48-40	11584-11593	following	_	
48-41	11594-11606	combinations	_	
48-42	11606-11607	:	_	
48-43	11608-11611	day	_	
48-44	11612-11613	A	_	
48-45	11613-11614	:	_	
48-46	11615-11617	PL	_	
48-47	11617-11618	/	_	
48-48	11618-11620	PL	_	
48-49	11621-11630	following	_	
48-50	11631-11633	PL	_	
48-51	11633-11634	/	_	
48-52	11634-11636	MP	_	
48-53	11637-11640	and	_	
48-54	11641-11644	day	_	
48-55	11645-11646	B	_	
48-56	11646-11647	:	_	
48-57	11648-11650	MP	_	
48-58	11650-11651	/	_	
48-59	11651-11653	PL	_	
48-60	11654-11663	following	_	
48-61	11664-11666	MP	_	
48-62	11666-11667	/	_	
48-63	11667-11669	MP	_	
48-64	11669-11670	;	_	
48-65	11671-11673	or	_	
48-66	11674-11677	day	_	
48-67	11678-11679	A	_	
48-68	11679-11680	:	_	
48-69	11681-11683	PL	_	
48-70	11683-11684	/	_	
48-71	11684-11686	PL	_	
48-72	11687-11696	following	_	
48-73	11697-11699	MP	_	
48-74	11699-11700	/	_	
48-75	11700-11702	MP	_	
48-76	11703-11706	and	_	
48-77	11707-11710	day	_	
48-78	11711-11712	B	_	
48-79	11712-11713	:	_	
48-80	11714-11716	MP	_	
48-81	11716-11717	/	_	
48-82	11717-11719	PL	_	
48-83	11720-11729	following	_	
48-84	11730-11732	PL	_	
48-85	11732-11733	/	_	
48-86	11733-11735	MP	_	
48-87	11735-11736	.	_	

#Text=MP (0.5 mg/kg) or PL (saline 3.0 ml) was administrated iv for 30 s.
49-1	11737-11739	MP	_	
49-2	11740-11741	(	_	
49-3	11741-11744	0.5	_	
49-4	11745-11747	mg	_	
49-5	11747-11748	/	_	
49-6	11748-11750	kg	_	
49-7	11750-11751	)	_	
49-8	11752-11754	or	_	
49-9	11755-11757	PL	_	
49-10	11758-11759	(	_	
49-11	11759-11765	saline	_	
49-12	11766-11769	3.0	_	
49-13	11770-11772	ml	_	
49-14	11772-11773	)	_	
49-15	11774-11777	was	_	
49-16	11778-11791	administrated	_	
49-17	11792-11794	iv	_	
49-18	11795-11798	for	_	
49-19	11799-11801	30	_	
49-20	11802-11803	s	_	
49-21	11803-11804	.	_	

#Text=Drug expectation
#Text=Thirty minutes before the injections, participants were told by the experimenter which injection they would receive (PL or MP).
50-1	11805-11809	Drug	_	
50-2	11810-11821	expectation	_	
50-3	11822-11828	Thirty	_	
50-4	11829-11836	minutes	_	
50-5	11837-11843	before	_	
50-6	11844-11847	the	_	
50-7	11848-11858	injections	_	
50-8	11858-11859	,	_	
50-9	11860-11872	participants	_	
50-10	11873-11877	were	_	
50-11	11878-11882	told	_	
50-12	11883-11885	by	_	
50-13	11886-11889	the	_	
50-14	11890-11902	experimenter	_	
50-15	11903-11908	which	_	
50-16	11909-11918	injection	_	
50-17	11919-11923	they	_	
50-18	11924-11929	would	_	
50-19	11930-11937	receive	_	
50-20	11938-11939	(	_	
50-21	11939-11941	PL	_	
50-22	11942-11944	or	_	
50-23	11945-11947	MP	_	
50-24	11947-11948	)	_	
50-25	11948-11949	.	_	

#Text=Participants were also told that there was a chance that they would be deceived.
51-1	11950-11962	Participants	_	
51-2	11963-11967	were	_	
51-3	11968-11972	also	_	
51-4	11973-11977	told	_	
51-5	11978-11982	that	_	
51-6	11983-11988	there	_	
51-7	11989-11992	was	_	
51-8	11993-11994	a	_	
51-9	11995-12001	chance	_	
51-10	12002-12006	that	_	
51-11	12007-12011	they	_	
51-12	12012-12017	would	_	
51-13	12018-12020	be	_	
51-14	12021-12029	deceived	_	
51-15	12029-12030	.	_	

#Text=Participants were not debriefed after their scans to minimize learning effects on the effects of MP or PL.
52-1	12031-12043	Participants	_	
52-2	12044-12048	were	_	
52-3	12049-12052	not	_	
52-4	12053-12062	debriefed	_	
52-5	12063-12068	after	_	
52-6	12069-12074	their	_	
52-7	12075-12080	scans	_	
52-8	12081-12083	to	_	
52-9	12084-12092	minimize	_	
52-10	12093-12101	learning	_	
52-11	12102-12109	effects	_	
52-12	12110-12112	on	_	
52-13	12113-12116	the	_	
52-14	12117-12124	effects	_	
52-15	12125-12127	of	_	
52-16	12128-12130	MP	_	
52-17	12131-12133	or	_	
52-18	12134-12136	PL	_	
52-19	12136-12137	.	_	

#Text=Plasma MP concentrations, cardiovascular, and self-report ratings
#Text=Blood samples were obtained to measure plasma MP concentration prior to and at 15, 30, 45, and 60 min after MP.
53-1	12138-12144	Plasma	_	
53-2	12145-12147	MP	_	
53-3	12148-12162	concentrations	_	
53-4	12162-12163	,	_	
53-5	12164-12178	cardiovascular	_	
53-6	12178-12179	,	_	
53-7	12180-12183	and	_	
53-8	12184-12195	self-report	_	
53-9	12196-12203	ratings	_	
53-10	12204-12209	Blood	_	
53-11	12210-12217	samples	_	
53-12	12218-12222	were	_	
53-13	12223-12231	obtained	_	
53-14	12232-12234	to	_	
53-15	12235-12242	measure	_	
53-16	12243-12249	plasma	_	
53-17	12250-12252	MP	_	
53-18	12253-12266	concentration	_	
53-19	12267-12272	prior	_	
53-20	12273-12275	to	_	
53-21	12276-12279	and	_	
53-22	12280-12282	at	_	
53-23	12283-12285	15	_	
53-24	12285-12286	,	_	
53-25	12287-12289	30	_	
53-26	12289-12290	,	_	
53-27	12291-12293	45	_	
53-28	12293-12294	,	_	
53-29	12295-12298	and	_	
53-30	12299-12301	60	_	
53-31	12302-12305	min	_	
53-32	12306-12311	after	_	
53-33	12312-12314	MP	_	
53-34	12314-12315	.	_	

#Text=The plasma concentration of MP was analyzed at Dr.
54-1	12316-12319	The	_	
54-2	12320-12326	plasma	_	
54-3	12327-12340	concentration	_	
54-4	12341-12343	of	_	
54-5	12344-12346	MP	_	
54-6	12347-12350	was	_	
54-7	12351-12359	analyzed	_	
54-8	12360-12362	at	_	
54-9	12363-12365	Dr	_	
54-10	12365-12366	.	_	

#Text=Thomas Cooper’s laboratory (Nathan Kline Institute, New York).
55-1	12367-12373	Thomas	_	
55-2	12374-12380	Cooper	_	
55-3	12380-12381	’	_	
55-4	12381-12382	s	_	
55-5	12383-12393	laboratory	_	
55-6	12394-12395	(	_	
55-7	12395-12401	Nathan	_	
55-8	12402-12407	Kline	_	
55-9	12408-12417	Institute	_	
55-10	12417-12418	,	_	
55-11	12419-12422	New	_	
55-12	12423-12427	York	_	
55-13	12427-12428	)	_	
55-14	12428-12429	.	_	

#Text=In addition, cardiovascular responses (i.e., heart rate, blood pressure, and EKG lead II) and self-report ratings (i.e., high, rush, anxious) to MP and PL were recorded prior to their injection and then every minute for the first 20 min after injection, then every 5 min at the end of the MP and PL PET scans.
56-1	12430-12432	In	_	
56-2	12433-12441	addition	_	
56-3	12441-12442	,	_	
56-4	12443-12457	cardiovascular	_	
56-5	12458-12467	responses	_	
56-6	12468-12469	(	_	
56-7	12469-12472	i.e	_	
56-8	12472-12473	.	_	
56-9	12473-12474	,	_	
56-10	12475-12480	heart	_	
56-11	12481-12485	rate	_	
56-12	12485-12486	,	_	
56-13	12487-12492	blood	_	
56-14	12493-12501	pressure	_	
56-15	12501-12502	,	_	
56-16	12503-12506	and	_	
56-17	12507-12510	EKG	_	
56-18	12511-12515	lead	_	
56-19	12516-12518	II	_	
56-20	12518-12519	)	_	
56-21	12520-12523	and	_	
56-22	12524-12535	self-report	_	
56-23	12536-12543	ratings	_	
56-24	12544-12545	(	_	
56-25	12545-12548	i.e	_	
56-26	12548-12549	.	_	
56-27	12549-12550	,	_	
56-28	12551-12555	high	_	
56-29	12555-12556	,	_	
56-30	12557-12561	rush	_	
56-31	12561-12562	,	_	
56-32	12563-12570	anxious	_	
56-33	12570-12571	)	_	
56-34	12572-12574	to	_	
56-35	12575-12577	MP	_	
56-36	12578-12581	and	_	
56-37	12582-12584	PL	_	
56-38	12585-12589	were	_	
56-39	12590-12598	recorded	_	
56-40	12599-12604	prior	_	
56-41	12605-12607	to	_	
56-42	12608-12613	their	_	
56-43	12614-12623	injection	_	
56-44	12624-12627	and	_	
56-45	12628-12632	then	_	
56-46	12633-12638	every	_	
56-47	12639-12645	minute	_	
56-48	12646-12649	for	_	
56-49	12650-12653	the	_	
56-50	12654-12659	first	_	
56-51	12660-12662	20	_	
56-52	12663-12666	min	_	
56-53	12667-12672	after	_	
56-54	12673-12682	injection	_	
56-55	12682-12683	,	_	
56-56	12684-12688	then	_	
56-57	12689-12694	every	_	
56-58	12695-12696	5	_	
56-59	12697-12700	min	_	
56-60	12701-12703	at	_	
56-61	12704-12707	the	_	
56-62	12708-12711	end	_	
56-63	12712-12714	of	_	
56-64	12715-12718	the	_	
56-65	12719-12721	MP	_	
56-66	12722-12725	and	_	
56-67	12726-12728	PL	_	
56-68	12729-12732	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
56-69	12733-12738	scans	_	
56-70	12738-12739	.	_	

#Text=Effects of MP on cardiovascular responses and self-report ratings were tested by comparing the average scores obtained between 0 and 60 min after iv PL and MP administration using a mixed analysis of variance (ANOVA) with Group × Challenge × Expectation in SPSS 22 (IBM, Armonk, NY).
57-1	12740-12747	Effects	_	
57-2	12748-12750	of	_	
57-3	12751-12753	MP	_	
57-4	12754-12756	on	_	
57-5	12757-12771	cardiovascular	_	
57-6	12772-12781	responses	_	
57-7	12782-12785	and	_	
57-8	12786-12797	self-report	_	
57-9	12798-12805	ratings	_	
57-10	12806-12810	were	_	
57-11	12811-12817	tested	_	
57-12	12818-12820	by	_	
57-13	12821-12830	comparing	_	
57-14	12831-12834	the	_	
57-15	12835-12842	average	_	
57-16	12843-12849	scores	_	
57-17	12850-12858	obtained	_	
57-18	12859-12866	between	_	
57-19	12867-12868	0	_	
57-20	12869-12872	and	_	
57-21	12873-12875	60	_	
57-22	12876-12879	min	_	
57-23	12880-12885	after	_	
57-24	12886-12888	iv	_	
57-25	12889-12891	PL	_	
57-26	12892-12895	and	_	
57-27	12896-12898	MP	_	
57-28	12899-12913	administration	_	
57-29	12914-12919	using	_	
57-30	12920-12921	a	_	
57-31	12922-12927	mixed	_	
57-32	12928-12936	analysis	_	
57-33	12937-12939	of	_	
57-34	12940-12948	variance	_	
57-35	12949-12950	(	_	
57-36	12950-12955	ANOVA	_	
57-37	12955-12956	)	_	
57-38	12957-12961	with	_	
57-39	12962-12967	Group	_	
57-40	12968-12969	×	_	
57-41	12970-12979	Challenge	_	
57-42	12980-12981	×	_	
57-43	12982-12993	Expectation	_	
57-44	12994-12996	in	_	
57-45	12997-13001	SPSS	_	
57-46	13002-13004	22	_	
57-47	13005-13006	(	_	
57-48	13006-13009	IBM	_	
57-49	13009-13010	,	_	
57-50	13011-13017	Armonk	_	
57-51	13017-13018	,	_	
57-52	13019-13021	NY	_	
57-53	13021-13022	)	_	
57-54	13022-13023	.	_	

#Text=Post hoc t tests were performed to determine the direction of findings.
58-1	13024-13028	Post	_	
58-2	13029-13032	hoc	_	
58-3	13033-13034	t	_	
58-4	13035-13040	tests	_	
58-5	13041-13045	were	_	
58-6	13046-13055	performed	_	
58-7	13056-13058	to	_	
58-8	13059-13068	determine	_	
58-9	13069-13072	the	_	
58-10	13073-13082	direction	_	
58-11	13083-13085	of	_	
58-12	13086-13094	findings	_	
58-13	13094-13095	.	_	

#Text=Cardiac data and self-reports were further correlated with MP-induced changes in striatal non-displaceable binding potential (BPND).
59-1	13096-13103	Cardiac	_	
59-2	13104-13108	data	_	
59-3	13109-13112	and	_	
59-4	13113-13125	self-reports	_	
59-5	13126-13130	were	_	
59-6	13131-13138	further	_	
59-7	13139-13149	correlated	_	
59-8	13150-13154	with	_	
59-9	13155-13165	MP-induced	_	
59-10	13166-13173	changes	_	
59-11	13174-13176	in	_	
59-12	13177-13185	striatal	_	
59-13	13186-13202	non-displaceable	_	
59-14	13203-13210	binding	_	
59-15	13211-13220	potential	_	
59-16	13221-13222	(	_	
59-17	13222-13226	BPND	_	
59-18	13226-13227	)	_	
59-19	13227-13228	.	_	

#Text=PET scanning and processing
#Text=PET scans were started at 2 min after PL or MP administration for 1 h.
60-1	13229-13232	PET	_	
60-2	13233-13241	scanning	_	
60-3	13242-13245	and	_	
60-4	13246-13256	processing	_	
60-5	13257-13260	PET	_	
60-6	13261-13266	scans	_	
60-7	13267-13271	were	_	
60-8	13272-13279	started	_	
60-9	13280-13282	at	_	
60-10	13283-13284	2	_	
60-11	13285-13288	min	_	
60-12	13289-13294	after	_	
60-13	13295-13297	PL	_	
60-14	13298-13300	or	_	
60-15	13301-13303	MP	_	
60-16	13304-13318	administration	_	
60-17	13319-13322	for	_	
60-18	13323-13324	1	_	
60-19	13325-13326	h	_	
60-20	13326-13327	.	_	

#Text=Dynamic emission scans were done using the Siemens HR+ tomograph (4.5 × 4.5 × 4.2 mm3; three-dimensional acquisition mode) and were started after iv injection of ~7 mCi of [11C]raclopride.
61-1	13328-13335	Dynamic	_	
61-2	13336-13344	emission	_	
61-3	13345-13350	scans	_	
61-4	13351-13355	were	_	
61-5	13356-13360	done	_	
61-6	13361-13366	using	_	
61-7	13367-13370	the	_	
61-8	13371-13378	Siemens	_	
61-9	13379-13381	HR	_	
61-10	13381-13382	+	_	
61-11	13383-13392	tomograph	_	
61-12	13393-13394	(	_	
61-13	13394-13397	4.5	_	
61-14	13398-13399	×	_	
61-15	13400-13403	4.5	_	
61-16	13404-13405	×	_	
61-17	13406-13409	4.2	_	
61-18	13410-13413	mm3	_	
61-19	13413-13414	;	_	
61-20	13415-13432	three-dimensional	_	
61-21	13433-13444	acquisition	_	
61-22	13445-13449	mode	_	
61-23	13449-13450	)	_	
61-24	13451-13454	and	_	
61-25	13455-13459	were	_	
61-26	13460-13467	started	_	
61-27	13468-13473	after	_	
61-28	13474-13476	iv	_	
61-29	13477-13486	injection	_	
61-30	13487-13489	of	_	
61-31	13490-13491	~	_	
61-32	13491-13492	7	_	
61-33	13493-13496	mCi	_	
61-34	13497-13499	of	_	
61-35	13500-13501	[	_	
61-36	13501-13504	11C	_	
61-37	13504-13505	]	_	
61-38	13505-13515	raclopride	_	
61-39	13515-13516	.	_	

#Text=Twenty dynamic emission scans were obtained from the time of injection up to 60 min, which has been our standard procedure for [11C]raclopride scans, and included 15 1-min, 3 5-min and 2 15-min scans.
62-1	13517-13523	Twenty	_	
62-2	13524-13531	dynamic	_	
62-3	13532-13540	emission	_	
62-4	13541-13546	scans	_	
62-5	13547-13551	were	_	
62-6	13552-13560	obtained	_	
62-7	13561-13565	from	_	
62-8	13566-13569	the	_	
62-9	13570-13574	time	_	
62-10	13575-13577	of	_	
62-11	13578-13587	injection	_	
62-12	13588-13590	up	_	
62-13	13591-13593	to	_	
62-14	13594-13596	60	_	
62-15	13597-13600	min	_	
62-16	13600-13601	,	_	
62-17	13602-13607	which	_	
62-18	13608-13611	has	_	
62-19	13612-13616	been	_	
62-20	13617-13620	our	_	
62-21	13621-13629	standard	_	
62-22	13630-13639	procedure	_	
62-23	13640-13643	for	_	
62-24	13644-13645	[	_	
62-25	13645-13648	11C	_	
62-26	13648-13649	]	_	
62-27	13649-13659	raclopride	_	
62-28	13660-13665	scans	_	
62-29	13665-13666	,	_	
62-30	13667-13670	and	_	
62-31	13671-13679	included	_	
62-32	13680-13682	15	_	
62-33	13683-13684	1	_	
62-34	13684-13685	-	_	
62-35	13685-13688	min	_	
62-36	13688-13689	,	_	
62-37	13690-13691	3	_	
62-38	13692-13693	5	_	
62-39	13693-13694	-	_	
62-40	13694-13697	min	_	
62-41	13698-13701	and	_	
62-42	13702-13703	2	_	
62-43	13704-13706	15	_	
62-44	13706-13707	-	_	
62-45	13707-13710	min	_	
62-46	13711-13716	scans	_	
62-47	13716-13717	.	_	

#Text=There were 120 min between injections, thus 60 min of break between scans.
63-1	13718-13723	There	_	
63-2	13724-13728	were	_	
63-3	13729-13732	120	_	
63-4	13733-13736	min	_	
63-5	13737-13744	between	_	
63-6	13745-13755	injections	_	
63-7	13755-13756	,	_	
63-8	13757-13761	thus	_	
63-9	13762-13764	60	_	
63-10	13765-13768	min	_	
63-11	13769-13771	of	_	
63-12	13772-13777	break	_	
63-13	13778-13785	between	_	
63-14	13786-13791	scans	_	
63-15	13791-13792	.	_	

#Text=We normalized the distribution volume (DV) in each voxel to that in the cerebellum (left and right regions of interest (ROIs)) to compute the DV ratio (DVR) images.
64-1	13793-13795	We	_	
64-2	13796-13806	normalized	_	
64-3	13807-13810	the	_	
64-4	13811-13823	distribution	_	
64-5	13824-13830	volume	_	
64-6	13831-13832	(	_	
64-7	13832-13834	DV	_	
64-8	13834-13835	)	_	
64-9	13836-13838	in	_	
64-10	13839-13843	each	_	
64-11	13844-13849	voxel	_	
64-12	13850-13852	to	_	
64-13	13853-13857	that	_	
64-14	13858-13860	in	_	
64-15	13861-13864	the	_	
64-16	13865-13875	cerebellum	_	
64-17	13876-13877	(	_	
64-18	13877-13881	left	_	
64-19	13882-13885	and	_	
64-20	13886-13891	right	_	
64-21	13892-13899	regions	_	
64-22	13900-13902	of	_	
64-23	13903-13911	interest	_	
64-24	13912-13913	(	_	
64-25	13913-13917	ROIs	_	
64-26	13917-13918	)	_	
64-27	13918-13919	)	_	
64-28	13920-13922	to	_	
64-29	13923-13930	compute	_	
64-30	13931-13934	the	_	
64-31	13935-13937	DV	_	
64-32	13938-13943	ratio	_	
64-33	13944-13945	(	_	
64-34	13945-13948	DVR	_	
64-35	13948-13949	)	_	
64-36	13950-13956	images	_	
64-37	13956-13957	.	_	

#Text=DVR images were spatially normalized (2-mm isotropic voxels) to the stereotactic space of the Montreal Neurological Institute (MNI) using a 12-parameter affine transformation and a DVR template and spatially smoothed (full width half maximum, FWHM = 8 mm) in SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK).
65-1	13958-13961	DVR	_	
65-2	13962-13968	images	_	
65-3	13969-13973	were	_	
65-4	13974-13983	spatially	_	
65-5	13984-13994	normalized	_	
65-6	13995-13996	(	_	
65-7	13996-13997	2	_	
65-8	13997-13998	-	_	
65-9	13998-14000	mm	_	
65-10	14001-14010	isotropic	_	
65-11	14011-14017	voxels	_	
65-12	14017-14018	)	_	
65-13	14019-14021	to	_	
65-14	14022-14025	the	_	
65-15	14026-14038	stereotactic	_	
65-16	14039-14044	space	_	
65-17	14045-14047	of	_	
65-18	14048-14051	the	_	
65-19	14052-14060	Montreal	_	
65-20	14061-14073	Neurological	_	
65-21	14074-14083	Institute	_	
65-22	14084-14085	(	_	
65-23	14085-14088	MNI	_	
65-24	14088-14089	)	_	
65-25	14090-14095	using	_	
65-26	14096-14097	a	_	
65-27	14098-14100	12	_	
65-28	14100-14101	-	_	
65-29	14101-14110	parameter	_	
65-30	14111-14117	affine	_	
65-31	14118-14132	transformation	_	
65-32	14133-14136	and	_	
65-33	14137-14138	a	_	
65-34	14139-14142	DVR	_	
65-35	14143-14151	template	_	
65-36	14152-14155	and	_	
65-37	14156-14165	spatially	_	
65-38	14166-14174	smoothed	_	
65-39	14175-14176	(	_	
65-40	14176-14180	full	_	
65-41	14181-14186	width	_	
65-42	14187-14191	half	_	
65-43	14192-14199	maximum	_	
65-44	14199-14200	,	_	
65-45	14201-14205	FWHM	_	
65-46	14206-14207	=	_	
65-47	14208-14209	8	_	
65-48	14210-14212	mm	_	
65-49	14212-14213	)	_	
65-50	14214-14216	in	_	
65-51	14217-14221	SPM8	_	
65-52	14222-14223	(	_	
65-53	14223-14231	Wellcome	_	
65-54	14232-14237	Trust	_	
65-55	14238-14244	Centre	_	
65-56	14245-14248	for	_	
65-57	14249-14261	Neuroimaging	_	
65-58	14261-14262	,	_	
65-59	14263-14269	London	_	
65-60	14269-14270	,	_	
65-61	14271-14273	UK	_	
65-62	14273-14274	)	_	
65-63	14274-14275	.	_	

#Text=The DVR template was developed from DVR images of 34 healthy subjects that were acquired with [11C]raclopride using the same PET scanning sequence.
66-1	14276-14279	The	_	
66-2	14280-14283	DVR	_	
66-3	14284-14292	template	_	
66-4	14293-14296	was	_	
66-5	14297-14306	developed	_	
66-6	14307-14311	from	_	
66-7	14312-14315	DVR	_	
66-8	14316-14322	images	_	
66-9	14323-14325	of	_	
66-10	14326-14328	34	_	
66-11	14329-14336	healthy	_	
66-12	14337-14345	subjects	_	
66-13	14346-14350	that	_	
66-14	14351-14355	were	_	
66-15	14356-14364	acquired	_	
66-16	14365-14369	with	_	
66-17	14370-14371	[	_	
66-18	14371-14374	11C	_	
66-19	14374-14375	]	_	
66-20	14375-14385	raclopride	_	
66-21	14386-14391	using	_	
66-22	14392-14395	the	_	
66-23	14396-14400	same	_	
66-24	14401-14404	PET	_	
66-25	14405-14413	scanning	_	
66-26	14414-14422	sequence	_	
66-27	14422-14423	.	_	

#Text=Specifically, all 34 images were carefully inspected to ensure whole-brain coverage and images with potential artifacts were excluded.
67-1	14424-14436	Specifically	_	
67-2	14436-14437	,	_	
67-3	14438-14441	all	_	
67-4	14442-14444	34	_	
67-5	14445-14451	images	_	
67-6	14452-14456	were	_	
67-7	14457-14466	carefully	_	
67-8	14467-14476	inspected	_	
67-9	14477-14479	to	_	
67-10	14480-14486	ensure	_	
67-11	14487-14498	whole-brain	_	
67-12	14499-14507	coverage	_	
67-13	14508-14511	and	_	
67-14	14512-14518	images	_	
67-15	14519-14523	with	_	
67-16	14524-14533	potential	_	
67-17	14534-14543	artifacts	_	
67-18	14544-14548	were	_	
67-19	14549-14557	excluded	_	
67-20	14557-14558	.	_	

#Text=A 12-parameter affine transformation with 16 nonlinear iterations was used to register the 34 images to the PD.mnc MNI template provided with the SPM8 package.
68-1	14559-14560	A	_	
68-2	14561-14563	12	_	
68-3	14563-14564	-	_	
68-4	14564-14573	parameter	_	
68-5	14574-14580	affine	_	
68-6	14581-14595	transformation	_	
68-7	14596-14600	with	_	
68-8	14601-14603	16	_	
68-9	14604-14613	nonlinear	_	
68-10	14614-14624	iterations	_	
68-11	14625-14628	was	_	
68-12	14629-14633	used	_	
68-13	14634-14636	to	_	
68-14	14637-14645	register	_	
68-15	14646-14649	the	_	
68-16	14650-14652	34	_	
68-17	14653-14659	images	_	
68-18	14660-14662	to	_	
68-19	14663-14666	the	_	
68-20	14667-14673	PD.mnc	_	
68-21	14674-14677	MNI	_	
68-22	14678-14686	template	_	
68-23	14687-14695	provided	_	
68-24	14696-14700	with	_	
68-25	14701-14704	the	_	
68-26	14705-14709	SPM8	_	
68-27	14710-14717	package	_	
68-28	14717-14718	.	_	

#Text=The images were resliced using the bounding box: x = 90:90 mm, y = 126:90 mm, and z = 72:108 mm and a voxel size of 2 × 2 × 2 mm3 using bilinear interpolation, averaged and smoothed (FWHM = 8 mm) to compute BPND in MNI space, which corresponds to D2R availability.
69-1	14719-14722	The	_	
69-2	14723-14729	images	_	
69-3	14730-14734	were	_	
69-4	14735-14743	resliced	_	
69-5	14744-14749	using	_	
69-6	14750-14753	the	_	
69-7	14754-14762	bounding	_	
69-8	14763-14766	box	_	
69-9	14766-14767	:	_	
69-10	14768-14769	x	_	
69-11	14770-14771	=	_	
69-12	14772-14774	90	_	
69-13	14774-14775	:	_	
69-14	14775-14777	90	_	
69-15	14778-14780	mm	_	
69-16	14780-14781	,	_	
69-17	14782-14783	y	_	
69-18	14784-14785	=	_	
69-19	14786-14789	126	_	
69-20	14789-14790	:	_	
69-21	14790-14792	90	_	
69-22	14793-14795	mm	_	
69-23	14795-14796	,	_	
69-24	14797-14800	and	_	
69-25	14801-14802	z	_	
69-26	14803-14804	=	_	
69-27	14805-14807	72	_	
69-28	14807-14808	:	_	
69-29	14808-14811	108	_	
69-30	14812-14814	mm	_	
69-31	14815-14818	and	_	
69-32	14819-14820	a	_	
69-33	14821-14826	voxel	_	
69-34	14827-14831	size	_	
69-35	14832-14834	of	_	
69-36	14835-14836	2	_	
69-37	14837-14838	×	_	
69-38	14839-14840	2	_	
69-39	14841-14842	×	_	
69-40	14843-14844	2	_	
69-41	14845-14848	mm3	_	
69-42	14849-14854	using	_	
69-43	14855-14863	bilinear	_	
69-44	14864-14877	interpolation	_	
69-45	14877-14878	,	_	
69-46	14879-14887	averaged	_	
69-47	14888-14891	and	_	
69-48	14892-14900	smoothed	_	
69-49	14901-14902	(	_	
69-50	14902-14906	FWHM	_	
69-51	14907-14908	=	_	
69-52	14909-14910	8	_	
69-53	14911-14913	mm	_	
69-54	14913-14914	)	_	
69-55	14915-14917	to	_	
69-56	14918-14925	compute	_	
69-57	14926-14930	BPND	_	
69-58	14931-14933	in	_	
69-59	14934-14937	MNI	_	
69-60	14938-14943	space	_	
69-61	14943-14944	,	_	
69-62	14945-14950	which	_	
69-63	14951-14962	corresponds	_	
69-64	14963-14965	to	_	
69-65	14966-14969	D2R	_	
69-66	14970-14982	availability	_	
69-67	14982-14983	.	_	

#Text=This left each participant with 4 BPND scans: (1) expecting PL/receiving PL, (2) expecting PL/receiving MP, (3) expecting MP/receiving PL, (4) expecting MP/receiving MP.
70-1	14984-14988	This	_	
70-2	14989-14993	left	_	
70-3	14994-14998	each	_	
70-4	14999-15010	participant	_	
70-5	15011-15015	with	_	
70-6	15016-15017	4	_	
70-7	15018-15022	BPND	_	
70-8	15023-15028	scans	_	
70-9	15028-15029	:	_	
70-10	15030-15031	(	_	
70-11	15031-15032	1	_	
70-12	15032-15033	)	_	
70-13	15034-15043	expecting	_	
70-14	15044-15046	PL	_	
70-15	15046-15047	/	_	
70-16	15047-15056	receiving	_	
70-17	15057-15059	PL	_	
70-18	15059-15060	,	_	
70-19	15061-15062	(	_	
70-20	15062-15063	2	_	
70-21	15063-15064	)	_	
70-22	15065-15074	expecting	_	
70-23	15075-15077	PL	_	
70-24	15077-15078	/	_	
70-25	15078-15087	receiving	_	
70-26	15088-15090	MP	_	
70-27	15090-15091	,	_	
70-28	15092-15093	(	_	
70-29	15093-15094	3	_	
70-30	15094-15095	)	_	
70-31	15096-15105	expecting	_	
70-32	15106-15108	MP	_	
70-33	15108-15109	/	_	
70-34	15109-15118	receiving	_	
70-35	15119-15121	PL	_	
70-36	15121-15122	,	_	
70-37	15123-15124	(	_	
70-38	15124-15125	4	_	
70-39	15125-15126	)	_	
70-40	15127-15136	expecting	_	
70-41	15137-15139	MP	_	
70-42	15139-15140	/	_	
70-43	15140-15149	receiving	_	
70-44	15150-15152	MP	_	
70-45	15152-15153	.	_	

#Text=Data analysis
#Text=For each participant, difference scans of (receive PL–receive MP) were computed, as a measure of MP-induced DA release, both for the expecting MP and expecting PL conditions.
71-1	15154-15158	Data	_	
71-2	15159-15167	analysis	_	
71-3	15168-15171	For	_	
71-4	15172-15176	each	_	
71-5	15177-15188	participant	_	
71-6	15188-15189	,	_	
71-7	15190-15200	difference	_	
71-8	15201-15206	scans	_	
71-9	15207-15209	of	_	
71-10	15210-15211	(	_	
71-11	15211-15218	receive	_	
71-12	15219-15229	PL–receive	_	
71-13	15230-15232	MP	_	
71-14	15232-15233	)	_	
71-15	15234-15238	were	_	
71-16	15239-15247	computed	_	
71-17	15247-15248	,	_	
71-18	15249-15251	as	_	
71-19	15252-15253	a	_	
71-20	15254-15261	measure	_	
71-21	15262-15264	of	_	
71-22	15265-15275	MP-induced	_	
71-23	15276-15278	DA	_	
71-24	15279-15286	release	_	
71-25	15286-15287	,	_	
71-26	15288-15292	both	_	
71-27	15293-15296	for	_	
71-28	15297-15300	the	_	
71-29	15301-15310	expecting	_	
71-30	15311-15313	MP	_	
71-31	15314-15317	and	_	
71-32	15318-15327	expecting	_	
71-33	15328-15330	PL	_	
71-34	15331-15341	conditions	_	
71-35	15341-15342	.	_	

#Text=Voxel-wise analyses were performed in SPM8 using a mixed design ANOVA model on these DA release scans, with Group (CUD versus HC) as a between-subject factor, and Expectation (expecting PL versus expecting MP) as a within-subject factor.
72-1	15343-15353	Voxel-wise	_	
72-2	15354-15362	analyses	_	
72-3	15363-15367	were	_	
72-4	15368-15377	performed	_	
72-5	15378-15380	in	_	
72-6	15381-15385	SPM8	_	
72-7	15386-15391	using	_	
72-8	15392-15393	a	_	
72-9	15394-15399	mixed	_	
72-10	15400-15406	design	_	
72-11	15407-15412	ANOVA	_	
72-12	15413-15418	model	_	
72-13	15419-15421	on	_	
72-14	15422-15427	these	_	
72-15	15428-15430	DA	_	
72-16	15431-15438	release	_	
72-17	15439-15444	scans	_	
72-18	15444-15445	,	_	
72-19	15446-15450	with	_	
72-20	15451-15456	Group	_	
72-21	15457-15458	(	_	
72-22	15458-15461	CUD	_	
72-23	15462-15468	versus	_	
72-24	15469-15471	HC	_	
72-25	15471-15472	)	_	
72-26	15473-15475	as	_	
72-27	15476-15477	a	_	
72-28	15478-15493	between-subject	_	
72-29	15494-15500	factor	_	
72-30	15500-15501	,	_	
72-31	15502-15505	and	_	
72-32	15506-15517	Expectation	_	
72-33	15518-15519	(	_	
72-34	15519-15528	expecting	_	
72-35	15529-15531	PL	_	
72-36	15532-15538	versus	_	
72-37	15539-15548	expecting	_	
72-38	15549-15551	MP	_	
72-39	15551-15552	)	_	
72-40	15553-15555	as	_	
72-41	15556-15557	a	_	
72-42	15558-15572	within-subject	_	
72-43	15573-15579	factor	_	
72-44	15579-15580	.	_	

#Text=Corrections for multiple comparisons were performed via the random field theory, an approach that is less conservative than the traditional Bonferroni method.
73-1	15581-15592	Corrections	_	
73-2	15593-15596	for	_	
73-3	15597-15605	multiple	_	
73-4	15606-15617	comparisons	_	
73-5	15618-15622	were	_	
73-6	15623-15632	performed	_	
73-7	15633-15636	via	_	
73-8	15637-15640	the	_	
73-9	15641-15647	random	_	
73-10	15648-15653	field	_	
73-11	15654-15660	theory	_	
73-12	15660-15661	,	_	
73-13	15662-15664	an	_	
73-14	15665-15673	approach	_	
73-15	15674-15678	that	_	
73-16	15679-15681	is	_	
73-17	15682-15686	less	_	
73-18	15687-15699	conservative	_	
73-19	15700-15704	than	_	
73-20	15705-15708	the	_	
73-21	15709-15720	traditional	_	
73-22	15721-15731	Bonferroni	_	
73-23	15732-15738	method	_	
73-24	15738-15739	.	_	

#Text=Imaging voxels that were significantly different between conditions were identified using an uncorrected voxel threshold p ≤ 0.005 with a minimum cluster size of 100 voxels, and p < 0.05 family-wise error (FWE) cluster-corrected.
74-1	15740-15747	Imaging	_	
74-2	15748-15754	voxels	_	
74-3	15755-15759	that	_	
74-4	15760-15764	were	_	
74-5	15765-15778	significantly	_	
74-6	15779-15788	different	_	
74-7	15789-15796	between	_	
74-8	15797-15807	conditions	_	
74-9	15808-15812	were	_	
74-10	15813-15823	identified	_	
74-11	15824-15829	using	_	
74-12	15830-15832	an	_	
74-13	15833-15844	uncorrected	_	
74-14	15845-15850	voxel	_	
74-15	15851-15860	threshold	_	
74-16	15861-15862	p	_	
74-17	15863-15864	≤	_	
74-18	15865-15870	0.005	_	
74-19	15871-15875	with	_	
74-20	15876-15877	a	_	
74-21	15878-15885	minimum	_	
74-22	15886-15893	cluster	_	
74-23	15894-15898	size	_	
74-24	15899-15901	of	_	
74-25	15902-15905	100	_	
74-26	15906-15912	voxels	_	
74-27	15912-15913	,	_	
74-28	15914-15917	and	_	
74-29	15918-15919	p	_	
74-30	15920-15921	<	_	
74-31	15922-15926	0.05	_	
74-32	15927-15938	family-wise	_	
74-33	15939-15944	error	_	
74-34	15945-15946	(	_	
74-35	15946-15949	FWE	_	
74-36	15949-15950	)	_	
74-37	15951-15968	cluster-corrected	_	
74-38	15968-15969	.	_	

#Text=Moreover, for DA regions and their projections targets (caudate, putamen, NAc, midbrain), we created bilateral anatomical masks using Wake Forest University Pickatlas.
75-1	15970-15978	Moreover	_	
75-2	15978-15979	,	_	
75-3	15980-15983	for	_	
75-4	15984-15986	DA	_	
75-5	15987-15994	regions	_	
75-6	15995-15998	and	_	
75-7	15999-16004	their	_	
75-8	16005-16016	projections	_	
75-9	16017-16024	targets	_	
75-10	16025-16026	(	_	
75-11	16026-16033	caudate	_	
75-12	16033-16034	,	_	
75-13	16035-16042	putamen	_	
75-14	16042-16043	,	_	
75-15	16044-16047	NAc	_	
75-16	16047-16048	,	_	
75-17	16049-16057	midbrain	_	
75-18	16057-16058	)	_	
75-19	16058-16059	,	_	
75-20	16060-16062	we	_	
75-21	16063-16070	created	_	
75-22	16071-16080	bilateral	_	
75-23	16081-16091	anatomical	_	
75-24	16092-16097	masks	_	
75-25	16098-16103	using	_	
75-26	16104-16108	Wake	_	
75-27	16109-16115	Forest	_	
75-28	16116-16126	University	_	
75-29	16127-16136	Pickatlas	_	
75-30	16136-16137	.	_	

#Text=For each contrast, these masks were used for small-volume correction (SVC) in SPM8 with a significance threshold of p < 0.05 FWE, k > 10, as described previously.
76-1	16138-16141	For	_	
76-2	16142-16146	each	_	
76-3	16147-16155	contrast	_	
76-4	16155-16156	,	_	
76-5	16157-16162	these	_	
76-6	16163-16168	masks	_	
76-7	16169-16173	were	_	
76-8	16174-16178	used	_	
76-9	16179-16182	for	_	
76-10	16183-16195	small-volume	_	
76-11	16196-16206	correction	_	
76-12	16207-16208	(	_	
76-13	16208-16211	SVC	_	
76-14	16211-16212	)	_	
76-15	16213-16215	in	_	
76-16	16216-16220	SPM8	_	
76-17	16221-16225	with	_	
76-18	16226-16227	a	_	
76-19	16228-16240	significance	_	
76-20	16241-16250	threshold	_	
76-21	16251-16253	of	_	
76-22	16254-16255	p	_	
76-23	16256-16257	<	_	
76-24	16258-16262	0.05	_	
76-25	16263-16266	FWE	_	
76-26	16266-16267	,	_	
76-27	16268-16269	k	_	
76-28	16270-16271	>	_	
76-29	16272-16274	10	_	
76-30	16274-16275	,	_	
76-31	16276-16278	as	_	
76-32	16279-16288	described	_	
76-33	16289-16299	previously	_	
76-34	16299-16300	.	_	

#Text=Bilateral mask sizes were the following: caudate (3571), putamen (3592), NAc (313), midbrain (2289).
77-1	16301-16310	Bilateral	_	
77-2	16311-16315	mask	_	
77-3	16316-16321	sizes	_	
77-4	16322-16326	were	_	
77-5	16327-16330	the	_	
77-6	16331-16340	following	_	
77-7	16340-16341	:	_	
77-8	16342-16349	caudate	_	
77-9	16350-16351	(	_	
77-10	16351-16355	3571	_	
77-11	16355-16356	)	_	
77-12	16356-16357	,	_	
77-13	16358-16365	putamen	_	
77-14	16366-16367	(	_	
77-15	16367-16371	3592	_	
77-16	16371-16372	)	_	
77-17	16372-16373	,	_	
77-18	16374-16377	NAc	_	
77-19	16378-16379	(	_	
77-20	16379-16382	313	_	
77-21	16382-16383	)	_	
77-22	16383-16384	,	_	
77-23	16385-16393	midbrain	_	
77-24	16394-16395	(	_	
77-25	16395-16399	2289	_	
77-26	16399-16400	)	_	
77-27	16400-16401	.	_	

#Text=Results
#Text=Plasma MP concentrations
#Text=Plasma methylphenidate (MP) concentration (ng/ml) after intravenous MP injection in the CUD and HC in the unexpected (PL/MP) and expected (MP/MP) conditions
#Text=\tCUD (n = 23)\tHC (n = 21)\tp Value\t \tPL/MP\t \t 15 min\t181.0 (56.7)\t161.0 (60.1)\tns\t \t 30 min\t117.6 (24.1)\t136.4 (49.2)\tns\t \t 45 min\t92.3 (19.9)\t106.6 (21.9)\t0.03\t \t 60 min\t79.1 (18.7)\t93.4 (20.0)\t0.02\t \t Mean\t117.6 (25.8)\t123.3 (30.0)\t0.4\t \tMP/MP\t \t 15 min\t182.0 (61.2)\t150.1 (53.9)\tns\t \t 30 min\t114.8 (34.0)\t133.2 (41.0)\tns\t \t 45 min\t91.9 (22.7)\t105.6 (19.7)\t0.04\t \t 60 min\t77.8 (16.7)\t89.1 (17.4)\t0.04\t \t Mean\t116.9 (30.2)\t119.5 (27.0)\tns\t \t
#Text=CUD cocaine use disorder, HC healthy controls, PL placebo, ns not significant
#Text=Plasma MP concentrations of two HC subjects were missing due to technical failure, leaving 23 CUD and 21 HC for further analyses.
78-1	16402-16409	Results	_	
78-2	16410-16416	Plasma	_	
78-3	16417-16419	MP	_	
78-4	16420-16434	concentrations	_	
78-5	16435-16441	Plasma	_	
78-6	16442-16457	methylphenidate	_	
78-7	16458-16459	(	_	
78-8	16459-16461	MP	_	
78-9	16461-16462	)	_	
78-10	16463-16476	concentration	_	
78-11	16477-16478	(	_	
78-12	16478-16480	ng	_	
78-13	16480-16481	/	_	
78-14	16481-16483	ml	_	
78-15	16483-16484	)	_	
78-16	16485-16490	after	_	
78-17	16491-16502	intravenous	_	
78-18	16503-16505	MP	_	
78-19	16506-16515	injection	_	
78-20	16516-16518	in	_	
78-21	16519-16522	the	_	
78-22	16523-16526	CUD	_	
78-23	16527-16530	and	_	
78-24	16531-16533	HC	_	
78-25	16534-16536	in	_	
78-26	16537-16540	the	_	
78-27	16541-16551	unexpected	_	
78-28	16552-16553	(	_	
78-29	16553-16555	PL	_	
78-30	16555-16556	/	_	
78-31	16556-16558	MP	_	
78-32	16558-16559	)	_	
78-33	16560-16563	and	_	
78-34	16564-16572	expected	_	
78-35	16573-16574	(	_	
78-36	16574-16576	MP	_	
78-37	16576-16577	/	_	
78-38	16577-16579	MP	_	
78-39	16579-16580	)	_	
78-40	16581-16591	conditions	_	
78-41	16593-16596	CUD	_	
78-42	16597-16598	(	_	
78-43	16598-16599	n	_	
78-44	16600-16601	=	_	
78-45	16602-16604	23	_	
78-46	16604-16605	)	_	
78-47	16606-16608	HC	_	
78-48	16609-16610	(	_	
78-49	16610-16611	n	_	
78-50	16612-16613	=	_	
78-51	16614-16616	21	_	
78-52	16616-16617	)	_	
78-53	16618-16619	p	_	
78-54	16620-16625	Value	_	
78-55	16628-16630	PL	_	
78-56	16630-16631	/	_	
78-57	16631-16633	MP	_	
78-58	16637-16639	15	_	
78-59	16640-16643	min	_	
78-60	16644-16649	181.0	_	
78-61	16650-16651	(	_	
78-62	16651-16655	56.7	_	
78-63	16655-16656	)	_	
78-64	16657-16662	161.0	_	
78-65	16663-16664	(	_	
78-66	16664-16668	60.1	_	
78-67	16668-16669	)	_	
78-68	16670-16672	ns	_	
78-69	16676-16678	30	_	
78-70	16679-16682	min	_	
78-71	16683-16688	117.6	_	
78-72	16689-16690	(	_	
78-73	16690-16694	24.1	_	
78-74	16694-16695	)	_	
78-75	16696-16701	136.4	_	
78-76	16702-16703	(	_	
78-77	16703-16707	49.2	_	
78-78	16707-16708	)	_	
78-79	16709-16711	ns	_	
78-80	16715-16717	45	_	
78-81	16718-16721	min	_	
78-82	16722-16726	92.3	_	
78-83	16727-16728	(	_	
78-84	16728-16732	19.9	_	
78-85	16732-16733	)	_	
78-86	16734-16739	106.6	_	
78-87	16740-16741	(	_	
78-88	16741-16745	21.9	_	
78-89	16745-16746	)	_	
78-90	16747-16751	0.03	_	
78-91	16755-16757	60	_	
78-92	16758-16761	min	_	
78-93	16762-16766	79.1	_	
78-94	16767-16768	(	_	
78-95	16768-16772	18.7	_	
78-96	16772-16773	)	_	
78-97	16774-16778	93.4	_	
78-98	16779-16780	(	_	
78-99	16780-16784	20.0	_	
78-100	16784-16785	)	_	
78-101	16786-16790	0.02	_	
78-102	16794-16798	Mean	_	
78-103	16799-16804	117.6	_	
78-104	16805-16806	(	_	
78-105	16806-16810	25.8	_	
78-106	16810-16811	)	_	
78-107	16812-16817	123.3	_	
78-108	16818-16819	(	_	
78-109	16819-16823	30.0	_	
78-110	16823-16824	)	_	
78-111	16825-16828	0.4	_	
78-112	16831-16833	MP	_	
78-113	16833-16834	/	_	
78-114	16834-16836	MP	_	
78-115	16840-16842	15	_	
78-116	16843-16846	min	_	
78-117	16847-16852	182.0	_	
78-118	16853-16854	(	_	
78-119	16854-16858	61.2	_	
78-120	16858-16859	)	_	
78-121	16860-16865	150.1	_	
78-122	16866-16867	(	_	
78-123	16867-16871	53.9	_	
78-124	16871-16872	)	_	
78-125	16873-16875	ns	_	
78-126	16879-16881	30	_	
78-127	16882-16885	min	_	
78-128	16886-16891	114.8	_	
78-129	16892-16893	(	_	
78-130	16893-16897	34.0	_	
78-131	16897-16898	)	_	
78-132	16899-16904	133.2	_	
78-133	16905-16906	(	_	
78-134	16906-16910	41.0	_	
78-135	16910-16911	)	_	
78-136	16912-16914	ns	_	
78-137	16918-16920	45	_	
78-138	16921-16924	min	_	
78-139	16925-16929	91.9	_	
78-140	16930-16931	(	_	
78-141	16931-16935	22.7	_	
78-142	16935-16936	)	_	
78-143	16937-16942	105.6	_	
78-144	16943-16944	(	_	
78-145	16944-16948	19.7	_	
78-146	16948-16949	)	_	
78-147	16950-16954	0.04	_	
78-148	16958-16960	60	_	
78-149	16961-16964	min	_	
78-150	16965-16969	77.8	_	
78-151	16970-16971	(	_	
78-152	16971-16975	16.7	_	
78-153	16975-16976	)	_	
78-154	16977-16981	89.1	_	
78-155	16982-16983	(	_	
78-156	16983-16987	17.4	_	
78-157	16987-16988	)	_	
78-158	16989-16993	0.04	_	
78-159	16997-17001	Mean	_	
78-160	17002-17007	116.9	_	
78-161	17008-17009	(	_	
78-162	17009-17013	30.2	_	
78-163	17013-17014	)	_	
78-164	17015-17020	119.5	_	
78-165	17021-17022	(	_	
78-166	17022-17026	27.0	_	
78-167	17026-17027	)	_	
78-168	17028-17030	ns	_	
78-169	17034-17037	CUD	_	
78-170	17038-17045	cocaine	_	
78-171	17046-17049	use	_	
78-172	17050-17058	disorder	_	
78-173	17058-17059	,	_	
78-174	17060-17062	HC	_	
78-175	17063-17070	healthy	_	
78-176	17071-17079	controls	_	
78-177	17079-17080	,	_	
78-178	17081-17083	PL	_	
78-179	17084-17091	placebo	_	
78-180	17091-17092	,	_	
78-181	17093-17095	ns	_	
78-182	17096-17099	not	_	
78-183	17100-17111	significant	_	
78-184	17112-17118	Plasma	_	
78-185	17119-17121	MP	_	
78-186	17122-17136	concentrations	_	
78-187	17137-17139	of	_	
78-188	17140-17143	two	_	
78-189	17144-17146	HC	_	
78-190	17147-17155	subjects	_	
78-191	17156-17160	were	_	
78-192	17161-17168	missing	_	
78-193	17169-17172	due	_	
78-194	17173-17175	to	_	
78-195	17176-17185	technical	_	
78-196	17186-17193	failure	_	
78-197	17193-17194	,	_	
78-198	17195-17202	leaving	_	
78-199	17203-17205	23	_	
78-200	17206-17209	CUD	_	
78-201	17210-17213	and	_	
78-202	17214-17216	21	_	
78-203	17217-17219	HC	_	
78-204	17220-17223	for	_	
78-205	17224-17231	further	_	
78-206	17232-17240	analyses	_	
78-207	17240-17241	.	_	

#Text=For mean MP concentrations, there were no effects of Group (F1,42 = 0.3, p = 0.6), Expectation (F1,43 = 0.8, p = 0.4), and no interaction effect of Group × Expectation (F1,43 = 0.5, p = 0.5) (Table 2).
79-1	17242-17245	For	_	
79-2	17246-17250	mean	_	
79-3	17251-17253	MP	_	
79-4	17254-17268	concentrations	_	
79-5	17268-17269	,	_	
79-6	17270-17275	there	_	
79-7	17276-17280	were	_	
79-8	17281-17283	no	_	
79-9	17284-17291	effects	_	
79-10	17292-17294	of	_	
79-11	17295-17300	Group	_	
79-12	17301-17302	(	_	
79-13	17302-17307	F1,42	_	
79-14	17308-17309	=	_	
79-15	17310-17313	0.3	_	
79-16	17313-17314	,	_	
79-17	17315-17316	p	_	
79-18	17317-17318	=	_	
79-19	17319-17322	0.6	_	
79-20	17322-17323	)	_	
79-21	17323-17324	,	_	
79-22	17325-17336	Expectation	_	
79-23	17337-17338	(	_	
79-24	17338-17343	F1,43	_	
79-25	17344-17345	=	_	
79-26	17346-17349	0.8	_	
79-27	17349-17350	,	_	
79-28	17351-17352	p	_	
79-29	17353-17354	=	_	
79-30	17355-17358	0.4	_	
79-31	17358-17359	)	_	
79-32	17359-17360	,	_	
79-33	17361-17364	and	_	
79-34	17365-17367	no	_	
79-35	17368-17379	interaction	_	
79-36	17380-17386	effect	_	
79-37	17387-17389	of	_	
79-38	17390-17395	Group	_	
79-39	17396-17397	×	_	
79-40	17398-17409	Expectation	_	
79-41	17410-17411	(	_	
79-42	17411-17416	F1,43	_	
79-43	17417-17418	=	_	
79-44	17419-17422	0.5	_	
79-45	17422-17423	,	_	
79-46	17424-17425	p	_	
79-47	17426-17427	=	_	
79-48	17428-17431	0.5	_	
79-49	17431-17432	)	_	
79-50	17433-17434	(	_	
79-51	17434-17439	Table	_	
79-52	17440-17441	2	_	
79-53	17441-17442	)	_	
79-54	17442-17443	.	_	

#Text=Plasma MP concentrations decreased significantly over time (F3,36 = 69.7, p < 0.0001).
80-1	17444-17450	Plasma	_	
80-2	17451-17453	MP	_	
80-3	17454-17468	concentrations	_	
80-4	17469-17478	decreased	_	
80-5	17479-17492	significantly	_	
80-6	17493-17497	over	_	
80-7	17498-17502	time	_	
80-8	17503-17504	(	_	
80-9	17504-17509	F3,36	_	
80-10	17510-17511	=	_	
80-11	17512-17516	69.7	_	
80-12	17516-17517	,	_	
80-13	17518-17519	p	_	
80-14	17520-17521	<	_	
80-15	17522-17528	0.0001	_	
80-16	17528-17529	)	_	
80-17	17529-17530	.	_	

#Text=MP concentrations decreased faster in CUD than in HC (F3,36 = 6.3, p = 0.002) (see Table 2 for MP plasma values at 15, 30, 45, and 60 min after MP injection in CUD and HC; both for expected and unexpected MP).
81-1	17531-17533	MP	_	
81-2	17534-17548	concentrations	_	
81-3	17549-17558	decreased	_	
81-4	17559-17565	faster	_	
81-5	17566-17568	in	_	
81-6	17569-17572	CUD	_	
81-7	17573-17577	than	_	
81-8	17578-17580	in	_	
81-9	17581-17583	HC	_	
81-10	17584-17585	(	_	
81-11	17585-17590	F3,36	_	
81-12	17591-17592	=	_	
81-13	17593-17596	6.3	_	
81-14	17596-17597	,	_	
81-15	17598-17599	p	_	
81-16	17600-17601	=	_	
81-17	17602-17607	0.002	_	
81-18	17607-17608	)	_	
81-19	17609-17610	(	_	
81-20	17610-17613	see	_	
81-21	17614-17619	Table	_	
81-22	17620-17621	2	_	
81-23	17622-17625	for	_	
81-24	17626-17628	MP	_	
81-25	17629-17635	plasma	_	
81-26	17636-17642	values	_	
81-27	17643-17645	at	_	
81-28	17646-17648	15	_	
81-29	17648-17649	,	_	
81-30	17650-17652	30	_	
81-31	17652-17653	,	_	
81-32	17654-17656	45	_	
81-33	17656-17657	,	_	
81-34	17658-17661	and	_	
81-35	17662-17664	60	_	
81-36	17665-17668	min	_	
81-37	17669-17674	after	_	
81-38	17675-17677	MP	_	
81-39	17678-17687	injection	_	
81-40	17688-17690	in	_	
81-41	17691-17694	CUD	_	
81-42	17695-17698	and	_	
81-43	17699-17701	HC	_	
81-44	17701-17702	;	_	
81-45	17703-17707	both	_	
81-46	17708-17711	for	_	
81-47	17712-17720	expected	_	
81-48	17721-17724	and	_	
81-49	17725-17735	unexpected	_	
81-50	17736-17738	MP	_	
81-51	17738-17739	)	_	
81-52	17739-17740	.	_	

#Text=There were no effects of expectations on MP decrease rates (F3,36 = 0.6, p = 0.6).
82-1	17741-17746	There	_	
82-2	17747-17751	were	_	
82-3	17752-17754	no	_	
82-4	17755-17762	effects	_	
82-5	17763-17765	of	_	
82-6	17766-17778	expectations	_	
82-7	17779-17781	on	_	
82-8	17782-17784	MP	_	
82-9	17785-17793	decrease	_	
82-10	17794-17799	rates	_	
82-11	17800-17801	(	_	
82-12	17801-17806	F3,36	_	
82-13	17807-17808	=	_	
82-14	17809-17812	0.6	_	
82-15	17812-17813	,	_	
82-16	17814-17815	p	_	
82-17	17816-17817	=	_	
82-18	17818-17821	0.6	_	
82-19	17821-17822	)	_	
82-20	17822-17823	.	_	

#Text=Cardiovascular responses to MP
#Text=a Healthy controls (HC) showed stronger MP-induced increases in pulse rate and systolic blood pressure than cocaine use disorder (CUD). b CUD reported lower rush and high compared to HC during the MP challenge.
83-1	17824-17838	Cardiovascular	_	
83-2	17839-17848	responses	_	
83-3	17849-17851	to	_	
83-4	17852-17854	MP	_	
83-5	17855-17856	a	_	
83-6	17857-17864	Healthy	_	
83-7	17865-17873	controls	_	
83-8	17874-17875	(	_	
83-9	17875-17877	HC	_	
83-10	17877-17878	)	_	
83-11	17879-17885	showed	_	
83-12	17886-17894	stronger	_	
83-13	17895-17905	MP-induced	_	
83-14	17906-17915	increases	_	
83-15	17916-17918	in	_	
83-16	17919-17924	pulse	_	
83-17	17925-17929	rate	_	
83-18	17930-17933	and	_	
83-19	17934-17942	systolic	_	
83-20	17943-17948	blood	_	
83-21	17949-17957	pressure	_	
83-22	17958-17962	than	_	
83-23	17963-17970	cocaine	_	
83-24	17971-17974	use	_	
83-25	17975-17983	disorder	_	
83-26	17984-17985	(	_	
83-27	17985-17988	CUD	_	
83-28	17988-17989	)	_	
83-29	17989-17990	.	_	
83-30	17991-17992	b	_	
83-31	17993-17996	CUD	_	
83-32	17997-18005	reported	_	
83-33	18006-18011	lower	_	
83-34	18012-18016	rush	_	
83-35	18017-18020	and	_	
83-36	18021-18025	high	_	
83-37	18026-18034	compared	_	
83-38	18035-18037	to	_	
83-39	18038-18040	HC	_	
83-40	18041-18047	during	_	
83-41	18048-18051	the	_	
83-42	18052-18054	MP	_	
83-43	18055-18064	challenge	_	
83-44	18064-18065	.	_	

#Text=There was no effect on expectation on anxiety when challenged with PL in either group.
84-1	18066-18071	There	_	
84-2	18072-18075	was	_	
84-3	18076-18078	no	_	
84-4	18079-18085	effect	_	
84-5	18086-18088	on	_	
84-6	18089-18100	expectation	_	
84-7	18101-18103	on	_	
84-8	18104-18111	anxiety	_	
84-9	18112-18116	when	_	
84-10	18117-18127	challenged	_	
84-11	18128-18132	with	_	
84-12	18133-18135	PL	_	
84-13	18136-18138	in	_	
84-14	18139-18145	either	_	
84-15	18146-18151	group	_	
84-16	18151-18152	.	_	

#Text=When challenged with MP, HC had higher anxiety whereas CUD showed reduced anxiety in unexpected condition
#Text=MP administration significantly increased cardiovascular responses (pulse rate, systolic and diastolic blood pressure) in both unexpected MP and expected MP conditions, compared to PL (all p < 0.0001).
85-1	18153-18157	When	_	
85-2	18158-18168	challenged	_	
85-3	18169-18173	with	_	
85-4	18174-18176	MP	_	
85-5	18176-18177	,	_	
85-6	18178-18180	HC	_	
85-7	18181-18184	had	_	
85-8	18185-18191	higher	_	
85-9	18192-18199	anxiety	_	
85-10	18200-18207	whereas	_	
85-11	18208-18211	CUD	_	
85-12	18212-18218	showed	_	
85-13	18219-18226	reduced	_	
85-14	18227-18234	anxiety	_	
85-15	18235-18237	in	_	
85-16	18238-18248	unexpected	_	
85-17	18249-18258	condition	_	
85-18	18259-18261	MP	_	
85-19	18262-18276	administration	_	
85-20	18277-18290	significantly	_	
85-21	18291-18300	increased	_	
85-22	18301-18315	cardiovascular	_	
85-23	18316-18325	responses	_	
85-24	18326-18327	(	_	
85-25	18327-18332	pulse	_	
85-26	18333-18337	rate	_	
85-27	18337-18338	,	_	
85-28	18339-18347	systolic	_	
85-29	18348-18351	and	_	
85-30	18352-18361	diastolic	_	
85-31	18362-18367	blood	_	
85-32	18368-18376	pressure	_	
85-33	18376-18377	)	_	
85-34	18378-18380	in	_	
85-35	18381-18385	both	_	
85-36	18386-18396	unexpected	_	
85-37	18397-18399	MP	_	
85-38	18400-18403	and	_	
85-39	18404-18412	expected	_	
85-40	18413-18415	MP	_	
85-41	18416-18426	conditions	_	
85-42	18426-18427	,	_	
85-43	18428-18436	compared	_	
85-44	18437-18439	to	_	
85-45	18440-18442	PL	_	
85-46	18443-18444	(	_	
85-47	18444-18447	all	_	
85-48	18448-18449	p	_	
85-49	18450-18451	<	_	
85-50	18452-18458	0.0001	_	
85-51	18458-18459	)	_	
85-52	18459-18460	.	_	

#Text=There was a main effect of Expectation on pulse rate (F1,44 = 8.2, p = 0.006); with the expectation of MP increasing pulse rate for both the PL challenge (t45 = 2.0 p = 0.05) and the MP challenge (t45 = 1.9 p = 0.07).
86-1	18461-18466	There	_	
86-2	18467-18470	was	_	
86-3	18471-18472	a	_	
86-4	18473-18477	main	_	
86-5	18478-18484	effect	_	
86-6	18485-18487	of	_	
86-7	18488-18499	Expectation	_	
86-8	18500-18502	on	_	
86-9	18503-18508	pulse	_	
86-10	18509-18513	rate	_	
86-11	18514-18515	(	_	
86-12	18515-18520	F1,44	_	
86-13	18521-18522	=	_	
86-14	18523-18526	8.2	_	
86-15	18526-18527	,	_	
86-16	18528-18529	p	_	
86-17	18530-18531	=	_	
86-18	18532-18537	0.006	_	
86-19	18537-18538	)	_	
86-20	18538-18539	;	_	
86-21	18540-18544	with	_	
86-22	18545-18548	the	_	
86-23	18549-18560	expectation	_	
86-24	18561-18563	of	_	
86-25	18564-18566	MP	_	
86-26	18567-18577	increasing	_	
86-27	18578-18583	pulse	_	
86-28	18584-18588	rate	_	
86-29	18589-18592	for	_	
86-30	18593-18597	both	_	
86-31	18598-18601	the	_	
86-32	18602-18604	PL	_	
86-33	18605-18614	challenge	_	
86-34	18615-18616	(	_	
86-35	18616-18619	t45	_	
86-36	18620-18621	=	_	
86-37	18622-18625	2.0	_	
86-38	18626-18627	p	_	
86-39	18628-18629	=	_	
86-40	18630-18634	0.05	_	
86-41	18634-18635	)	_	
86-42	18636-18639	and	_	
86-43	18640-18643	the	_	
86-44	18644-18646	MP	_	
86-45	18647-18656	challenge	_	
86-46	18657-18658	(	_	
86-47	18658-18661	t45	_	
86-48	18662-18663	=	_	
86-49	18664-18667	1.9	_	
86-50	18668-18669	p	_	
86-51	18670-18671	=	_	
86-52	18672-18676	0.07	_	
86-53	18676-18677	)	_	
86-54	18677-18678	.	_	

#Text=There were, however, no effects of Expectation × Group, Expectation × Challenge, or Expectation × Challenge × Group.
87-1	18679-18684	There	_	
87-2	18685-18689	were	_	
87-3	18689-18690	,	_	
87-4	18691-18698	however	_	
87-5	18698-18699	,	_	
87-6	18700-18702	no	_	
87-7	18703-18710	effects	_	
87-8	18711-18713	of	_	
87-9	18714-18725	Expectation	_	
87-10	18726-18727	×	_	
87-11	18728-18733	Group	_	
87-12	18733-18734	,	_	
87-13	18735-18746	Expectation	_	
87-14	18747-18748	×	_	
87-15	18749-18758	Challenge	_	
87-16	18758-18759	,	_	
87-17	18760-18762	or	_	
87-18	18763-18774	Expectation	_	
87-19	18775-18776	×	_	
87-20	18777-18786	Challenge	_	
87-21	18787-18788	×	_	
87-22	18789-18794	Group	_	
87-23	18794-18795	.	_	

#Text=There was a Challenge × Group effect for pulse rate (F1,44 = 4.9, p = 0.032) and systolic (F1,44 = 10.1, p = 0.003) but not diastolic blood pressure (F1,44 = 1.3, p = 0.3), with stronger MP-induced increases in pulse rate (t44 = 2.2, p = 0.03) and systolic blood pressure (t44 = 3.2, p = 0.003) in HC than in CUD.
88-1	18796-18801	There	_	
88-2	18802-18805	was	_	
88-3	18806-18807	a	_	
88-4	18808-18817	Challenge	_	
88-5	18818-18819	×	_	
88-6	18820-18825	Group	_	
88-7	18826-18832	effect	_	
88-8	18833-18836	for	_	
88-9	18837-18842	pulse	_	
88-10	18843-18847	rate	_	
88-11	18848-18849	(	_	
88-12	18849-18854	F1,44	_	
88-13	18855-18856	=	_	
88-14	18857-18860	4.9	_	
88-15	18860-18861	,	_	
88-16	18862-18863	p	_	
88-17	18864-18865	=	_	
88-18	18866-18871	0.032	_	
88-19	18871-18872	)	_	
88-20	18873-18876	and	_	
88-21	18877-18885	systolic	_	
88-22	18886-18887	(	_	
88-23	18887-18892	F1,44	_	
88-24	18893-18894	=	_	
88-25	18895-18899	10.1	_	
88-26	18899-18900	,	_	
88-27	18901-18902	p	_	
88-28	18903-18904	=	_	
88-29	18905-18910	0.003	_	
88-30	18910-18911	)	_	
88-31	18912-18915	but	_	
88-32	18916-18919	not	_	
88-33	18920-18929	diastolic	_	
88-34	18930-18935	blood	_	
88-35	18936-18944	pressure	_	
88-36	18945-18946	(	_	
88-37	18946-18951	F1,44	_	
88-38	18952-18953	=	_	
88-39	18954-18957	1.3	_	
88-40	18957-18958	,	_	
88-41	18959-18960	p	_	
88-42	18961-18962	=	_	
88-43	18963-18966	0.3	_	
88-44	18966-18967	)	_	
88-45	18967-18968	,	_	
88-46	18969-18973	with	_	
88-47	18974-18982	stronger	_	
88-48	18983-18993	MP-induced	_	
88-49	18994-19003	increases	_	
88-50	19004-19006	in	_	
88-51	19007-19012	pulse	_	
88-52	19013-19017	rate	_	
88-53	19018-19019	(	_	
88-54	19019-19022	t44	_	
88-55	19023-19024	=	_	
88-56	19025-19028	2.2	_	
88-57	19028-19029	,	_	
88-58	19030-19031	p	_	
88-59	19032-19033	=	_	
88-60	19034-19038	0.03	_	
88-61	19038-19039	)	_	
88-62	19040-19043	and	_	
88-63	19044-19052	systolic	_	
88-64	19053-19058	blood	_	
88-65	19059-19067	pressure	_	
88-66	19068-19069	(	_	
88-67	19069-19072	t44	_	
88-68	19073-19074	=	_	
88-69	19075-19078	3.2	_	
88-70	19078-19079	,	_	
88-71	19080-19081	p	_	
88-72	19082-19083	=	_	
88-73	19084-19089	0.003	_	
88-74	19089-19090	)	_	
88-75	19091-19093	in	_	
88-76	19094-19096	HC	_	
88-77	19097-19101	than	_	
88-78	19102-19104	in	_	
88-79	19105-19108	CUD	_	
88-80	19108-19109	.	_	

#Text=Figure 1a depicts cardiovascular responses to MP in both groups.
89-1	19110-19116	Figure	_	
89-2	19117-19119	1a	_	
89-3	19120-19127	depicts	_	
89-4	19128-19142	cardiovascular	_	
89-5	19143-19152	responses	_	
89-6	19153-19155	to	_	
89-7	19156-19158	MP	_	
89-8	19159-19161	in	_	
89-9	19162-19166	both	_	
89-10	19167-19173	groups	_	
89-11	19173-19174	.	_	

#Text=These findings on cardiovascular responses are highly consistent with an earlier study with iv injection of MP in abstinent cocaine users.
90-1	19175-19180	These	_	
90-2	19181-19189	findings	_	
90-3	19190-19192	on	_	
90-4	19193-19207	cardiovascular	_	
90-5	19208-19217	responses	_	
90-6	19218-19221	are	_	
90-7	19222-19228	highly	_	
90-8	19229-19239	consistent	_	
90-9	19240-19244	with	_	
90-10	19245-19247	an	_	
90-11	19248-19255	earlier	_	
90-12	19256-19261	study	_	
90-13	19262-19266	with	_	
90-14	19267-19269	iv	_	
90-15	19270-19279	injection	_	
90-16	19280-19282	of	_	
90-17	19283-19285	MP	_	
90-18	19286-19288	in	_	
90-19	19289-19298	abstinent	_	
90-20	19299-19306	cocaine	_	
90-21	19307-19312	users	_	
90-22	19312-19313	.	_	

#Text=Behavioral responses to MP
#Text=MP challenge increased ratings of “rush,” “high,” and “anxiety” compared to PL (all p < 0.0001).
91-1	19314-19324	Behavioral	_	
91-2	19325-19334	responses	_	
91-3	19335-19337	to	_	
91-4	19338-19340	MP	_	
91-5	19341-19343	MP	_	
91-6	19344-19353	challenge	_	
91-7	19354-19363	increased	_	
91-8	19364-19371	ratings	_	
91-9	19372-19374	of	_	
91-10	19375-19376	“	_	
91-11	19376-19380	rush	_	
91-12	19380-19381	,	_	
91-13	19381-19382	”	_	
91-14	19383-19384	“	_	
91-15	19384-19388	high	_	
91-16	19388-19389	,	_	
91-17	19389-19390	”	_	
91-18	19391-19394	and	_	
91-19	19395-19396	“	_	
91-20	19396-19403	anxiety	_	
91-21	19403-19404	”	_	
91-22	19405-19413	compared	_	
91-23	19414-19416	to	_	
91-24	19417-19419	PL	_	
91-25	19420-19421	(	_	
91-26	19421-19424	all	_	
91-27	19425-19426	p	_	
91-28	19427-19428	<	_	
91-29	19429-19435	0.0001	_	
91-30	19435-19436	)	_	
91-31	19436-19437	.	_	

#Text=There were, however, no main effects of expectation on self-report ratings.
92-1	19438-19443	There	_	
92-2	19444-19448	were	_	
92-3	19448-19449	,	_	
92-4	19450-19457	however	_	
92-5	19457-19458	,	_	
92-6	19459-19461	no	_	
92-7	19462-19466	main	_	
92-8	19467-19474	effects	_	
92-9	19475-19477	of	_	
92-10	19478-19489	expectation	_	
92-11	19490-19492	on	_	
92-12	19493-19504	self-report	_	
92-13	19505-19512	ratings	_	
92-14	19512-19513	.	_	

#Text=For “rush” and “high,” there was a main effect of Group (rush: F1,44 = 7.7, p = 0.008; high: F1,44 = 5.9, p = 0.02), and an interaction effect of Challenge × Group (rush: F1,44 = 8.4, p = 0.006; high: F1,44 = 8.1, p = 0.007), showing that during the MP challenge CUD reported lower “rush” (t44 = 2.9, p = 0.006) and “high” (t44 = 2.6, p = 0.01) compared to HC, but there were no group differences for PL challenges (p > 0.05).
93-1	19514-19517	For	_	
93-2	19518-19519	“	_	
93-3	19519-19523	rush	_	
93-4	19523-19524	”	_	
93-5	19525-19528	and	_	
93-6	19529-19530	“	_	
93-7	19530-19534	high	_	
93-8	19534-19535	,	_	
93-9	19535-19536	”	_	
93-10	19537-19542	there	_	
93-11	19543-19546	was	_	
93-12	19547-19548	a	_	
93-13	19549-19553	main	_	
93-14	19554-19560	effect	_	
93-15	19561-19563	of	_	
93-16	19564-19569	Group	_	
93-17	19570-19571	(	_	
93-18	19571-19575	rush	_	
93-19	19575-19576	:	_	
93-20	19577-19582	F1,44	_	
93-21	19583-19584	=	_	
93-22	19585-19588	7.7	_	
93-23	19588-19589	,	_	
93-24	19590-19591	p	_	
93-25	19592-19593	=	_	
93-26	19594-19599	0.008	_	
93-27	19599-19600	;	_	
93-28	19601-19605	high	_	
93-29	19605-19606	:	_	
93-30	19607-19612	F1,44	_	
93-31	19613-19614	=	_	
93-32	19615-19618	5.9	_	
93-33	19618-19619	,	_	
93-34	19620-19621	p	_	
93-35	19622-19623	=	_	
93-36	19624-19628	0.02	_	
93-37	19628-19629	)	_	
93-38	19629-19630	,	_	
93-39	19631-19634	and	_	
93-40	19635-19637	an	_	
93-41	19638-19649	interaction	_	
93-42	19650-19656	effect	_	
93-43	19657-19659	of	_	
93-44	19660-19669	Challenge	_	
93-45	19670-19671	×	_	
93-46	19672-19677	Group	_	
93-47	19678-19679	(	_	
93-48	19679-19683	rush	_	
93-49	19683-19684	:	_	
93-50	19685-19690	F1,44	_	
93-51	19691-19692	=	_	
93-52	19693-19696	8.4	_	
93-53	19696-19697	,	_	
93-54	19698-19699	p	_	
93-55	19700-19701	=	_	
93-56	19702-19707	0.006	_	
93-57	19707-19708	;	_	
93-58	19709-19713	high	_	
93-59	19713-19714	:	_	
93-60	19715-19720	F1,44	_	
93-61	19721-19722	=	_	
93-62	19723-19726	8.1	_	
93-63	19726-19727	,	_	
93-64	19728-19729	p	_	
93-65	19730-19731	=	_	
93-66	19732-19737	0.007	_	
93-67	19737-19738	)	_	
93-68	19738-19739	,	_	
93-69	19740-19747	showing	_	
93-70	19748-19752	that	_	
93-71	19753-19759	during	_	
93-72	19760-19763	the	_	
93-73	19764-19766	MP	_	
93-74	19767-19776	challenge	_	
93-75	19777-19780	CUD	_	
93-76	19781-19789	reported	_	
93-77	19790-19795	lower	_	
93-78	19796-19797	“	_	
93-79	19797-19801	rush	_	
93-80	19801-19802	”	_	
93-81	19803-19804	(	_	
93-82	19804-19807	t44	_	
93-83	19808-19809	=	_	
93-84	19810-19813	2.9	_	
93-85	19813-19814	,	_	
93-86	19815-19816	p	_	
93-87	19817-19818	=	_	
93-88	19819-19824	0.006	_	
93-89	19824-19825	)	_	
93-90	19826-19829	and	_	
93-91	19830-19831	“	_	
93-92	19831-19835	high	_	
93-93	19835-19836	”	_	
93-94	19837-19838	(	_	
93-95	19838-19841	t44	_	
93-96	19842-19843	=	_	
93-97	19844-19847	2.6	_	
93-98	19847-19848	,	_	
93-99	19849-19850	p	_	
93-100	19851-19852	=	_	
93-101	19853-19857	0.01	_	
93-102	19857-19858	)	_	
93-103	19859-19867	compared	_	
93-104	19868-19870	to	_	
93-105	19871-19873	HC	_	
93-106	19873-19874	,	_	
93-107	19875-19878	but	_	
93-108	19879-19884	there	_	
93-109	19885-19889	were	_	
93-110	19890-19892	no	_	
93-111	19893-19898	group	_	
93-112	19899-19910	differences	_	
93-113	19911-19914	for	_	
93-114	19915-19917	PL	_	
93-115	19918-19928	challenges	_	
93-116	19929-19930	(	_	
93-117	19930-19931	p	_	
93-118	19932-19933	>	_	
93-119	19934-19938	0.05	_	
93-120	19938-19939	)	_	
93-121	19939-19940	.	_	

#Text=For “anxiety” there was a Challenge × Group effect (F1,44 = 5.9, p = 0.02), with higher anxiety ratings during the PL challenges in CUD (mean = 2.3 ± 1.9) compared to HC (mean = 1.4 ± 0.8; t44 = 2.0, p = 0.05), but no differences in MP.
94-1	19941-19944	For	_	
94-2	19945-19946	“	_	
94-3	19946-19953	anxiety	_	
94-4	19953-19954	”	_	
94-5	19955-19960	there	_	
94-6	19961-19964	was	_	
94-7	19965-19966	a	_	
94-8	19967-19976	Challenge	_	
94-9	19977-19978	×	_	
94-10	19979-19984	Group	_	
94-11	19985-19991	effect	_	
94-12	19992-19993	(	_	
94-13	19993-19998	F1,44	_	
94-14	19999-20000	=	_	
94-15	20001-20004	5.9	_	
94-16	20004-20005	,	_	
94-17	20006-20007	p	_	
94-18	20008-20009	=	_	
94-19	20010-20014	0.02	_	
94-20	20014-20015	)	_	
94-21	20015-20016	,	_	
94-22	20017-20021	with	_	
94-23	20022-20028	higher	_	
94-24	20029-20036	anxiety	_	
94-25	20037-20044	ratings	_	
94-26	20045-20051	during	_	
94-27	20052-20055	the	_	
94-28	20056-20058	PL	_	
94-29	20059-20069	challenges	_	
94-30	20070-20072	in	_	
94-31	20073-20076	CUD	_	
94-32	20077-20078	(	_	
94-33	20078-20082	mean	_	
94-34	20083-20084	=	_	
94-35	20085-20088	2.3	_	
94-36	20089-20090	±	_	
94-37	20091-20094	1.9	_	
94-38	20094-20095	)	_	
94-39	20096-20104	compared	_	
94-40	20105-20107	to	_	
94-41	20108-20110	HC	_	
94-42	20111-20112	(	_	
94-43	20112-20116	mean	_	
94-44	20117-20118	=	_	
94-45	20119-20122	1.4	_	
94-46	20123-20124	±	_	
94-47	20125-20128	0.8	_	
94-48	20128-20129	;	_	
94-49	20130-20133	t44	_	
94-50	20134-20135	=	_	
94-51	20136-20139	2.0	_	
94-52	20139-20140	,	_	
94-53	20141-20142	p	_	
94-54	20143-20144	=	_	
94-55	20145-20149	0.05	_	
94-56	20149-20150	)	_	
94-57	20150-20151	,	_	
94-58	20152-20155	but	_	
94-59	20156-20158	no	_	
94-60	20159-20170	differences	_	
94-61	20171-20173	in	_	
94-62	20174-20176	MP	_	
94-63	20176-20177	.	_	

#Text=For “anxiety,” there was an Expectation × Group (F1,44 = 4.5, p = 0.04) and an Expectation × Challenge × Group effect (F1,44 = 7.2, p = 0.01).
95-1	20178-20181	For	_	
95-2	20182-20183	“	_	
95-3	20183-20190	anxiety	_	
95-4	20190-20191	,	_	
95-5	20191-20192	”	_	
95-6	20193-20198	there	_	
95-7	20199-20202	was	_	
95-8	20203-20205	an	_	
95-9	20206-20217	Expectation	_	
95-10	20218-20219	×	_	
95-11	20220-20225	Group	_	
95-12	20226-20227	(	_	
95-13	20227-20232	F1,44	_	
95-14	20233-20234	=	_	
95-15	20235-20238	4.5	_	
95-16	20238-20239	,	_	
95-17	20240-20241	p	_	
95-18	20242-20243	=	_	
95-19	20244-20248	0.04	_	
95-20	20248-20249	)	_	
95-21	20250-20253	and	_	
95-22	20254-20256	an	_	
95-23	20257-20268	Expectation	_	
95-24	20269-20270	×	_	
95-25	20271-20280	Challenge	_	
95-26	20281-20282	×	_	
95-27	20283-20288	Group	_	
95-28	20289-20295	effect	_	
95-29	20296-20297	(	_	
95-30	20297-20302	F1,44	_	
95-31	20303-20304	=	_	
95-32	20305-20308	7.2	_	
95-33	20308-20309	,	_	
95-34	20310-20311	p	_	
95-35	20312-20313	=	_	
95-36	20314-20318	0.01	_	
95-37	20318-20319	)	_	
95-38	20319-20320	.	_	

#Text=Paired t tests showed that there was no effect on Expectation on anxiety when challenged with PL in either group (p > 0.18).
96-1	20321-20327	Paired	_	
96-2	20328-20329	t	_	
96-3	20330-20335	tests	_	
96-4	20336-20342	showed	_	
96-5	20343-20347	that	_	
96-6	20348-20353	there	_	
96-7	20354-20357	was	_	
96-8	20358-20360	no	_	
96-9	20361-20367	effect	_	
96-10	20368-20370	on	_	
96-11	20371-20382	Expectation	_	
96-12	20383-20385	on	_	
96-13	20386-20393	anxiety	_	
96-14	20394-20398	when	_	
96-15	20399-20409	challenged	_	
96-16	20410-20414	with	_	
96-17	20415-20417	PL	_	
96-18	20418-20420	in	_	
96-19	20421-20427	either	_	
96-20	20428-20433	group	_	
96-21	20434-20435	(	_	
96-22	20435-20436	p	_	
96-23	20437-20438	>	_	
96-24	20439-20443	0.18	_	
96-25	20443-20444	)	_	
96-26	20444-20445	.	_	

#Text=However, when challenged with MP, controls had higher anxiety when expecting PL (mean = 4.7 ± 2.6) than expecting MP (mean = 3.7 ± 2.1; t22 = 2.4, p = 0.02), whereas CUD showed reduced anxiety when expecting PL than MP at trend level (t22 = 1.9, p = 0.073).
97-1	20446-20453	However	_	
97-2	20453-20454	,	_	
97-3	20455-20459	when	_	
97-4	20460-20470	challenged	_	
97-5	20471-20475	with	_	
97-6	20476-20478	MP	_	
97-7	20478-20479	,	_	
97-8	20480-20488	controls	_	
97-9	20489-20492	had	_	
97-10	20493-20499	higher	_	
97-11	20500-20507	anxiety	_	
97-12	20508-20512	when	_	
97-13	20513-20522	expecting	_	
97-14	20523-20525	PL	_	
97-15	20526-20527	(	_	
97-16	20527-20531	mean	_	
97-17	20532-20533	=	_	
97-18	20534-20537	4.7	_	
97-19	20538-20539	±	_	
97-20	20540-20543	2.6	_	
97-21	20543-20544	)	_	
97-22	20545-20549	than	_	
97-23	20550-20559	expecting	_	
97-24	20560-20562	MP	_	
97-25	20563-20564	(	_	
97-26	20564-20568	mean	_	
97-27	20569-20570	=	_	
97-28	20571-20574	3.7	_	
97-29	20575-20576	±	_	
97-30	20577-20580	2.1	_	
97-31	20580-20581	;	_	
97-32	20582-20585	t22	_	
97-33	20586-20587	=	_	
97-34	20588-20591	2.4	_	
97-35	20591-20592	,	_	
97-36	20593-20594	p	_	
97-37	20595-20596	=	_	
97-38	20597-20601	0.02	_	
97-39	20601-20602	)	_	
97-40	20602-20603	,	_	
97-41	20604-20611	whereas	_	
97-42	20612-20615	CUD	_	
97-43	20616-20622	showed	_	
97-44	20623-20630	reduced	_	
97-45	20631-20638	anxiety	_	
97-46	20639-20643	when	_	
97-47	20644-20653	expecting	_	
97-48	20654-20656	PL	_	
97-49	20657-20661	than	_	
97-50	20662-20664	MP	_	
97-51	20665-20667	at	_	
97-52	20668-20673	trend	_	
97-53	20674-20679	level	_	
97-54	20680-20681	(	_	
97-55	20681-20684	t22	_	
97-56	20685-20686	=	_	
97-57	20687-20690	1.9	_	
97-58	20690-20691	,	_	
97-59	20692-20693	p	_	
97-60	20694-20695	=	_	
97-61	20696-20701	0.073	_	
97-62	20701-20702	)	_	
97-63	20702-20703	.	_	

#Text=Figure 1b depicts self-reported responses to MP in both groups.
98-1	20704-20710	Figure	_	
98-2	20711-20713	1b	_	
98-3	20714-20721	depicts	_	
98-4	20722-20735	self-reported	_	
98-5	20736-20745	responses	_	
98-6	20746-20748	to	_	
98-7	20749-20751	MP	_	
98-8	20752-20754	in	_	
98-9	20755-20759	both	_	
98-10	20760-20766	groups	_	
98-11	20766-20767	.	_	

#Text=PET results
#Text=Baseline D2R availability between CUD and HC
#Text=For iv-PL conditions (baseline), there was a main effect of Group in the bilateral putamen, with CUD showing lower D2R availability than HC (p < 0.05 SVC), which is consistent with previous findings (Supplementary Figure 1; Supplementary Table 1).
99-1	20768-20771	PET	_	
99-2	20772-20779	results	_	
99-3	20780-20788	Baseline	_	
99-4	20789-20792	D2R	_	
99-5	20793-20805	availability	_	
99-6	20806-20813	between	_	
99-7	20814-20817	CUD	_	
99-8	20818-20821	and	_	
99-9	20822-20824	HC	_	
99-10	20825-20828	For	_	
99-11	20829-20834	iv-PL	_	
99-12	20835-20845	conditions	_	
99-13	20846-20847	(	_	
99-14	20847-20855	baseline	_	
99-15	20855-20856	)	_	
99-16	20856-20857	,	_	
99-17	20858-20863	there	_	
99-18	20864-20867	was	_	
99-19	20868-20869	a	_	
99-20	20870-20874	main	_	
99-21	20875-20881	effect	_	
99-22	20882-20884	of	_	
99-23	20885-20890	Group	_	
99-24	20891-20893	in	_	
99-25	20894-20897	the	_	
99-26	20898-20907	bilateral	_	
99-27	20908-20915	putamen	_	
99-28	20915-20916	,	_	
99-29	20917-20921	with	_	
99-30	20922-20925	CUD	_	
99-31	20926-20933	showing	_	
99-32	20934-20939	lower	_	
99-33	20940-20943	D2R	_	
99-34	20944-20956	availability	_	
99-35	20957-20961	than	_	
99-36	20962-20964	HC	_	
99-37	20965-20966	(	_	
99-38	20966-20967	p	_	
99-39	20968-20969	<	_	
99-40	20970-20974	0.05	_	
99-41	20975-20978	SVC	_	
99-42	20978-20979	)	_	
99-43	20979-20980	,	_	
99-44	20981-20986	which	_	
99-45	20987-20989	is	_	
99-46	20990-21000	consistent	_	
99-47	21001-21005	with	_	
99-48	21006-21014	previous	_	
99-49	21015-21023	findings	_	
99-50	21024-21025	(	_	
99-51	21025-21038	Supplementary	_	
99-52	21039-21045	Figure	_	
99-53	21046-21047	1	_	
99-54	21047-21048	;	_	
99-55	21049-21062	Supplementary	_	
99-56	21063-21068	Table	_	
99-57	21069-21070	1	_	
99-58	21070-21071	)	_	
99-59	21071-21072	.	_	

#Text=However, there was no main effect of Expectation and no Group × Expectation interaction effect at p > 0.05 SVC.
100-1	21073-21080	However	_	
100-2	21080-21081	,	_	
100-3	21082-21087	there	_	
100-4	21088-21091	was	_	
100-5	21092-21094	no	_	
100-6	21095-21099	main	_	
100-7	21100-21106	effect	_	
100-8	21107-21109	of	_	
100-9	21110-21121	Expectation	_	
100-10	21122-21125	and	_	
100-11	21126-21128	no	_	
100-12	21129-21134	Group	_	
100-13	21135-21136	×	_	
100-14	21137-21148	Expectation	_	
100-15	21149-21160	interaction	_	
100-16	21161-21167	effect	_	
100-17	21168-21170	at	_	
100-18	21171-21172	p	_	
100-19	21173-21174	>	_	
100-20	21175-21179	0.05	_	
100-21	21180-21183	SVC	_	
100-22	21183-21184	.	_	

#Text=Effects of MP on DA release as measured by the difference in [11C]raclopride BP between the PL and MP conditions
#Text=Methylphenidate (MP) increased dopamine (DA) release in striatal areas as measured by the difference between BPPL and BPMP.
101-1	21185-21192	Effects	_	
101-2	21193-21195	of	_	
101-3	21196-21198	MP	_	
101-4	21199-21201	on	_	
101-5	21202-21204	DA	_	
101-6	21205-21212	release	_	
101-7	21213-21215	as	_	
101-8	21216-21224	measured	_	
101-9	21225-21227	by	_	
101-10	21228-21231	the	_	
101-11	21232-21242	difference	_	
101-12	21243-21245	in	_	
101-13	21246-21247	[	_	
101-14	21247-21250	11C	_	
101-15	21250-21251	]	_	
101-16	21251-21261	raclopride	_	
101-17	21262-21264	BP	_	
101-18	21265-21272	between	_	
101-19	21273-21276	the	_	
101-20	21277-21279	PL	_	
101-21	21280-21283	and	_	
101-22	21284-21286	MP	_	
101-23	21287-21297	conditions	_	
101-24	21298-21313	Methylphenidate	_	
101-25	21314-21315	(	_	
101-26	21315-21317	MP	_	
101-27	21317-21318	)	_	
101-28	21319-21328	increased	_	
101-29	21329-21337	dopamine	_	
101-30	21338-21339	(	_	
101-31	21339-21341	DA	_	
101-32	21341-21342	)	_	
101-33	21343-21350	release	_	
101-34	21351-21353	in	_	
101-35	21354-21362	striatal	_	
101-36	21363-21368	areas	_	
101-37	21369-21371	as	_	
101-38	21372-21380	measured	_	
101-39	21381-21383	by	_	
101-40	21384-21387	the	_	
101-41	21388-21398	difference	_	
101-42	21399-21406	between	_	
101-43	21407-21411	BPPL	_	
101-44	21412-21415	and	_	
101-45	21416-21420	BPMP	_	
101-46	21420-21421	.	_	

#Text=The SPM difference images were superimposed onto T2-weighted magnetic resonance images in coronal (left upper), sagittal (right upper), and transverse (left lower) views.
102-1	21422-21425	The	_	
102-2	21426-21429	SPM	_	
102-3	21430-21440	difference	_	
102-4	21441-21447	images	_	
102-5	21448-21452	were	_	
102-6	21453-21465	superimposed	_	
102-7	21466-21470	onto	_	
102-8	21471-21473	T2	_	
102-9	21473-21474	-	_	
102-10	21474-21482	weighted	_	
102-11	21483-21491	magnetic	_	
102-12	21492-21501	resonance	_	
102-13	21502-21508	images	_	
102-14	21509-21511	in	_	
102-15	21512-21519	coronal	_	
102-16	21520-21521	(	_	
102-17	21521-21525	left	_	
102-18	21526-21531	upper	_	
102-19	21531-21532	)	_	
102-20	21532-21533	,	_	
102-21	21534-21542	sagittal	_	
102-22	21543-21544	(	_	
102-23	21544-21549	right	_	
102-24	21550-21555	upper	_	
102-25	21555-21556	)	_	
102-26	21556-21557	,	_	
102-27	21558-21561	and	_	
102-28	21562-21572	transverse	_	
102-29	21573-21574	(	_	
102-30	21574-21578	left	_	
102-31	21579-21584	lower	_	
102-32	21584-21585	)	_	
102-33	21586-21591	views	_	
102-34	21591-21592	.	_	

#Text=The color bar indicates t score values.
103-1	21593-21596	The	_	
103-2	21597-21602	color	_	
103-3	21603-21606	bar	_	
103-4	21607-21616	indicates	_	
103-5	21617-21618	t	_	
103-6	21619-21624	score	_	
103-7	21625-21631	values	_	
103-8	21631-21632	.	_	

#Text=Red represents the highest value and dark violet represents the lowest value.
104-1	21633-21636	Red	_	
104-2	21637-21647	represents	_	
104-3	21648-21651	the	_	
104-4	21652-21659	highest	_	
104-5	21660-21665	value	_	
104-6	21666-21669	and	_	
104-7	21670-21674	dark	_	
104-8	21675-21681	violet	_	
104-9	21682-21692	represents	_	
104-10	21693-21696	the	_	
104-11	21697-21703	lowest	_	
104-12	21704-21709	value	_	
104-13	21709-21710	.	_	

#Text=The bar chart showed DA release (PL–MP) in striatal regions in cocaine use disorder and healthy controls
#Text=Whole-brain results of Group × Expectation for iv-PL > iv-MP
#Text=Brain region\tL/R\tK\tMNI (xyz)\tt Value\t \tMain effect of Challenge: iv-PL > iv-MP\t \t Putamen\tR\t4924\t30\t−6\t−4\t11.38a\t \tL\t\t−28\t−4\t−6\t10.88a\t \t Caudate\tL\t756\t−8\t12\t−12\t10.30b\t \tR\t\t10\t12\t−12\t8.96b\t \t NAc\tR\t132\t10\t12\t−12\t8.96b\t \tGroup × Challenge: CUD < HC, iv-PL > iv-MP\t \t Putamen\tR\t1086\t30\t−8\t−6\t9.74a\t \tL\t1110\t−28\t−8\t−6\t8.47a\t \t Caudate\tL\t163\t−14\t14\t−12\t4.85b\t \tR\t209\t12\t16\t6\t4.43b\t \t NAc\tL\t48\t−14\t14\t−12\t4.85b\t \tR\t12\t20\t12\t−12\t3.73b\t \tExpectation × Challenge: Expect PL > Expect MP, iv-PL > iv-MP\t \t No significant voxels\t \tGroup × Expectation × Challenge: CUD > HC, Expect PL > Expect MP, iv-PL > iv-MP\t \t Caudate\tL\t95\t−16\t−12\t22\t4.06b\t \t Midbrain\tL\t53\t−8\t−12\t−16\t3.64b\t \t\tR\t43\t2\t−26\t0\t3.63b\t \t
#Text=BA Brodmann area, CUD cocaine use disorder, HC healthy controls, iv intravenous, K cluster size, L left, MNI (x y z) coordinates in Montreal Neurological Institute space (x
#Text=y
#Text=z), MP methylphenidate, NAc nucleus accumbens, PL placebo, R right
#Text=ap < 0.05 family-wise error corrected (FWE) whole brain, cluster-corrected
#Text=bp < 0.05 FWE small-volume corrected
#Text=MP increased DA release in the bilateral putamen (p < 0.0001 FWE cluster-corrected), as well as in bilateral ROIs NAc and caudate (all p < 0.05 SVC) (Fig. 2; Table 3).
105-1	21711-21714	The	_	
105-2	21715-21718	bar	_	
105-3	21719-21724	chart	_	
105-4	21725-21731	showed	_	
105-5	21732-21734	DA	_	
105-6	21735-21742	release	_	
105-7	21743-21744	(	_	
105-8	21744-21749	PL–MP	_	
105-9	21749-21750	)	_	
105-10	21751-21753	in	_	
105-11	21754-21762	striatal	_	
105-12	21763-21770	regions	_	
105-13	21771-21773	in	_	
105-14	21774-21781	cocaine	_	
105-15	21782-21785	use	_	
105-16	21786-21794	disorder	_	
105-17	21795-21798	and	_	
105-18	21799-21806	healthy	_	
105-19	21807-21815	controls	_	
105-20	21816-21827	Whole-brain	_	
105-21	21828-21835	results	_	
105-22	21836-21838	of	_	
105-23	21839-21844	Group	_	
105-24	21845-21846	×	_	
105-25	21847-21858	Expectation	_	
105-26	21859-21862	for	_	
105-27	21863-21868	iv-PL	_	
105-28	21869-21870	>	_	
105-29	21871-21876	iv-MP	_	
105-30	21877-21882	Brain	_	
105-31	21883-21889	region	_	
105-32	21890-21891	L	_	
105-33	21891-21892	/	_	
105-34	21892-21893	R	_	
105-35	21894-21895	K	_	
105-36	21896-21899	MNI	_	
105-37	21900-21901	(	_	
105-38	21901-21904	xyz	_	
105-39	21904-21905	)	_	
105-40	21906-21907	t	_	
105-41	21908-21913	Value	_	
105-42	21916-21920	Main	_	
105-43	21921-21927	effect	_	
105-44	21928-21930	of	_	
105-45	21931-21940	Challenge	_	
105-46	21940-21941	:	_	
105-47	21942-21947	iv-PL	_	
105-48	21948-21949	>	_	
105-49	21950-21955	iv-MP	_	
105-50	21959-21966	Putamen	_	
105-51	21967-21968	R	_	
105-52	21969-21973	4924	_	
105-53	21974-21976	30	_	
105-54	21977-21978	−	_	
105-55	21978-21979	6	_	
105-56	21980-21981	−	_	
105-57	21981-21982	4	_	
105-58	21983-21989	11.38a	_	
105-59	21992-21993	L	_	
105-60	21995-21996	−	_	
105-61	21996-21998	28	_	
105-62	21999-22000	−	_	
105-63	22000-22001	4	_	
105-64	22002-22003	−	_	
105-65	22003-22004	6	_	
105-66	22005-22011	10.88a	_	
105-67	22015-22022	Caudate	_	
105-68	22023-22024	L	_	
105-69	22025-22028	756	_	
105-70	22029-22030	−	_	
105-71	22030-22031	8	_	
105-72	22032-22034	12	_	
105-73	22035-22036	−	_	
105-74	22036-22038	12	_	
105-75	22039-22045	10.30b	_	
105-76	22048-22049	R	_	
105-77	22051-22053	10	_	
105-78	22054-22056	12	_	
105-79	22057-22058	−	_	
105-80	22058-22060	12	_	
105-81	22061-22066	8.96b	_	
105-82	22070-22073	NAc	_	
105-83	22074-22075	R	_	
105-84	22076-22079	132	_	
105-85	22080-22082	10	_	
105-86	22083-22085	12	_	
105-87	22086-22087	−	_	
105-88	22087-22089	12	_	
105-89	22090-22095	8.96b	_	
105-90	22098-22103	Group	_	
105-91	22104-22105	×	_	
105-92	22106-22115	Challenge	_	
105-93	22115-22116	:	_	
105-94	22117-22120	CUD	_	
105-95	22121-22122	<	_	
105-96	22123-22125	HC	_	
105-97	22125-22126	,	_	
105-98	22127-22132	iv-PL	_	
105-99	22133-22134	>	_	
105-100	22135-22140	iv-MP	_	
105-101	22144-22151	Putamen	_	
105-102	22152-22153	R	_	
105-103	22154-22158	1086	_	
105-104	22159-22161	30	_	
105-105	22162-22163	−	_	
105-106	22163-22164	8	_	
105-107	22165-22166	−	_	
105-108	22166-22167	6	_	
105-109	22168-22173	9.74a	_	
105-110	22176-22177	L	_	
105-111	22178-22182	1110	_	
105-112	22183-22184	−	_	
105-113	22184-22186	28	_	
105-114	22187-22188	−	_	
105-115	22188-22189	8	_	
105-116	22190-22191	−	_	
105-117	22191-22192	6	_	
105-118	22193-22198	8.47a	_	
105-119	22202-22209	Caudate	_	
105-120	22210-22211	L	_	
105-121	22212-22215	163	_	
105-122	22216-22217	−	_	
105-123	22217-22219	14	_	
105-124	22220-22222	14	_	
105-125	22223-22224	−	_	
105-126	22224-22226	12	_	
105-127	22227-22232	4.85b	_	
105-128	22235-22236	R	_	
105-129	22237-22240	209	_	
105-130	22241-22243	12	_	
105-131	22244-22246	16	_	
105-132	22247-22248	6	_	
105-133	22249-22254	4.43b	_	
105-134	22258-22261	NAc	_	
105-135	22262-22263	L	_	
105-136	22264-22266	48	_	
105-137	22267-22268	−	_	
105-138	22268-22270	14	_	
105-139	22271-22273	14	_	
105-140	22274-22275	−	_	
105-141	22275-22277	12	_	
105-142	22278-22283	4.85b	_	
105-143	22286-22287	R	_	
105-144	22288-22290	12	_	
105-145	22291-22293	20	_	
105-146	22294-22296	12	_	
105-147	22297-22298	−	_	
105-148	22298-22300	12	_	
105-149	22301-22306	3.73b	_	
105-150	22309-22320	Expectation	_	
105-151	22321-22322	×	_	
105-152	22323-22332	Challenge	_	
105-153	22332-22333	:	_	
105-154	22334-22340	Expect	_	
105-155	22341-22343	PL	_	
105-156	22344-22345	>	_	
105-157	22346-22352	Expect	_	
105-158	22353-22355	MP	_	
105-159	22355-22356	,	_	
105-160	22357-22362	iv-PL	_	
105-161	22363-22364	>	_	
105-162	22365-22370	iv-MP	_	
105-163	22374-22376	No	_	
105-164	22377-22388	significant	_	
105-165	22389-22395	voxels	_	
105-166	22398-22403	Group	_	
105-167	22404-22405	×	_	
105-168	22406-22417	Expectation	_	
105-169	22418-22419	×	_	
105-170	22420-22429	Challenge	_	
105-171	22429-22430	:	_	
105-172	22431-22434	CUD	_	
105-173	22435-22436	>	_	
105-174	22437-22439	HC	_	
105-175	22439-22440	,	_	
105-176	22441-22447	Expect	_	
105-177	22448-22450	PL	_	
105-178	22451-22452	>	_	
105-179	22453-22459	Expect	_	
105-180	22460-22462	MP	_	
105-181	22462-22463	,	_	
105-182	22464-22469	iv-PL	_	
105-183	22470-22471	>	_	
105-184	22472-22477	iv-MP	_	
105-185	22481-22488	Caudate	_	
105-186	22489-22490	L	_	
105-187	22491-22493	95	_	
105-188	22494-22495	−	_	
105-189	22495-22497	16	_	
105-190	22498-22499	−	_	
105-191	22499-22501	12	_	
105-192	22502-22504	22	_	
105-193	22505-22510	4.06b	_	
105-194	22514-22522	Midbrain	_	
105-195	22523-22524	L	_	
105-196	22525-22527	53	_	
105-197	22528-22529	−	_	
105-198	22529-22530	8	_	
105-199	22531-22532	−	_	
105-200	22532-22534	12	_	
105-201	22535-22536	−	_	
105-202	22536-22538	16	_	
105-203	22539-22544	3.64b	_	
105-204	22548-22549	R	_	
105-205	22550-22552	43	_	
105-206	22553-22554	2	_	
105-207	22555-22556	−	_	
105-208	22556-22558	26	_	
105-209	22559-22560	0	_	
105-210	22561-22566	3.63b	_	
105-211	22570-22572	BA	_	
105-212	22573-22581	Brodmann	_	
105-213	22582-22586	area	_	
105-214	22586-22587	,	_	
105-215	22588-22591	CUD	_	
105-216	22592-22599	cocaine	_	
105-217	22600-22603	use	_	
105-218	22604-22612	disorder	_	
105-219	22612-22613	,	_	
105-220	22614-22616	HC	_	
105-221	22617-22624	healthy	_	
105-222	22625-22633	controls	_	
105-223	22633-22634	,	_	
105-224	22635-22637	iv	_	
105-225	22638-22649	intravenous	_	
105-226	22649-22650	,	_	
105-227	22651-22652	K	_	
105-228	22653-22660	cluster	_	
105-229	22661-22665	size	_	
105-230	22665-22666	,	_	
105-231	22667-22668	L	_	
105-232	22669-22673	left	_	
105-233	22673-22674	,	_	
105-234	22675-22678	MNI	_	
105-235	22679-22680	(	_	
105-236	22680-22681	x	_	
105-237	22682-22683	y	_	
105-238	22684-22685	z	_	
105-239	22685-22686	)	_	
105-240	22687-22698	coordinates	_	
105-241	22699-22701	in	_	
105-242	22702-22710	Montreal	_	
105-243	22711-22723	Neurological	_	
105-244	22724-22733	Institute	_	
105-245	22734-22739	space	_	
105-246	22740-22741	(	_	
105-247	22741-22742	x	_	
105-248	22743-22744	y	_	
105-249	22745-22746	z	_	
105-250	22746-22747	)	_	
105-251	22747-22748	,	_	
105-252	22749-22751	MP	_	
105-253	22752-22767	methylphenidate	_	
105-254	22767-22768	,	_	
105-255	22769-22772	NAc	_	
105-256	22773-22780	nucleus	_	
105-257	22781-22790	accumbens	_	
105-258	22790-22791	,	_	
105-259	22792-22794	PL	_	
105-260	22795-22802	placebo	_	
105-261	22802-22803	,	_	
105-262	22804-22805	R	_	
105-263	22806-22811	right	_	
105-264	22812-22814	ap	_	
105-265	22815-22816	<	_	
105-266	22817-22821	0.05	_	
105-267	22822-22833	family-wise	_	
105-268	22834-22839	error	_	
105-269	22840-22849	corrected	_	
105-270	22850-22851	(	_	
105-271	22851-22854	FWE	_	
105-272	22854-22855	)	_	
105-273	22856-22861	whole	_	
105-274	22862-22867	brain	_	
105-275	22867-22868	,	_	
105-276	22869-22886	cluster-corrected	_	
105-277	22887-22889	bp	_	
105-278	22890-22891	<	_	
105-279	22892-22896	0.05	_	
105-280	22897-22900	FWE	_	
105-281	22901-22913	small-volume	_	
105-282	22914-22923	corrected	_	
105-283	22924-22926	MP	_	
105-284	22927-22936	increased	_	
105-285	22937-22939	DA	_	
105-286	22940-22947	release	_	
105-287	22948-22950	in	_	
105-288	22951-22954	the	_	
105-289	22955-22964	bilateral	_	
105-290	22965-22972	putamen	_	
105-291	22973-22974	(	_	
105-292	22974-22975	p	_	
105-293	22976-22977	<	_	
105-294	22978-22984	0.0001	_	
105-295	22985-22988	FWE	_	
105-296	22989-23006	cluster-corrected	_	
105-297	23006-23007	)	_	
105-298	23007-23008	,	_	
105-299	23009-23011	as	_	
105-300	23012-23016	well	_	
105-301	23017-23019	as	_	
105-302	23020-23022	in	_	
105-303	23023-23032	bilateral	_	
105-304	23033-23037	ROIs	_	
105-305	23038-23041	NAc	_	
105-306	23042-23045	and	_	
105-307	23046-23053	caudate	_	
105-308	23054-23055	(	_	
105-309	23055-23058	all	_	
105-310	23059-23060	p	_	
105-311	23061-23062	<	_	
105-312	23063-23067	0.05	_	
105-313	23068-23071	SVC	_	
105-314	23071-23072	)	_	
105-315	23073-23074	(	_	
105-316	23074-23077	Fig	_	
105-317	23077-23078	.	_	
105-318	23079-23080	2	_	
105-319	23080-23081	;	_	
105-320	23082-23087	Table	_	
105-321	23088-23089	3	_	
105-322	23089-23090	)	_	
105-323	23090-23091	.	_	

#Text=Interaction effects of Group × Challenge × Expectation
#Text=Interaction effects of Group × methylphenidate (MP) Challenge between cocaine use disorder (CUD) and healthy controls (HC).
106-1	23092-23103	Interaction	_	
106-2	23104-23111	effects	_	
106-3	23112-23114	of	_	
106-4	23115-23120	Group	_	
106-5	23121-23122	×	_	
106-6	23123-23132	Challenge	_	
106-7	23133-23134	×	_	
106-8	23135-23146	Expectation	_	
106-9	23147-23158	Interaction	_	
106-10	23159-23166	effects	_	
106-11	23167-23169	of	_	
106-12	23170-23175	Group	_	
106-13	23176-23177	×	_	
106-14	23178-23193	methylphenidate	_	
106-15	23194-23195	(	_	
106-16	23195-23197	MP	_	
106-17	23197-23198	)	_	
106-18	23199-23208	Challenge	_	
106-19	23209-23216	between	_	
106-20	23217-23224	cocaine	_	
106-21	23225-23228	use	_	
106-22	23229-23237	disorder	_	
106-23	23238-23239	(	_	
106-24	23239-23242	CUD	_	
106-25	23242-23243	)	_	
106-26	23244-23247	and	_	
106-27	23248-23255	healthy	_	
106-28	23256-23264	controls	_	
106-29	23265-23266	(	_	
106-30	23266-23268	HC	_	
106-31	23268-23269	)	_	
106-32	23269-23270	.	_	

#Text=CUD has blunted responses to MP in putamen, caudate, and nucleus accumbens as compared to HC.
107-1	23271-23274	CUD	_	
107-2	23275-23278	has	_	
107-3	23279-23286	blunted	_	
107-4	23287-23296	responses	_	
107-5	23297-23299	to	_	
107-6	23300-23302	MP	_	
107-7	23303-23305	in	_	
107-8	23306-23313	putamen	_	
107-9	23313-23314	,	_	
107-10	23315-23322	caudate	_	
107-11	23322-23323	,	_	
107-12	23324-23327	and	_	
107-13	23328-23335	nucleus	_	
107-14	23336-23345	accumbens	_	
107-15	23346-23348	as	_	
107-16	23349-23357	compared	_	
107-17	23358-23360	to	_	
107-18	23361-23363	HC	_	
107-19	23363-23364	.	_	

#Text=The SPM images were superimposed onto T2-weighted magnetic resonance images in coronal (left upper) and sagittal (right upper) views.
108-1	23365-23368	The	_	
108-2	23369-23372	SPM	_	
108-3	23373-23379	images	_	
108-4	23380-23384	were	_	
108-5	23385-23397	superimposed	_	
108-6	23398-23402	onto	_	
108-7	23403-23405	T2	_	
108-8	23405-23406	-	_	
108-9	23406-23414	weighted	_	
108-10	23415-23423	magnetic	_	
108-11	23424-23433	resonance	_	
108-12	23434-23440	images	_	
108-13	23441-23443	in	_	
108-14	23444-23451	coronal	_	
108-15	23452-23453	(	_	
108-16	23453-23457	left	_	
108-17	23458-23463	upper	_	
108-18	23463-23464	)	_	
108-19	23465-23468	and	_	
108-20	23469-23477	sagittal	_	
108-21	23478-23479	(	_	
108-22	23479-23484	right	_	
108-23	23485-23490	upper	_	
108-24	23490-23491	)	_	
108-25	23492-23497	views	_	
108-26	23497-23498	.	_	

#Text=The color bar indicates t score values.
109-1	23499-23502	The	_	
109-2	23503-23508	color	_	
109-3	23509-23512	bar	_	
109-4	23513-23522	indicates	_	
109-5	23523-23524	t	_	
109-6	23525-23530	score	_	
109-7	23531-23537	values	_	
109-8	23537-23538	.	_	

#Text=Red represents the highest value and dark violet represents the lowest value.
110-1	23539-23542	Red	_	
110-2	23543-23553	represents	_	
110-3	23554-23557	the	_	
110-4	23558-23565	highest	_	
110-5	23566-23571	value	_	
110-6	23572-23575	and	_	
110-7	23576-23580	dark	_	
110-8	23581-23587	violet	_	
110-9	23588-23598	represents	_	
110-10	23599-23602	the	_	
110-11	23603-23609	lowest	_	
110-12	23610-23615	value	_	
110-13	23615-23616	.	_	

#Text=The bar chart showed DA release (PL–MP) in striatal regions in CUD and HC
#Text=Interaction effect of Group × Challenge × Expectation in the caudate and midbrain (p < 0.05 small-volume corrected).
111-1	23617-23620	The	_	
111-2	23621-23624	bar	_	
111-3	23625-23630	chart	_	
111-4	23631-23637	showed	_	
111-5	23638-23640	DA	_	
111-6	23641-23648	release	_	
111-7	23649-23650	(	_	
111-8	23650-23655	PL–MP	_	
111-9	23655-23656	)	_	
111-10	23657-23659	in	_	
111-11	23660-23668	striatal	_	
111-12	23669-23676	regions	_	
111-13	23677-23679	in	_	
111-14	23680-23683	CUD	_	
111-15	23684-23687	and	_	
111-16	23688-23690	HC	_	
111-17	23691-23702	Interaction	_	
111-18	23703-23709	effect	_	
111-19	23710-23712	of	_	
111-20	23713-23718	Group	_	
111-21	23719-23720	×	_	
111-22	23721-23730	Challenge	_	
111-23	23731-23732	×	_	
111-24	23733-23744	Expectation	_	
111-25	23745-23747	in	_	
111-26	23748-23751	the	_	
111-27	23752-23759	caudate	_	
111-28	23760-23763	and	_	
111-29	23764-23772	midbrain	_	
111-30	23773-23774	(	_	
111-31	23774-23775	p	_	
111-32	23776-23777	<	_	
111-33	23778-23782	0.05	_	
111-34	23783-23795	small-volume	_	
111-35	23796-23805	corrected	_	
111-36	23805-23806	)	_	
111-37	23806-23807	.	_	

#Text=The expectation of methylphenidate (MP) increased MP-induced dopamine (DA) release (PL–MP) in healthy controls (HC) but not in cocaine use disorder (CUD) in whom it tended to reduce it, whereas expectation of PL tended to increase DA release in CUD and decrease in HC.
112-1	23808-23811	The	_	
112-2	23812-23823	expectation	_	
112-3	23824-23826	of	_	
112-4	23827-23842	methylphenidate	_	
112-5	23843-23844	(	_	
112-6	23844-23846	MP	_	
112-7	23846-23847	)	_	
112-8	23848-23857	increased	_	
112-9	23858-23868	MP-induced	_	
112-10	23869-23877	dopamine	_	
112-11	23878-23879	(	_	
112-12	23879-23881	DA	_	
112-13	23881-23882	)	_	
112-14	23883-23890	release	_	
112-15	23891-23892	(	_	
112-16	23892-23897	PL–MP	_	
112-17	23897-23898	)	_	
112-18	23899-23901	in	_	
112-19	23902-23909	healthy	_	
112-20	23910-23918	controls	_	
112-21	23919-23920	(	_	
112-22	23920-23922	HC	_	
112-23	23922-23923	)	_	
112-24	23924-23927	but	_	
112-25	23928-23931	not	_	
112-26	23932-23934	in	_	
112-27	23935-23942	cocaine	_	
112-28	23943-23946	use	_	
112-29	23947-23955	disorder	_	
112-30	23956-23957	(	_	
112-31	23957-23960	CUD	_	
112-32	23960-23961	)	_	
112-33	23962-23964	in	_	
112-34	23965-23969	whom	_	
112-35	23970-23972	it	_	
112-36	23973-23979	tended	_	
112-37	23980-23982	to	_	
112-38	23983-23989	reduce	_	
112-39	23990-23992	it	_	
112-40	23992-23993	,	_	
112-41	23994-24001	whereas	_	
112-42	24002-24013	expectation	_	
112-43	24014-24016	of	_	
112-44	24017-24019	PL	_	
112-45	24020-24026	tended	_	
112-46	24027-24029	to	_	
112-47	24030-24038	increase	_	
112-48	24039-24041	DA	_	
112-49	24042-24049	release	_	
112-50	24050-24052	in	_	
112-51	24053-24056	CUD	_	
112-52	24057-24060	and	_	
112-53	24061-24069	decrease	_	
112-54	24070-24072	in	_	
112-55	24073-24075	HC	_	
112-56	24075-24076	.	_	

#Text=The SPM images were superimposed onto T2-weighted magnetic resonance images in coronal (left upper) and sagittal (right upper) views.
113-1	24077-24080	The	_	
113-2	24081-24084	SPM	_	
113-3	24085-24091	images	_	
113-4	24092-24096	were	_	
113-5	24097-24109	superimposed	_	
113-6	24110-24114	onto	_	
113-7	24115-24117	T2	_	
113-8	24117-24118	-	_	
113-9	24118-24126	weighted	_	
113-10	24127-24135	magnetic	_	
113-11	24136-24145	resonance	_	
113-12	24146-24152	images	_	
113-13	24153-24155	in	_	
113-14	24156-24163	coronal	_	
113-15	24164-24165	(	_	
113-16	24165-24169	left	_	
113-17	24170-24175	upper	_	
113-18	24175-24176	)	_	
113-19	24177-24180	and	_	
113-20	24181-24189	sagittal	_	
113-21	24190-24191	(	_	
113-22	24191-24196	right	_	
113-23	24197-24202	upper	_	
113-24	24202-24203	)	_	
113-25	24204-24209	views	_	
113-26	24209-24210	.	_	

#Text=The color bar indicates t score values.
114-1	24211-24214	The	_	
114-2	24215-24220	color	_	
114-3	24221-24224	bar	_	
114-4	24225-24234	indicates	_	
114-5	24235-24236	t	_	
114-6	24237-24242	score	_	
114-7	24243-24249	values	_	
114-8	24249-24250	.	_	

#Text=Red represents the highest value and dark violet represents the lowest value.
115-1	24251-24254	Red	_	
115-2	24255-24265	represents	_	
115-3	24266-24269	the	_	
115-4	24270-24277	highest	_	
115-5	24278-24283	value	_	
115-6	24284-24287	and	_	
115-7	24288-24292	dark	_	
115-8	24293-24299	violet	_	
115-9	24300-24310	represents	_	
115-10	24311-24314	the	_	
115-11	24315-24321	lowest	_	
115-12	24322-24327	value	_	
115-13	24327-24328	.	_	

#Text=The bar chart showed DA release (PL–MP) in caudate and midbrain of CUD and HC
#Text=There was a Group × Challenge interaction effect, with putamen, caudate, and NAc (all p < 0.05 SVC) showing blunted responses to MP in CUD compared to HC (Fig. 3; Table 3), although the effects of Group × Expectation or Challenge × Expectation were not significant (Table 3).
116-1	24329-24332	The	_	
116-2	24333-24336	bar	_	
116-3	24337-24342	chart	_	
116-4	24343-24349	showed	_	
116-5	24350-24352	DA	_	
116-6	24353-24360	release	_	
116-7	24361-24362	(	_	
116-8	24362-24367	PL–MP	_	
116-9	24367-24368	)	_	
116-10	24369-24371	in	_	
116-11	24372-24379	caudate	_	
116-12	24380-24383	and	_	
116-13	24384-24392	midbrain	_	
116-14	24393-24395	of	_	
116-15	24396-24399	CUD	_	
116-16	24400-24403	and	_	
116-17	24404-24406	HC	_	
116-18	24407-24412	There	_	
116-19	24413-24416	was	_	
116-20	24417-24418	a	_	
116-21	24419-24424	Group	_	
116-22	24425-24426	×	_	
116-23	24427-24436	Challenge	_	
116-24	24437-24448	interaction	_	
116-25	24449-24455	effect	_	
116-26	24455-24456	,	_	
116-27	24457-24461	with	_	
116-28	24462-24469	putamen	_	
116-29	24469-24470	,	_	
116-30	24471-24478	caudate	_	
116-31	24478-24479	,	_	
116-32	24480-24483	and	_	
116-33	24484-24487	NAc	_	
116-34	24488-24489	(	_	
116-35	24489-24492	all	_	
116-36	24493-24494	p	_	
116-37	24495-24496	<	_	
116-38	24497-24501	0.05	_	
116-39	24502-24505	SVC	_	
116-40	24505-24506	)	_	
116-41	24507-24514	showing	_	
116-42	24515-24522	blunted	_	
116-43	24523-24532	responses	_	
116-44	24533-24535	to	_	
116-45	24536-24538	MP	_	
116-46	24539-24541	in	_	
116-47	24542-24545	CUD	_	
116-48	24546-24554	compared	_	
116-49	24555-24557	to	_	
116-50	24558-24560	HC	_	
116-51	24561-24562	(	_	
116-52	24562-24565	Fig	_	
116-53	24565-24566	.	_	
116-54	24567-24568	3	_	
116-55	24568-24569	;	_	
116-56	24570-24575	Table	_	
116-57	24576-24577	3	_	
116-58	24577-24578	)	_	
116-59	24578-24579	,	_	
116-60	24580-24588	although	_	
116-61	24589-24592	the	_	
116-62	24593-24600	effects	_	
116-63	24601-24603	of	_	
116-64	24604-24609	Group	_	
116-65	24610-24611	×	_	
116-66	24612-24623	Expectation	_	
116-67	24624-24626	or	_	
116-68	24627-24636	Challenge	_	
116-69	24637-24638	×	_	
116-70	24639-24650	Expectation	_	
116-71	24651-24655	were	_	
116-72	24656-24659	not	_	
116-73	24660-24671	significant	_	
116-74	24672-24673	(	_	
116-75	24673-24678	Table	_	
116-76	24679-24680	3	_	
116-77	24680-24681	)	_	
116-78	24681-24682	.	_	

#Text=In contrast, there was a Group × Challenge × Expectation effect in caudate and midbrain (p < 0.05 SVC; Fig. 4), showing the effects of expectation on MP-induced DA increases to have opposite effects in CUD than in HC in these two regions.
117-1	24683-24685	In	_	
117-2	24686-24694	contrast	_	
117-3	24694-24695	,	_	
117-4	24696-24701	there	_	
117-5	24702-24705	was	_	
117-6	24706-24707	a	_	
117-7	24708-24713	Group	_	
117-8	24714-24715	×	_	
117-9	24716-24725	Challenge	_	
117-10	24726-24727	×	_	
117-11	24728-24739	Expectation	_	
117-12	24740-24746	effect	_	
117-13	24747-24749	in	_	
117-14	24750-24757	caudate	_	
117-15	24758-24761	and	_	
117-16	24762-24770	midbrain	_	
117-17	24771-24772	(	_	
117-18	24772-24773	p	_	
117-19	24774-24775	<	_	
117-20	24776-24780	0.05	_	
117-21	24781-24784	SVC	_	
117-22	24784-24785	;	_	
117-23	24786-24789	Fig	_	
117-24	24789-24790	.	_	
117-25	24791-24792	4	_	
117-26	24792-24793	)	_	
117-27	24793-24794	,	_	
117-28	24795-24802	showing	_	
117-29	24803-24806	the	_	
117-30	24807-24814	effects	_	
117-31	24815-24817	of	_	
117-32	24818-24829	expectation	_	
117-33	24830-24832	on	_	
117-34	24833-24843	MP-induced	_	
117-35	24844-24846	DA	_	
117-36	24847-24856	increases	_	
117-37	24857-24859	to	_	
117-38	24860-24864	have	_	
117-39	24865-24873	opposite	_	
117-40	24874-24881	effects	_	
117-41	24882-24884	in	_	
117-42	24885-24888	CUD	_	
117-43	24889-24893	than	_	
117-44	24894-24896	in	_	
117-45	24897-24899	HC	_	
117-46	24900-24902	in	_	
117-47	24903-24908	these	_	
117-48	24909-24912	two	_	
117-49	24913-24920	regions	_	
117-50	24920-24921	.	_	

#Text=Specifically, in HC expectation increased the effects of MP, whereas in CUD it decreased them; in juxtaposition, when expecting PL in HC MP tended to inhibit DA release, whereas in CUD it increased DA.
118-1	24922-24934	Specifically	_	
118-2	24934-24935	,	_	
118-3	24936-24938	in	_	
118-4	24939-24941	HC	_	
118-5	24942-24953	expectation	_	
118-6	24954-24963	increased	_	
118-7	24964-24967	the	_	
118-8	24968-24975	effects	_	
118-9	24976-24978	of	_	
118-10	24979-24981	MP	_	
118-11	24981-24982	,	_	
118-12	24983-24990	whereas	_	
118-13	24991-24993	in	_	
118-14	24994-24997	CUD	_	
118-15	24998-25000	it	_	
118-16	25001-25010	decreased	_	
118-17	25011-25015	them	_	
118-18	25015-25016	;	_	
118-19	25017-25019	in	_	
118-20	25020-25033	juxtaposition	_	
118-21	25033-25034	,	_	
118-22	25035-25039	when	_	
118-23	25040-25049	expecting	_	
118-24	25050-25052	PL	_	
118-25	25053-25055	in	_	
118-26	25056-25058	HC	_	
118-27	25059-25061	MP	_	
118-28	25062-25068	tended	_	
118-29	25069-25071	to	_	
118-30	25072-25079	inhibit	_	
118-31	25080-25082	DA	_	
118-32	25083-25090	release	_	
118-33	25090-25091	,	_	
118-34	25092-25099	whereas	_	
118-35	25100-25102	in	_	
118-36	25103-25106	CUD	_	
118-37	25107-25109	it	_	
118-38	25110-25119	increased	_	
118-39	25120-25122	DA	_	
118-40	25122-25123	.	_	

#Text=Correlations with cardiovascular and self-report ratings
#Text=Correlations between dopamine (DA) release in putamen with methylphenidate-induced increases in self-report ratings (from 1 to 10) of “rush” and “high”.
#Text=a, b Significant correlations were present for groups pooled together and appear to be predominantly driven by the strong group difference in DA release in putamen (p < 0.0001) and ratings of “rush” (p = 0.006) and “high” (p = 0.007)
#Text=Activations for main effect of Challenge (putamen, caudate, NAc) were extracted using SPM8 and were correlated with its cardiovascular and self-reported responses.
119-1	25124-25136	Correlations	_	
119-2	25137-25141	with	_	
119-3	25142-25156	cardiovascular	_	
119-4	25157-25160	and	_	
119-5	25161-25172	self-report	_	
119-6	25173-25180	ratings	_	
119-7	25181-25193	Correlations	_	
119-8	25194-25201	between	_	
119-9	25202-25210	dopamine	_	
119-10	25211-25212	(	_	
119-11	25212-25214	DA	_	
119-12	25214-25215	)	_	
119-13	25216-25223	release	_	
119-14	25224-25226	in	_	
119-15	25227-25234	putamen	_	
119-16	25235-25239	with	_	
119-17	25240-25263	methylphenidate-induced	_	
119-18	25264-25273	increases	_	
119-19	25274-25276	in	_	
119-20	25277-25288	self-report	_	
119-21	25289-25296	ratings	_	
119-22	25297-25298	(	_	
119-23	25298-25302	from	_	
119-24	25303-25304	1	_	
119-25	25305-25307	to	_	
119-26	25308-25310	10	_	
119-27	25310-25311	)	_	
119-28	25312-25314	of	_	
119-29	25315-25316	“	_	
119-30	25316-25320	rush	_	
119-31	25320-25321	”	_	
119-32	25322-25325	and	_	
119-33	25326-25327	“	_	
119-34	25327-25331	high	_	
119-35	25331-25332	”	_	
119-36	25332-25333	.	_	
119-37	25334-25335	a	_	
119-38	25335-25336	,	_	
119-39	25337-25338	b	_	
119-40	25339-25350	Significant	_	
119-41	25351-25363	correlations	_	
119-42	25364-25368	were	_	
119-43	25369-25376	present	_	
119-44	25377-25380	for	_	
119-45	25381-25387	groups	_	
119-46	25388-25394	pooled	_	
119-47	25395-25403	together	_	
119-48	25404-25407	and	_	
119-49	25408-25414	appear	_	
119-50	25415-25417	to	_	
119-51	25418-25420	be	_	
119-52	25421-25434	predominantly	_	
119-53	25435-25441	driven	_	
119-54	25442-25444	by	_	
119-55	25445-25448	the	_	
119-56	25449-25455	strong	_	
119-57	25456-25461	group	_	
119-58	25462-25472	difference	_	
119-59	25473-25475	in	_	
119-60	25476-25478	DA	_	
119-61	25479-25486	release	_	
119-62	25487-25489	in	_	
119-63	25490-25497	putamen	_	
119-64	25498-25499	(	_	
119-65	25499-25500	p	_	
119-66	25501-25502	<	_	
119-67	25503-25509	0.0001	_	
119-68	25509-25510	)	_	
119-69	25511-25514	and	_	
119-70	25515-25522	ratings	_	
119-71	25523-25525	of	_	
119-72	25526-25527	“	_	
119-73	25527-25531	rush	_	
119-74	25531-25532	”	_	
119-75	25533-25534	(	_	
119-76	25534-25535	p	_	
119-77	25536-25537	=	_	
119-78	25538-25543	0.006	_	
119-79	25543-25544	)	_	
119-80	25545-25548	and	_	
119-81	25549-25550	“	_	
119-82	25550-25554	high	_	
119-83	25554-25555	”	_	
119-84	25556-25557	(	_	
119-85	25557-25558	p	_	
119-86	25559-25560	=	_	
119-87	25561-25566	0.007	_	
119-88	25566-25567	)	_	
119-89	25568-25579	Activations	_	
119-90	25580-25583	for	_	
119-91	25584-25588	main	_	
119-92	25589-25595	effect	_	
119-93	25596-25598	of	_	
119-94	25599-25608	Challenge	_	
119-95	25609-25610	(	_	
119-96	25610-25617	putamen	_	
119-97	25617-25618	,	_	
119-98	25619-25626	caudate	_	
119-99	25626-25627	,	_	
119-100	25628-25631	NAc	_	
119-101	25631-25632	)	_	
119-102	25633-25637	were	_	
119-103	25638-25647	extracted	_	
119-104	25648-25653	using	_	
119-105	25654-25658	SPM8	_	
119-106	25659-25662	and	_	
119-107	25663-25667	were	_	
119-108	25668-25678	correlated	_	
119-109	25679-25683	with	_	
119-110	25684-25687	its	_	
119-111	25688-25702	cardiovascular	_	
119-112	25703-25706	and	_	
119-113	25707-25720	self-reported	_	
119-114	25721-25730	responses	_	
119-115	25730-25731	.	_	

#Text=DA release in putamen correlated positively with MP-induced increases in self-report ratings of “rush” (r = 0.43, p = 0.003) and “high” (r = 0.39, p = 0.007) when groups were pooled together (Fig. 5).
120-1	25732-25734	DA	_	
120-2	25735-25742	release	_	
120-3	25743-25745	in	_	
120-4	25746-25753	putamen	_	
120-5	25754-25764	correlated	_	
120-6	25765-25775	positively	_	
120-7	25776-25780	with	_	
120-8	25781-25791	MP-induced	_	
120-9	25792-25801	increases	_	
120-10	25802-25804	in	_	
120-11	25805-25816	self-report	_	
120-12	25817-25824	ratings	_	
120-13	25825-25827	of	_	
120-14	25828-25829	“	_	
120-15	25829-25833	rush	_	
120-16	25833-25834	”	_	
120-17	25835-25836	(	_	
120-18	25836-25837	r	_	
120-19	25838-25839	=	_	
120-20	25840-25844	0.43	_	
120-21	25844-25845	,	_	
120-22	25846-25847	p	_	
120-23	25848-25849	=	_	
120-24	25850-25855	0.003	_	
120-25	25855-25856	)	_	
120-26	25857-25860	and	_	
120-27	25861-25862	“	_	
120-28	25862-25866	high	_	
120-29	25866-25867	”	_	
120-30	25868-25869	(	_	
120-31	25869-25870	r	_	
120-32	25871-25872	=	_	
120-33	25873-25877	0.39	_	
120-34	25877-25878	,	_	
120-35	25879-25880	p	_	
120-36	25881-25882	=	_	
120-37	25883-25888	0.007	_	
120-38	25888-25889	)	_	
120-39	25890-25894	when	_	
120-40	25895-25901	groups	_	
120-41	25902-25906	were	_	
120-42	25907-25913	pooled	_	
120-43	25914-25922	together	_	
120-44	25923-25924	(	_	
120-45	25924-25927	Fig	_	
120-46	25927-25928	.	_	
120-47	25929-25930	5	_	
120-48	25930-25931	)	_	
120-49	25931-25932	.	_	

#Text=However, these correlations were not present for each group separately (the correlations reached trend level only in HC: rush: r = 0.39, p = 0.06, high: r = 0.32, p = 0.14)) and thus are largely driven by the strong group difference in DA release in putamen (t = 8.8, p < 0.0001) and ratings of “rush” (t = 2.9, p = 0.006) and “high” (t = 2.8, p = 0.007) during MP–PL conditions.
121-1	25933-25940	However	_	
121-2	25940-25941	,	_	
121-3	25942-25947	these	_	
121-4	25948-25960	correlations	_	
121-5	25961-25965	were	_	
121-6	25966-25969	not	_	
121-7	25970-25977	present	_	
121-8	25978-25981	for	_	
121-9	25982-25986	each	_	
121-10	25987-25992	group	_	
121-11	25993-26003	separately	_	
121-12	26004-26005	(	_	
121-13	26005-26008	the	_	
121-14	26009-26021	correlations	_	
121-15	26022-26029	reached	_	
121-16	26030-26035	trend	_	
121-17	26036-26041	level	_	
121-18	26042-26046	only	_	
121-19	26047-26049	in	_	
121-20	26050-26052	HC	_	
121-21	26052-26053	:	_	
121-22	26054-26058	rush	_	
121-23	26058-26059	:	_	
121-24	26060-26061	r	_	
121-25	26062-26063	=	_	
121-26	26064-26068	0.39	_	
121-27	26068-26069	,	_	
121-28	26070-26071	p	_	
121-29	26072-26073	=	_	
121-30	26074-26078	0.06	_	
121-31	26078-26079	,	_	
121-32	26080-26084	high	_	
121-33	26084-26085	:	_	
121-34	26086-26087	r	_	
121-35	26088-26089	=	_	
121-36	26090-26094	0.32	_	
121-37	26094-26095	,	_	
121-38	26096-26097	p	_	
121-39	26098-26099	=	_	
121-40	26100-26104	0.14	_	
121-41	26104-26105	)	_	
121-42	26105-26106	)	_	
121-43	26107-26110	and	_	
121-44	26111-26115	thus	_	
121-45	26116-26119	are	_	
121-46	26120-26127	largely	_	
121-47	26128-26134	driven	_	
121-48	26135-26137	by	_	
121-49	26138-26141	the	_	
121-50	26142-26148	strong	_	
121-51	26149-26154	group	_	
121-52	26155-26165	difference	_	
121-53	26166-26168	in	_	
121-54	26169-26171	DA	_	
121-55	26172-26179	release	_	
121-56	26180-26182	in	_	
121-57	26183-26190	putamen	_	
121-58	26191-26192	(	_	
121-59	26192-26193	t	_	
121-60	26194-26195	=	_	
121-61	26196-26199	8.8	_	
121-62	26199-26200	,	_	
121-63	26201-26202	p	_	
121-64	26203-26204	<	_	
121-65	26205-26211	0.0001	_	
121-66	26211-26212	)	_	
121-67	26213-26216	and	_	
121-68	26217-26224	ratings	_	
121-69	26225-26227	of	_	
121-70	26228-26229	“	_	
121-71	26229-26233	rush	_	
121-72	26233-26234	”	_	
121-73	26235-26236	(	_	
121-74	26236-26237	t	_	
121-75	26238-26239	=	_	
121-76	26240-26243	2.9	_	
121-77	26243-26244	,	_	
121-78	26245-26246	p	_	
121-79	26247-26248	=	_	
121-80	26249-26254	0.006	_	
121-81	26254-26255	)	_	
121-82	26256-26259	and	_	
121-83	26260-26261	“	_	
121-84	26261-26265	high	_	
121-85	26265-26266	”	_	
121-86	26267-26268	(	_	
121-87	26268-26269	t	_	
121-88	26270-26271	=	_	
121-89	26272-26275	2.8	_	
121-90	26275-26276	,	_	
121-91	26277-26278	p	_	
121-92	26279-26280	=	_	
121-93	26281-26286	0.007	_	
121-94	26286-26287	)	_	
121-95	26288-26294	during	_	
121-96	26295-26300	MP–PL	_	
121-97	26301-26311	conditions	_	
121-98	26311-26312	.	_	

#Text=Group × Challenge × Expectation interaction values in caudate or midbrain did not correlate with interactions in behavior or cardiovascular responses.
122-1	26313-26318	Group	_	
122-2	26319-26320	×	_	
122-3	26321-26330	Challenge	_	
122-4	26331-26332	×	_	
122-5	26333-26344	Expectation	_	
122-6	26345-26356	interaction	_	
122-7	26357-26363	values	_	
122-8	26364-26366	in	_	
122-9	26367-26374	caudate	_	
122-10	26375-26377	or	_	
122-11	26378-26386	midbrain	_	
122-12	26387-26390	did	_	
122-13	26391-26394	not	_	
122-14	26395-26404	correlate	_	
122-15	26405-26409	with	_	
122-16	26410-26422	interactions	_	
122-17	26423-26425	in	_	
122-18	26426-26434	behavior	_	
122-19	26435-26437	or	_	
122-20	26438-26452	cardiovascular	_	
122-21	26453-26462	responses	_	
122-22	26462-26463	.	_	

#Text=Discussion
#Text=Our study replicated previous findings in showing lower D2R availability and blunted striatal DA release in CUD compared to HC and is consistent with prior reports of attenuated DA responses to MP in active and detoxified CUD and with attenuated DA increases to amphetamine in detoxified CUD.
123-1	26464-26474	Discussion	_	
123-2	26475-26478	Our	_	
123-3	26479-26484	study	_	
123-4	26485-26495	replicated	_	
123-5	26496-26504	previous	_	
123-6	26505-26513	findings	_	
123-7	26514-26516	in	_	
123-8	26517-26524	showing	_	
123-9	26525-26530	lower	_	
123-10	26531-26534	D2R	_	
123-11	26535-26547	availability	_	
123-12	26548-26551	and	_	
123-13	26552-26559	blunted	_	
123-14	26560-26568	striatal	_	
123-15	26569-26571	DA	_	
123-16	26572-26579	release	_	
123-17	26580-26582	in	_	
123-18	26583-26586	CUD	_	
123-19	26587-26595	compared	_	
123-20	26596-26598	to	_	
123-21	26599-26601	HC	_	
123-22	26602-26605	and	_	
123-23	26606-26608	is	_	
123-24	26609-26619	consistent	_	
123-25	26620-26624	with	_	
123-26	26625-26630	prior	_	
123-27	26631-26638	reports	_	
123-28	26639-26641	of	_	
123-29	26642-26652	attenuated	_	
123-30	26653-26655	DA	_	
123-31	26656-26665	responses	_	
123-32	26666-26668	to	_	
123-33	26669-26671	MP	_	
123-34	26672-26674	in	_	
123-35	26675-26681	active	_	
123-36	26682-26685	and	_	
123-37	26686-26696	detoxified	_	
123-38	26697-26700	CUD	_	
123-39	26701-26704	and	_	
123-40	26705-26709	with	_	
123-41	26710-26720	attenuated	_	
123-42	26721-26723	DA	_	
123-43	26724-26733	increases	_	
123-44	26734-26736	to	_	
123-45	26737-26748	amphetamine	_	
123-46	26749-26751	in	_	
123-47	26752-26762	detoxified	_	
123-48	26763-26766	CUD	_	
123-49	26766-26767	.	_	

#Text=The study further showed a Group × Challenge × Expectation effect in the left caudate and bilateral midbrain (p < 0.05 SVC).
124-1	26768-26771	The	_	
124-2	26772-26777	study	_	
124-3	26778-26785	further	_	
124-4	26786-26792	showed	_	
124-5	26793-26794	a	_	
124-6	26795-26800	Group	_	
124-7	26801-26802	×	_	
124-8	26803-26812	Challenge	_	
124-9	26813-26814	×	_	
124-10	26815-26826	Expectation	_	
124-11	26827-26833	effect	_	
124-12	26834-26836	in	_	
124-13	26837-26840	the	_	
124-14	26841-26845	left	_	
124-15	26846-26853	caudate	_	
124-16	26854-26857	and	_	
124-17	26858-26867	bilateral	_	
124-18	26868-26876	midbrain	_	
124-19	26877-26878	(	_	
124-20	26878-26879	p	_	
124-21	26880-26881	<	_	
124-22	26882-26886	0.05	_	
124-23	26887-26890	SVC	_	
124-24	26890-26891	)	_	
124-25	26891-26892	.	_	

#Text=More specifically, it showed opposite effects in HC and CUD such that expectation of receiving MP increased and decreased MP-induced DA release in HC and CUD, respectively; in juxtaposition, the expectation of receiving PL enhanced DA release in CUD but reduced it in HC.
125-1	26893-26897	More	_	
125-2	26898-26910	specifically	_	
125-3	26910-26911	,	_	
125-4	26912-26914	it	_	
125-5	26915-26921	showed	_	
125-6	26922-26930	opposite	_	
125-7	26931-26938	effects	_	
125-8	26939-26941	in	_	
125-9	26942-26944	HC	_	
125-10	26945-26948	and	_	
125-11	26949-26952	CUD	_	
125-12	26953-26957	such	_	
125-13	26958-26962	that	_	
125-14	26963-26974	expectation	_	
125-15	26975-26977	of	_	
125-16	26978-26987	receiving	_	
125-17	26988-26990	MP	_	
125-18	26991-27000	increased	_	
125-19	27001-27004	and	_	
125-20	27005-27014	decreased	_	
125-21	27015-27025	MP-induced	_	
125-22	27026-27028	DA	_	
125-23	27029-27036	release	_	
125-24	27037-27039	in	_	
125-25	27040-27042	HC	_	
125-26	27043-27046	and	_	
125-27	27047-27050	CUD	_	
125-28	27050-27051	,	_	
125-29	27052-27064	respectively	_	
125-30	27064-27065	;	_	
125-31	27066-27068	in	_	
125-32	27069-27082	juxtaposition	_	
125-33	27082-27083	,	_	
125-34	27084-27087	the	_	
125-35	27088-27099	expectation	_	
125-36	27100-27102	of	_	
125-37	27103-27112	receiving	_	
125-38	27113-27115	PL	_	
125-39	27116-27124	enhanced	_	
125-40	27125-27127	DA	_	
125-41	27128-27135	release	_	
125-42	27136-27138	in	_	
125-43	27139-27142	CUD	_	
125-44	27143-27146	but	_	
125-45	27147-27154	reduced	_	
125-46	27155-27157	it	_	
125-47	27158-27160	in	_	
125-48	27161-27163	HC	_	
125-49	27163-27164	.	_	

#Text=This finding was contrary to our hypothesis that CUD would show conditioned responses to expectation of MP hence an amplified effect, similar to our previous study in which we showed overall elevated brain glucose metabolism responses to expectation of MP in CUD versus HC.
126-1	27165-27169	This	_	
126-2	27170-27177	finding	_	
126-3	27178-27181	was	_	
126-4	27182-27190	contrary	_	
126-5	27191-27193	to	_	
126-6	27194-27197	our	_	
126-7	27198-27208	hypothesis	_	
126-8	27209-27213	that	_	
126-9	27214-27217	CUD	_	
126-10	27218-27223	would	_	
126-11	27224-27228	show	_	
126-12	27229-27240	conditioned	_	
126-13	27241-27250	responses	_	
126-14	27251-27253	to	_	
126-15	27254-27265	expectation	_	
126-16	27266-27268	of	_	
126-17	27269-27271	MP	_	
126-18	27272-27277	hence	_	
126-19	27278-27280	an	_	
126-20	27281-27290	amplified	_	
126-21	27291-27297	effect	_	
126-22	27297-27298	,	_	
126-23	27299-27306	similar	_	
126-24	27307-27309	to	_	
126-25	27310-27313	our	_	
126-26	27314-27322	previous	_	
126-27	27323-27328	study	_	
126-28	27329-27331	in	_	
126-29	27332-27337	which	_	
126-30	27338-27340	we	_	
126-31	27341-27347	showed	_	
126-32	27348-27355	overall	_	
126-33	27356-27364	elevated	_	
126-34	27365-27370	brain	_	
126-35	27371-27378	glucose	_	
126-36	27379-27389	metabolism	_	
126-37	27390-27399	responses	_	
126-38	27400-27402	to	_	
126-39	27403-27414	expectation	_	
126-40	27415-27417	of	_	
126-41	27418-27420	MP	_	
126-42	27421-27423	in	_	
126-43	27424-27427	CUD	_	
126-44	27428-27434	versus	_	
126-45	27435-27437	HC	_	
126-46	27437-27438	.	_	

#Text=This discrepancy is likely to reflect the fact that brain glucose metabolic responses reflect not just DA effects but also downstream DA responses as well as non-DA responses implicated in conditions (i.e., glutamatergic modulation).
127-1	27439-27443	This	_	
127-2	27444-27455	discrepancy	_	
127-3	27456-27458	is	_	
127-4	27459-27465	likely	_	
127-5	27466-27468	to	_	
127-6	27469-27476	reflect	_	
127-7	27477-27480	the	_	
127-8	27481-27485	fact	_	
127-9	27486-27490	that	_	
127-10	27491-27496	brain	_	
127-11	27497-27504	glucose	_	
127-12	27505-27514	metabolic	_	
127-13	27515-27524	responses	_	
127-14	27525-27532	reflect	_	
127-15	27533-27536	not	_	
127-16	27537-27541	just	_	
127-17	27542-27544	DA	_	
127-18	27545-27552	effects	_	
127-19	27553-27556	but	_	
127-20	27557-27561	also	_	
127-21	27562-27572	downstream	_	
127-22	27573-27575	DA	_	
127-23	27576-27585	responses	_	
127-24	27586-27588	as	_	
127-25	27589-27593	well	_	
127-26	27594-27596	as	_	
127-27	27597-27603	non-DA	_	
127-28	27604-27613	responses	_	
127-29	27614-27624	implicated	_	
127-30	27625-27627	in	_	
127-31	27628-27638	conditions	_	
127-32	27639-27640	(	_	
127-33	27640-27643	i.e	_	
127-34	27643-27644	.	_	
127-35	27644-27645	,	_	
127-36	27646-27659	glutamatergic	_	
127-37	27660-27670	modulation	_	
127-38	27670-27671	)	_	
127-39	27671-27672	.	_	

#Text=The DA system is critical for signaling expectation of rewards and for motivating behaviors needed to achieve the reward.
128-1	27673-27676	The	_	
128-2	27677-27679	DA	_	
128-3	27680-27686	system	_	
128-4	27687-27689	is	_	
128-5	27690-27698	critical	_	
128-6	27699-27702	for	_	
128-7	27703-27712	signaling	_	
128-8	27713-27724	expectation	_	
128-9	27725-27727	of	_	
128-10	27728-27735	rewards	_	
128-11	27736-27739	and	_	
128-12	27740-27743	for	_	
128-13	27744-27754	motivating	_	
128-14	27755-27764	behaviors	_	
128-15	27765-27771	needed	_	
128-16	27772-27774	to	_	
128-17	27775-27782	achieve	_	
128-18	27783-27786	the	_	
128-19	27787-27793	reward	_	
128-20	27793-27794	.	_	

#Text=DA neurons in midbrain initially respond to unexpected primary rewards and with repeated exposure eventually to the stimuli that predict those rewards.
129-1	27795-27797	DA	_	
129-2	27798-27805	neurons	_	
129-3	27806-27808	in	_	
129-4	27809-27817	midbrain	_	
129-5	27818-27827	initially	_	
129-6	27828-27835	respond	_	
129-7	27836-27838	to	_	
129-8	27839-27849	unexpected	_	
129-9	27850-27857	primary	_	
129-10	27858-27865	rewards	_	
129-11	27866-27869	and	_	
129-12	27870-27874	with	_	
129-13	27875-27883	repeated	_	
129-14	27884-27892	exposure	_	
129-15	27893-27903	eventually	_	
129-16	27904-27906	to	_	
129-17	27907-27910	the	_	
129-18	27911-27918	stimuli	_	
129-19	27919-27923	that	_	
129-20	27924-27931	predict	_	
129-21	27932-27937	those	_	
129-22	27938-27945	rewards	_	
129-23	27945-27946	.	_	

#Text=The anticipation of a rewarding outcome is often inferred based on activation in striatal regions, including caudate, putamen, NAc, and in ventral cingulate and orbitofrontal cortices.
130-1	27947-27950	The	_	
130-2	27951-27963	anticipation	_	
130-3	27964-27966	of	_	
130-4	27967-27968	a	_	
130-5	27969-27978	rewarding	_	
130-6	27979-27986	outcome	_	
130-7	27987-27989	is	_	
130-8	27990-27995	often	_	
130-9	27996-28004	inferred	_	
130-10	28005-28010	based	_	
130-11	28011-28013	on	_	
130-12	28014-28024	activation	_	
130-13	28025-28027	in	_	
130-14	28028-28036	striatal	_	
130-15	28037-28044	regions	_	
130-16	28044-28045	,	_	
130-17	28046-28055	including	_	
130-18	28056-28063	caudate	_	
130-19	28063-28064	,	_	
130-20	28065-28072	putamen	_	
130-21	28072-28073	,	_	
130-22	28074-28077	NAc	_	
130-23	28077-28078	,	_	
130-24	28079-28082	and	_	
130-25	28083-28085	in	_	
130-26	28086-28093	ventral	_	
130-27	28094-28103	cingulate	_	
130-28	28104-28107	and	_	
130-29	28108-28121	orbitofrontal	_	
130-30	28122-28130	cortices	_	
130-31	28130-28131	.	_	

#Text=Neurons in the midbrain code for a breach in expectation (i.e., prediction error).
131-1	28132-28139	Neurons	_	
131-2	28140-28142	in	_	
131-3	28143-28146	the	_	
131-4	28147-28155	midbrain	_	
131-5	28156-28160	code	_	
131-6	28161-28164	for	_	
131-7	28165-28166	a	_	
131-8	28167-28173	breach	_	
131-9	28174-28176	in	_	
131-10	28177-28188	expectation	_	
131-11	28189-28190	(	_	
131-12	28190-28193	i.e	_	
131-13	28193-28194	.	_	
131-14	28194-28195	,	_	
131-15	28196-28206	prediction	_	
131-16	28207-28212	error	_	
131-17	28212-28213	)	_	
131-18	28213-28214	.	_	

#Text=The activation is associated with a distributed network involved in detecting, signaling, and adjusting behavior and expectations toward violated prediction.
132-1	28215-28218	The	_	
132-2	28219-28229	activation	_	
132-3	28230-28232	is	_	
132-4	28233-28243	associated	_	
132-5	28244-28248	with	_	
132-6	28249-28250	a	_	
132-7	28251-28262	distributed	_	
132-8	28263-28270	network	_	
132-9	28271-28279	involved	_	
132-10	28280-28282	in	_	
132-11	28283-28292	detecting	_	
132-12	28292-28293	,	_	
132-13	28294-28303	signaling	_	
132-14	28303-28304	,	_	
132-15	28305-28308	and	_	
132-16	28309-28318	adjusting	_	
132-17	28319-28327	behavior	_	
132-18	28328-28331	and	_	
132-19	28332-28344	expectations	_	
132-20	28345-28351	toward	_	
132-21	28352-28360	violated	_	
132-22	28361-28371	prediction	_	
132-23	28371-28372	.	_	

#Text=Caudate neurons have been shown to participate in feature-based anticipation of visual information that predicts reward.
133-1	28373-28380	Caudate	_	
133-2	28381-28388	neurons	_	
133-3	28389-28393	have	_	
133-4	28394-28398	been	_	
133-5	28399-28404	shown	_	
133-6	28405-28407	to	_	
133-7	28408-28419	participate	_	
133-8	28420-28422	in	_	
133-9	28423-28436	feature-based	_	
133-10	28437-28449	anticipation	_	
133-11	28450-28452	of	_	
133-12	28453-28459	visual	_	
133-13	28460-28471	information	_	
133-14	28472-28476	that	_	
133-15	28477-28485	predicts	_	
133-16	28486-28492	reward	_	
133-17	28492-28493	.	_	

#Text=Caudate neurons fire not only before the onset of an expected target but also in preparatory responding to signals that predict reward.
134-1	28494-28501	Caudate	_	
134-2	28502-28509	neurons	_	
134-3	28510-28514	fire	_	
134-4	28515-28518	not	_	
134-5	28519-28523	only	_	
134-6	28524-28530	before	_	
134-7	28531-28534	the	_	
134-8	28535-28540	onset	_	
134-9	28541-28543	of	_	
134-10	28544-28546	an	_	
134-11	28547-28555	expected	_	
134-12	28556-28562	target	_	
134-13	28563-28566	but	_	
134-14	28567-28571	also	_	
134-15	28572-28574	in	_	
134-16	28575-28586	preparatory	_	
134-17	28587-28597	responding	_	
134-18	28598-28600	to	_	
134-19	28601-28608	signals	_	
134-20	28609-28613	that	_	
134-21	28614-28621	predict	_	
134-22	28622-28628	reward	_	
134-23	28628-28629	.	_	

#Text=When predictions are violated, caudate activity attenuates over the course of learning.
135-1	28630-28634	When	_	
135-2	28635-28646	predictions	_	
135-3	28647-28650	are	_	
135-4	28651-28659	violated	_	
135-5	28659-28660	,	_	
135-6	28661-28668	caudate	_	
135-7	28669-28677	activity	_	
135-8	28678-28688	attenuates	_	
135-9	28689-28693	over	_	
135-10	28694-28697	the	_	
135-11	28698-28704	course	_	
135-12	28705-28707	of	_	
135-13	28708-28716	learning	_	
135-14	28716-28717	.	_	

#Text=Once the rules have been established, breaches of expectation diminish and so does the caudate activity.
136-1	28718-28722	Once	_	
136-2	28723-28726	the	_	
136-3	28727-28732	rules	_	
136-4	28733-28737	have	_	
136-5	28738-28742	been	_	
136-6	28743-28754	established	_	
136-7	28754-28755	,	_	
136-8	28756-28764	breaches	_	
136-9	28765-28767	of	_	
136-10	28768-28779	expectation	_	
136-11	28780-28788	diminish	_	
136-12	28789-28792	and	_	
136-13	28793-28795	so	_	
136-14	28796-28800	does	_	
136-15	28801-28804	the	_	
136-16	28805-28812	caudate	_	
136-17	28813-28821	activity	_	
136-18	28821-28822	.	_	

#Text=The caudate signals for the occurrence of events that violate the predictions.
137-1	28823-28826	The	_	
137-2	28827-28834	caudate	_	
137-3	28835-28842	signals	_	
137-4	28843-28846	for	_	
137-5	28847-28850	the	_	
137-6	28851-28861	occurrence	_	
137-7	28862-28864	of	_	
137-8	28865-28871	events	_	
137-9	28872-28876	that	_	
137-10	28877-28884	violate	_	
137-11	28885-28888	the	_	
137-12	28889-28900	predictions	_	
137-13	28900-28901	.	_	

#Text=This signal is not due to the perception of salient events or the need to change one’s behavior.
138-1	28902-28906	This	_	
138-2	28907-28913	signal	_	
138-3	28914-28916	is	_	
138-4	28917-28920	not	_	
138-5	28921-28924	due	_	
138-6	28925-28927	to	_	
138-7	28928-28931	the	_	
138-8	28932-28942	perception	_	
138-9	28943-28945	of	_	
138-10	28946-28953	salient	_	
138-11	28954-28960	events	_	
138-12	28961-28963	or	_	
138-13	28964-28967	the	_	
138-14	28968-28972	need	_	
138-15	28973-28975	to	_	
138-16	28976-28982	change	_	
138-17	28983-28986	one	_	
138-18	28986-28987	’	_	
138-19	28987-28988	s	_	
138-20	28989-28997	behavior	_	
138-21	28997-28998	.	_	

#Text=Thus one interpretation of our findings is that in CUD the blunted DA and self-reported responses to MP was coded as an omission of reward that led to decrease DA cell firing and reduced DA release in caudate and midbrain consistent with the role of DA encoding for reward prediction error.
139-1	28999-29003	Thus	_	
139-2	29004-29007	one	_	
139-3	29008-29022	interpretation	_	
139-4	29023-29025	of	_	
139-5	29026-29029	our	_	
139-6	29030-29038	findings	_	
139-7	29039-29041	is	_	
139-8	29042-29046	that	_	
139-9	29047-29049	in	_	
139-10	29050-29053	CUD	_	
139-11	29054-29057	the	_	
139-12	29058-29065	blunted	_	
139-13	29066-29068	DA	_	
139-14	29069-29072	and	_	
139-15	29073-29086	self-reported	_	
139-16	29087-29096	responses	_	
139-17	29097-29099	to	_	
139-18	29100-29102	MP	_	
139-19	29103-29106	was	_	
139-20	29107-29112	coded	_	
139-21	29113-29115	as	_	
139-22	29116-29118	an	_	
139-23	29119-29127	omission	_	
139-24	29128-29130	of	_	
139-25	29131-29137	reward	_	
139-26	29138-29142	that	_	
139-27	29143-29146	led	_	
139-28	29147-29149	to	_	
139-29	29150-29158	decrease	_	
139-30	29159-29161	DA	_	
139-31	29162-29166	cell	_	
139-32	29167-29173	firing	_	
139-33	29174-29177	and	_	
139-34	29178-29185	reduced	_	
139-35	29186-29188	DA	_	
139-36	29189-29196	release	_	
139-37	29197-29199	in	_	
139-38	29200-29207	caudate	_	
139-39	29208-29211	and	_	
139-40	29212-29220	midbrain	_	
139-41	29221-29231	consistent	_	
139-42	29232-29236	with	_	
139-43	29237-29240	the	_	
139-44	29241-29245	role	_	
139-45	29246-29248	of	_	
139-46	29249-29251	DA	_	
139-47	29252-29260	encoding	_	
139-48	29261-29264	for	_	
139-49	29265-29271	reward	_	
139-50	29272-29282	prediction	_	
139-51	29283-29288	error	_	
139-52	29288-29289	.	_	

#Text=That is, DA neurons are activated when the reward is larger than predicted, whereas they are inhibited when the reward is less than predicted.
140-1	29290-29294	That	_	
140-2	29295-29297	is	_	
140-3	29297-29298	,	_	
140-4	29299-29301	DA	_	
140-5	29302-29309	neurons	_	
140-6	29310-29313	are	_	
140-7	29314-29323	activated	_	
140-8	29324-29328	when	_	
140-9	29329-29332	the	_	
140-10	29333-29339	reward	_	
140-11	29340-29342	is	_	
140-12	29343-29349	larger	_	
140-13	29350-29354	than	_	
140-14	29355-29364	predicted	_	
140-15	29364-29365	,	_	
140-16	29366-29373	whereas	_	
140-17	29374-29378	they	_	
140-18	29379-29382	are	_	
140-19	29383-29392	inhibited	_	
140-20	29393-29397	when	_	
140-21	29398-29401	the	_	
140-22	29402-29408	reward	_	
140-23	29409-29411	is	_	
140-24	29412-29416	less	_	
140-25	29417-29421	than	_	
140-26	29422-29431	predicted	_	
140-27	29431-29432	.	_	

#Text=This could also explain why an unexpected signal with PL might have led to increased DA release in CUD who might have responded to conditioning to the act of injection, which would have not been the case for HC.
141-1	29433-29437	This	_	
141-2	29438-29443	could	_	
141-3	29444-29448	also	_	
141-4	29449-29456	explain	_	
141-5	29457-29460	why	_	
141-6	29461-29463	an	_	
141-7	29464-29474	unexpected	_	
141-8	29475-29481	signal	_	
141-9	29482-29486	with	_	
141-10	29487-29489	PL	_	
141-11	29490-29495	might	_	
141-12	29496-29500	have	_	
141-13	29501-29504	led	_	
141-14	29505-29507	to	_	
141-15	29508-29517	increased	_	
141-16	29518-29520	DA	_	
141-17	29521-29528	release	_	
141-18	29529-29531	in	_	
141-19	29532-29535	CUD	_	
141-20	29536-29539	who	_	
141-21	29540-29545	might	_	
141-22	29546-29550	have	_	
141-23	29551-29560	responded	_	
141-24	29561-29563	to	_	
141-25	29564-29576	conditioning	_	
141-26	29577-29579	to	_	
141-27	29580-29583	the	_	
141-28	29584-29587	act	_	
141-29	29588-29590	of	_	
141-30	29591-29600	injection	_	
141-31	29600-29601	,	_	
141-32	29602-29607	which	_	
141-33	29608-29613	would	_	
141-34	29614-29618	have	_	
141-35	29619-29622	not	_	
141-36	29623-29627	been	_	
141-37	29628-29631	the	_	
141-38	29632-29636	case	_	
141-39	29637-29640	for	_	
141-40	29641-29643	HC	_	
141-41	29643-29644	.	_	

#Text=Moreover, recent studies in healthy adults showed that MP decreased midbrain connectivity with the putamen.
142-1	29645-29653	Moreover	_	
142-2	29653-29654	,	_	
142-3	29655-29661	recent	_	
142-4	29662-29669	studies	_	
142-5	29670-29672	in	_	
142-6	29673-29680	healthy	_	
142-7	29681-29687	adults	_	
142-8	29688-29694	showed	_	
142-9	29695-29699	that	_	
142-10	29700-29702	MP	_	
142-11	29703-29712	decreased	_	
142-12	29713-29721	midbrain	_	
142-13	29722-29734	connectivity	_	
142-14	29735-29739	with	_	
142-15	29740-29743	the	_	
142-16	29744-29751	putamen	_	
142-17	29751-29752	.	_	

#Text=Previous PET studies in healthy volunteers have shown that the expectation of stimulant drugs (e.g., MP, amphetamine, and caffeine), without active drug administration, is associated with dopaminergic PL effects, including D2R reductions in the striatum and thalamus.
143-1	29753-29761	Previous	_	
143-2	29762-29765	PET	_	
143-3	29766-29773	studies	_	
143-4	29774-29776	in	_	
143-5	29777-29784	healthy	_	
143-6	29785-29795	volunteers	_	
143-7	29796-29800	have	_	
143-8	29801-29806	shown	_	
143-9	29807-29811	that	_	
143-10	29812-29815	the	_	
143-11	29816-29827	expectation	_	
143-12	29828-29830	of	_	
143-13	29831-29840	stimulant	_	
143-14	29841-29846	drugs	_	
143-15	29847-29848	(	_	
143-16	29848-29851	e.g	_	
143-17	29851-29852	.	_	
143-18	29852-29853	,	_	
143-19	29854-29856	MP	_	
143-20	29856-29857	,	_	
143-21	29858-29869	amphetamine	_	
143-22	29869-29870	,	_	
143-23	29871-29874	and	_	
143-24	29875-29883	caffeine	_	
143-25	29883-29884	)	_	
143-26	29884-29885	,	_	
143-27	29886-29893	without	_	
143-28	29894-29900	active	_	
143-29	29901-29905	drug	_	
143-30	29906-29920	administration	_	
143-31	29920-29921	,	_	
143-32	29922-29924	is	_	
143-33	29925-29935	associated	_	
143-34	29936-29940	with	_	
143-35	29941-29953	dopaminergic	_	
143-36	29954-29956	PL	_	
143-37	29957-29964	effects	_	
143-38	29964-29965	,	_	
143-39	29966-29975	including	_	
143-40	29976-29979	D2R	_	
143-41	29980-29990	reductions	_	
143-42	29991-29993	in	_	
143-43	29994-29997	the	_	
143-44	29998-30006	striatum	_	
143-45	30007-30010	and	_	
143-46	30011-30019	thalamus	_	
143-47	30019-30020	.	_	

#Text=Moreover, PL analgesia has also shown increased striatal and extra-striatal dopaminergic responses under the expectation of analgesia in various studies with human pain models, and patients with Parkinson’s disease who clinically responded to PL treatment showed greater striatal DA release compared to non-responders.
144-1	30021-30029	Moreover	_	
144-2	30029-30030	,	_	
144-3	30031-30033	PL	_	
144-4	30034-30043	analgesia	_	
144-5	30044-30047	has	_	
144-6	30048-30052	also	_	
144-7	30053-30058	shown	_	
144-8	30059-30068	increased	_	
144-9	30069-30077	striatal	_	
144-10	30078-30081	and	_	
144-11	30082-30096	extra-striatal	_	
144-12	30097-30109	dopaminergic	_	
144-13	30110-30119	responses	_	
144-14	30120-30125	under	_	
144-15	30126-30129	the	_	
144-16	30130-30141	expectation	_	
144-17	30142-30144	of	_	
144-18	30145-30154	analgesia	_	
144-19	30155-30157	in	_	
144-20	30158-30165	various	_	
144-21	30166-30173	studies	_	
144-22	30174-30178	with	_	
144-23	30179-30184	human	_	
144-24	30185-30189	pain	_	
144-25	30190-30196	models	_	
144-26	30196-30197	,	_	
144-27	30198-30201	and	_	
144-28	30202-30210	patients	_	
144-29	30211-30215	with	_	
144-30	30216-30225	Parkinson	_	
144-31	30225-30226	’	_	
144-32	30226-30227	s	_	
144-33	30228-30235	disease	_	
144-34	30236-30239	who	_	
144-35	30240-30250	clinically	_	
144-36	30251-30260	responded	_	
144-37	30261-30263	to	_	
144-38	30264-30266	PL	_	
144-39	30267-30276	treatment	_	
144-40	30277-30283	showed	_	
144-41	30284-30291	greater	_	
144-42	30292-30300	striatal	_	
144-43	30301-30303	DA	_	
144-44	30304-30311	release	_	
144-45	30312-30320	compared	_	
144-46	30321-30323	to	_	
144-47	30324-30338	non-responders	_	
144-48	30338-30339	.	_	

#Text=A recent [11C]raclopride study compared dopaminergic responses to alcohol and PL beverages in AUD patients and in healthy participants with and without a family history of AUD.
145-1	30340-30341	A	_	
145-2	30342-30348	recent	_	
145-3	30349-30350	[	_	
145-4	30350-30353	11C	_	
145-5	30353-30354	]	_	
145-6	30354-30364	raclopride	_	
145-7	30365-30370	study	_	
145-8	30371-30379	compared	_	
145-9	30380-30392	dopaminergic	_	
145-10	30393-30402	responses	_	
145-11	30403-30405	to	_	
145-12	30406-30413	alcohol	_	
145-13	30414-30417	and	_	
145-14	30418-30420	PL	_	
145-15	30421-30430	beverages	_	
145-16	30431-30433	in	_	
145-17	30434-30437	AUD	_	
145-18	30438-30446	patients	_	
145-19	30447-30450	and	_	
145-20	30451-30453	in	_	
145-21	30454-30461	healthy	_	
145-22	30462-30474	participants	_	
145-23	30475-30479	with	_	
145-24	30480-30483	and	_	
145-25	30484-30491	without	_	
145-26	30492-30493	a	_	
145-27	30494-30500	family	_	
145-28	30501-30508	history	_	
145-29	30509-30511	of	_	
145-30	30512-30515	AUD	_	
145-31	30515-30516	.	_	

#Text=They found a drink order-by-group interaction such that the family history positive group who received PL first had lower PL BP and lower difference between PL and alcohol BP, which was in line with their subjective expectation of alcohol evoking DA release.
146-1	30517-30521	They	_	
146-2	30522-30527	found	_	
146-3	30528-30529	a	_	
146-4	30530-30535	drink	_	
146-5	30536-30550	order-by-group	_	
146-6	30551-30562	interaction	_	
146-7	30563-30567	such	_	
146-8	30568-30572	that	_	
146-9	30573-30576	the	_	
146-10	30577-30583	family	_	
146-11	30584-30591	history	_	
146-12	30592-30600	positive	_	
146-13	30601-30606	group	_	
146-14	30607-30610	who	_	
146-15	30611-30619	received	_	
146-16	30620-30622	PL	_	
146-17	30623-30628	first	_	
146-18	30629-30632	had	_	
146-19	30633-30638	lower	_	
146-20	30639-30641	PL	_	
146-21	30642-30644	BP	_	
146-22	30645-30648	and	_	
146-23	30649-30654	lower	_	
146-24	30655-30665	difference	_	
146-25	30666-30673	between	_	
146-26	30674-30676	PL	_	
146-27	30677-30680	and	_	
146-28	30681-30688	alcohol	_	
146-29	30689-30691	BP	_	
146-30	30691-30692	,	_	
146-31	30693-30698	which	_	
146-32	30699-30702	was	_	
146-33	30703-30705	in	_	
146-34	30706-30710	line	_	
146-35	30711-30715	with	_	
146-36	30716-30721	their	_	
146-37	30722-30732	subjective	_	
146-38	30733-30744	expectation	_	
146-39	30745-30747	of	_	
146-40	30748-30755	alcohol	_	
146-41	30756-30763	evoking	_	
146-42	30764-30766	DA	_	
146-43	30767-30774	release	_	
146-44	30774-30775	.	_	

#Text=Moreover, in tobacco smokers, the belief of “absence of nicotine in a cigarette” compared to “presence of nicotine in a cigarette” diminished neural blood oxygen-level-dependent responses in the ventral striatum to value and reward prediction errors and reduced its impact on smokers’ choices.
147-1	30776-30784	Moreover	_	
147-2	30784-30785	,	_	
147-3	30786-30788	in	_	
147-4	30789-30796	tobacco	_	
147-5	30797-30804	smokers	_	
147-6	30804-30805	,	_	
147-7	30806-30809	the	_	
147-8	30810-30816	belief	_	
147-9	30817-30819	of	_	
147-10	30820-30821	“	_	
147-11	30821-30828	absence	_	
147-12	30829-30831	of	_	
147-13	30832-30840	nicotine	_	
147-14	30841-30843	in	_	
147-15	30844-30845	a	_	
147-16	30846-30855	cigarette	_	
147-17	30855-30856	”	_	
147-18	30857-30865	compared	_	
147-19	30866-30868	to	_	
147-20	30869-30870	“	_	
147-21	30870-30878	presence	_	
147-22	30879-30881	of	_	
147-23	30882-30890	nicotine	_	
147-24	30891-30893	in	_	
147-25	30894-30895	a	_	
147-26	30896-30905	cigarette	_	
147-27	30905-30906	”	_	
147-28	30907-30917	diminished	_	
147-29	30918-30924	neural	_	
147-30	30925-30930	blood	_	
147-31	30931-30953	oxygen-level-dependent	_	
147-32	30954-30963	responses	_	
147-33	30964-30966	in	_	
147-34	30967-30970	the	_	
147-35	30971-30978	ventral	_	
147-36	30979-30987	striatum	_	
147-37	30988-30990	to	_	
147-38	30991-30996	value	_	
147-39	30997-31000	and	_	
147-40	31001-31007	reward	_	
147-41	31008-31018	prediction	_	
147-42	31019-31025	errors	_	
147-43	31026-31029	and	_	
147-44	31030-31037	reduced	_	
147-45	31038-31041	its	_	
147-46	31042-31048	impact	_	
147-47	31049-31051	on	_	
147-48	31052-31059	smokers	_	
147-49	31059-31060	’	_	
147-50	31061-31068	choices	_	
147-51	31068-31069	.	_	

#Text=However, the evidence for the conditioned DA responses to the expectation of drugs of abuse in drug abusers is scarce, and we based our hypothesis mainly on a previous brain glucose metabolism study in CUD and to brain cue reactivity experiments in which CUD show conditioned limbic responses to cocaine cues.
148-1	31070-31077	However	_	
148-2	31077-31078	,	_	
148-3	31079-31082	the	_	
148-4	31083-31091	evidence	_	
148-5	31092-31095	for	_	
148-6	31096-31099	the	_	
148-7	31100-31111	conditioned	_	
148-8	31112-31114	DA	_	
148-9	31115-31124	responses	_	
148-10	31125-31127	to	_	
148-11	31128-31131	the	_	
148-12	31132-31143	expectation	_	
148-13	31144-31146	of	_	
148-14	31147-31152	drugs	_	
148-15	31153-31155	of	_	
148-16	31156-31161	abuse	_	
148-17	31162-31164	in	_	
148-18	31165-31169	drug	_	
148-19	31170-31177	abusers	_	
148-20	31178-31180	is	_	
148-21	31181-31187	scarce	_	
148-22	31187-31188	,	_	
148-23	31189-31192	and	_	
148-24	31193-31195	we	_	
148-25	31196-31201	based	_	
148-26	31202-31205	our	_	
148-27	31206-31216	hypothesis	_	
148-28	31217-31223	mainly	_	
148-29	31224-31226	on	_	
148-30	31227-31228	a	_	
148-31	31229-31237	previous	_	
148-32	31238-31243	brain	_	
148-33	31244-31251	glucose	_	
148-34	31252-31262	metabolism	_	
148-35	31263-31268	study	_	
148-36	31269-31271	in	_	
148-37	31272-31275	CUD	_	
148-38	31276-31279	and	_	
148-39	31280-31282	to	_	
148-40	31283-31288	brain	_	
148-41	31289-31292	cue	_	
148-42	31293-31303	reactivity	_	
148-43	31304-31315	experiments	_	
148-44	31316-31318	in	_	
148-45	31319-31324	which	_	
148-46	31325-31328	CUD	_	
148-47	31329-31333	show	_	
148-48	31334-31345	conditioned	_	
148-49	31346-31352	limbic	_	
148-50	31353-31362	responses	_	
148-51	31363-31365	to	_	
148-52	31366-31373	cocaine	_	
148-53	31374-31378	cues	_	
148-54	31378-31379	.	_	

#Text=Potentially, our unexpected findings of blunted DA effects of MP expectation in CUD are due to the administration of MP.
149-1	31380-31391	Potentially	_	
149-2	31391-31392	,	_	
149-3	31393-31396	our	_	
149-4	31397-31407	unexpected	_	
149-5	31408-31416	findings	_	
149-6	31417-31419	of	_	
149-7	31420-31427	blunted	_	
149-8	31428-31430	DA	_	
149-9	31431-31438	effects	_	
149-10	31439-31441	of	_	
149-11	31442-31444	MP	_	
149-12	31445-31456	expectation	_	
149-13	31457-31459	in	_	
149-14	31460-31463	CUD	_	
149-15	31464-31467	are	_	
149-16	31468-31471	due	_	
149-17	31472-31474	to	_	
149-18	31475-31478	the	_	
149-19	31479-31493	administration	_	
149-20	31494-31496	of	_	
149-21	31497-31499	MP	_	
149-22	31499-31500	.	_	

#Text=MP is a psychostimulant drug that, similarly to cocaine, increases DA by blocking DATs, and it is distinct from cocaine in its route of administration (iv injection (MP) versus smoking (cocaine)) and drug effects.
150-1	31501-31503	MP	_	
150-2	31504-31506	is	_	
150-3	31507-31508	a	_	
150-4	31509-31524	psychostimulant	_	
150-5	31525-31529	drug	_	
150-6	31530-31534	that	_	
150-7	31534-31535	,	_	
150-8	31536-31545	similarly	_	
150-9	31546-31548	to	_	
150-10	31549-31556	cocaine	_	
150-11	31556-31557	,	_	
150-12	31558-31567	increases	_	
150-13	31568-31570	DA	_	
150-14	31571-31573	by	_	
150-15	31574-31582	blocking	_	
150-16	31583-31587	DATs	_	
150-17	31587-31588	,	_	
150-18	31589-31592	and	_	
150-19	31593-31595	it	_	
150-20	31596-31598	is	_	
150-21	31599-31607	distinct	_	
150-22	31608-31612	from	_	
150-23	31613-31620	cocaine	_	
150-24	31621-31623	in	_	
150-25	31624-31627	its	_	
150-26	31628-31633	route	_	
150-27	31634-31636	of	_	
150-28	31637-31651	administration	_	
150-29	31652-31653	(	_	
150-30	31653-31655	iv	_	
150-31	31656-31665	injection	_	
150-32	31666-31667	(	_	
150-33	31667-31669	MP	_	
150-34	31669-31670	)	_	
150-35	31671-31677	versus	_	
150-36	31678-31685	smoking	_	
150-37	31686-31687	(	_	
150-38	31687-31694	cocaine	_	
150-39	31694-31695	)	_	
150-40	31695-31696	)	_	
150-41	31697-31700	and	_	
150-42	31701-31705	drug	_	
150-43	31706-31713	effects	_	
150-44	31713-31714	.	_	

#Text=Thus expected conditioned responses to MP in CUDs may only occur if CUD expect to receive cocaine and not MP.
151-1	31715-31719	Thus	_	
151-2	31720-31728	expected	_	
151-3	31729-31740	conditioned	_	
151-4	31741-31750	responses	_	
151-5	31751-31753	to	_	
151-6	31754-31756	MP	_	
151-7	31757-31759	in	_	
151-8	31760-31764	CUDs	_	
151-9	31765-31768	may	_	
151-10	31769-31773	only	_	
151-11	31774-31779	occur	_	
151-12	31780-31782	if	_	
151-13	31783-31786	CUD	_	
151-14	31787-31793	expect	_	
151-15	31794-31796	to	_	
151-16	31797-31804	receive	_	
151-17	31805-31812	cocaine	_	
151-18	31813-31816	and	_	
151-19	31817-31820	not	_	
151-20	31821-31823	MP	_	
151-21	31823-31824	.	_	

#Text=We further found that DA release in putamen correlated with subjective “rush” and “high” across all subjects.
152-1	31825-31827	We	_	
152-2	31828-31835	further	_	
152-3	31836-31841	found	_	
152-4	31842-31846	that	_	
152-5	31847-31849	DA	_	
152-6	31850-31857	release	_	
152-7	31858-31860	in	_	
152-8	31861-31868	putamen	_	
152-9	31869-31879	correlated	_	
152-10	31880-31884	with	_	
152-11	31885-31895	subjective	_	
152-12	31896-31897	“	_	
152-13	31897-31901	rush	_	
152-14	31901-31902	”	_	
152-15	31903-31906	and	_	
152-16	31907-31908	“	_	
152-17	31908-31912	high	_	
152-18	31912-31913	”	_	
152-19	31914-31920	across	_	
152-20	31921-31924	all	_	
152-21	31925-31933	subjects	_	
152-22	31933-31934	.	_	

#Text=This is in line with previous studies that drug-induced increases in DA are related to subjective “high”: that is, increases in DA release plus faster drug uptake elicit more intensive highs.
153-1	31935-31939	This	_	
153-2	31940-31942	is	_	
153-3	31943-31945	in	_	
153-4	31946-31950	line	_	
153-5	31951-31955	with	_	
153-6	31956-31964	previous	_	
153-7	31965-31972	studies	_	
153-8	31973-31977	that	_	
153-9	31978-31990	drug-induced	_	
153-10	31991-32000	increases	_	
153-11	32001-32003	in	_	
153-12	32004-32006	DA	_	
153-13	32007-32010	are	_	
153-14	32011-32018	related	_	
153-15	32019-32021	to	_	
153-16	32022-32032	subjective	_	
153-17	32033-32034	“	_	
153-18	32034-32038	high	_	
153-19	32038-32039	”	_	
153-20	32039-32040	:	_	
153-21	32041-32045	that	_	
153-22	32046-32048	is	_	
153-23	32048-32049	,	_	
153-24	32050-32059	increases	_	
153-25	32060-32062	in	_	
153-26	32063-32065	DA	_	
153-27	32066-32073	release	_	
153-28	32074-32078	plus	_	
153-29	32079-32085	faster	_	
153-30	32086-32090	drug	_	
153-31	32091-32097	uptake	_	
153-32	32098-32104	elicit	_	
153-33	32105-32109	more	_	
153-34	32110-32119	intensive	_	
153-35	32120-32125	highs	_	
153-36	32125-32126	.	_	

#Text=Large and fast increases of DA mimic natural phasic increases in DA release, which are related to reward and salience.
154-1	32127-32132	Large	_	
154-2	32133-32136	and	_	
154-3	32137-32141	fast	_	
154-4	32142-32151	increases	_	
154-5	32152-32154	of	_	
154-6	32155-32157	DA	_	
154-7	32158-32163	mimic	_	
154-8	32164-32171	natural	_	
154-9	32172-32178	phasic	_	
154-10	32179-32188	increases	_	
154-11	32189-32191	in	_	
154-12	32192-32194	DA	_	
154-13	32195-32202	release	_	
154-14	32202-32203	,	_	
154-15	32204-32209	which	_	
154-16	32210-32213	are	_	
154-17	32214-32221	related	_	
154-18	32222-32224	to	_	
154-19	32225-32231	reward	_	
154-20	32232-32235	and	_	
154-21	32236-32244	salience	_	
154-22	32244-32245	.	_	

#Text=However, these correlations were not present for each group separately (only at trend level in controls) and thus were predominantly driven by the strong group differences in DA release in putamen and in the self-reports of “rush” and “high.”
155-1	32246-32253	However	_	
155-2	32253-32254	,	_	
155-3	32255-32260	these	_	
155-4	32261-32273	correlations	_	
155-5	32274-32278	were	_	
155-6	32279-32282	not	_	
155-7	32283-32290	present	_	
155-8	32291-32294	for	_	
155-9	32295-32299	each	_	
155-10	32300-32305	group	_	
155-11	32306-32316	separately	_	
155-12	32317-32318	(	_	
155-13	32318-32322	only	_	
155-14	32323-32325	at	_	
155-15	32326-32331	trend	_	
155-16	32332-32337	level	_	
155-17	32338-32340	in	_	
155-18	32341-32349	controls	_	
155-19	32349-32350	)	_	
155-20	32351-32354	and	_	
155-21	32355-32359	thus	_	
155-22	32360-32364	were	_	
155-23	32365-32378	predominantly	_	
155-24	32379-32385	driven	_	
155-25	32386-32388	by	_	
155-26	32389-32392	the	_	
155-27	32393-32399	strong	_	
155-28	32400-32405	group	_	
155-29	32406-32417	differences	_	
155-30	32418-32420	in	_	
155-31	32421-32423	DA	_	
155-32	32424-32431	release	_	
155-33	32432-32434	in	_	
155-34	32435-32442	putamen	_	
155-35	32443-32446	and	_	
155-36	32447-32449	in	_	
155-37	32450-32453	the	_	
155-38	32454-32466	self-reports	_	
155-39	32467-32469	of	_	
155-40	32470-32471	“	_	
155-41	32471-32475	rush	_	
155-42	32475-32476	”	_	
155-43	32477-32480	and	_	
155-44	32481-32482	“	_	
155-45	32482-32486	high	_	
155-46	32486-32487	.	_	
155-47	32487-32488	”	_	

#Text=Moreover, studies on expectation effects have also shown that arousal ratings during PL (expected caffeine) are associated with [11C]raclopride binding in putamen, and expected “high” was associated with a greater MP-induced metabolic increase in the thalamus in cocaine abusers.
156-1	32489-32497	Moreover	_	
156-2	32497-32498	,	_	
156-3	32499-32506	studies	_	
156-4	32507-32509	on	_	
156-5	32510-32521	expectation	_	
156-6	32522-32529	effects	_	
156-7	32530-32534	have	_	
156-8	32535-32539	also	_	
156-9	32540-32545	shown	_	
156-10	32546-32550	that	_	
156-11	32551-32558	arousal	_	
156-12	32559-32566	ratings	_	
156-13	32567-32573	during	_	
156-14	32574-32576	PL	_	
156-15	32577-32578	(	_	
156-16	32578-32586	expected	_	
156-17	32587-32595	caffeine	_	
156-18	32595-32596	)	_	
156-19	32597-32600	are	_	
156-20	32601-32611	associated	_	
156-21	32612-32616	with	_	
156-22	32617-32618	[	_	
156-23	32618-32621	11C	_	
156-24	32621-32622	]	_	
156-25	32622-32632	raclopride	_	
156-26	32633-32640	binding	_	
156-27	32641-32643	in	_	
156-28	32644-32651	putamen	_	
156-29	32651-32652	,	_	
156-30	32653-32656	and	_	
156-31	32657-32665	expected	_	
156-32	32666-32667	“	_	
156-33	32667-32671	high	_	
156-34	32671-32672	”	_	
156-35	32673-32676	was	_	
156-36	32677-32687	associated	_	
156-37	32688-32692	with	_	
156-38	32693-32694	a	_	
156-39	32695-32702	greater	_	
156-40	32703-32713	MP-induced	_	
156-41	32714-32723	metabolic	_	
156-42	32724-32732	increase	_	
156-43	32733-32735	in	_	
156-44	32736-32739	the	_	
156-45	32740-32748	thalamus	_	
156-46	32749-32751	in	_	
156-47	32752-32759	cocaine	_	
156-48	32760-32767	abusers	_	
156-49	32767-32768	.	_	

#Text=In our study, however, expected DA release did not correlate with self-report ratings.
157-1	32769-32771	In	_	
157-2	32772-32775	our	_	
157-3	32776-32781	study	_	
157-4	32781-32782	,	_	
157-5	32783-32790	however	_	
157-6	32790-32791	,	_	
157-7	32792-32800	expected	_	
157-8	32801-32803	DA	_	
157-9	32804-32811	release	_	
157-10	32812-32815	did	_	
157-11	32816-32819	not	_	
157-12	32820-32829	correlate	_	
157-13	32830-32834	with	_	
157-14	32835-32846	self-report	_	
157-15	32847-32854	ratings	_	
157-16	32854-32855	.	_	

#Text=Also because MP increases both dopaminergic and noradrenergic signaling, it is possible that some of the changes in self-report for drug effects such as increases in anxiety might have been mediated by noradrenergic effects rather than dopaminergic mechanisms.
158-1	32856-32860	Also	_	
158-2	32861-32868	because	_	
158-3	32869-32871	MP	_	
158-4	32872-32881	increases	_	
158-5	32882-32886	both	_	
158-6	32887-32899	dopaminergic	_	
158-7	32900-32903	and	_	
158-8	32904-32917	noradrenergic	_	
158-9	32918-32927	signaling	_	
158-10	32927-32928	,	_	
158-11	32929-32931	it	_	
158-12	32932-32934	is	_	
158-13	32935-32943	possible	_	
158-14	32944-32948	that	_	
158-15	32949-32953	some	_	
158-16	32954-32956	of	_	
158-17	32957-32960	the	_	
158-18	32961-32968	changes	_	
158-19	32969-32971	in	_	
158-20	32972-32983	self-report	_	
158-21	32984-32987	for	_	
158-22	32988-32992	drug	_	
158-23	32993-33000	effects	_	
158-24	33001-33005	such	_	
158-25	33006-33008	as	_	
158-26	33009-33018	increases	_	
158-27	33019-33021	in	_	
158-28	33022-33029	anxiety	_	
158-29	33030-33035	might	_	
158-30	33036-33040	have	_	
158-31	33041-33045	been	_	
158-32	33046-33054	mediated	_	
158-33	33055-33057	by	_	
158-34	33058-33071	noradrenergic	_	
158-35	33072-33079	effects	_	
158-36	33080-33086	rather	_	
158-37	33087-33091	than	_	
158-38	33092-33104	dopaminergic	_	
158-39	33105-33115	mechanisms	_	
158-40	33115-33116	.	_	

#Text=The findings from our study are clinically relevant since the difference between the expected outcome and the actual pharmacological effects of the drug in addicted individuals, which are markedly attenuated, could contribute to compulsive drug consumption in an attempt to achieve the expected outcome.
159-1	33117-33120	The	_	
159-2	33121-33129	findings	_	
159-3	33130-33134	from	_	
159-4	33135-33138	our	_	
159-5	33139-33144	study	_	
159-6	33145-33148	are	_	
159-7	33149-33159	clinically	_	
159-8	33160-33168	relevant	_	
159-9	33169-33174	since	_	
159-10	33175-33178	the	_	
159-11	33179-33189	difference	_	
159-12	33190-33197	between	_	
159-13	33198-33201	the	_	
159-14	33202-33210	expected	_	
159-15	33211-33218	outcome	_	
159-16	33219-33222	and	_	
159-17	33223-33226	the	_	
159-18	33227-33233	actual	_	
159-19	33234-33249	pharmacological	_	
159-20	33250-33257	effects	_	
159-21	33258-33260	of	_	
159-22	33261-33264	the	_	
159-23	33265-33269	drug	_	
159-24	33270-33272	in	_	
159-25	33273-33281	addicted	_	
159-26	33282-33293	individuals	_	
159-27	33293-33294	,	_	
159-28	33295-33300	which	_	
159-29	33301-33304	are	_	
159-30	33305-33313	markedly	_	
159-31	33314-33324	attenuated	_	
159-32	33324-33325	,	_	
159-33	33326-33331	could	_	
159-34	33332-33342	contribute	_	
159-35	33343-33345	to	_	
159-36	33346-33356	compulsive	_	
159-37	33357-33361	drug	_	
159-38	33362-33373	consumption	_	
159-39	33374-33376	in	_	
159-40	33377-33379	an	_	
159-41	33380-33387	attempt	_	
159-42	33388-33390	to	_	
159-43	33391-33398	achieve	_	
159-44	33399-33402	the	_	
159-45	33403-33411	expected	_	
159-46	33412-33419	outcome	_	
159-47	33419-33420	.	_	

#Text=Our findings documenting that individuals with a CUD showed reduced DA responses to MP when expecting it but enhanced responses when expecting PL (opposite to the responses in controls) support the model that dopaminergic responses reflect the predicted expectation of reward and document for the first time that these DA responses are altered in addiction when compared to controls.
160-1	33421-33424	Our	_	
160-2	33425-33433	findings	_	
160-3	33434-33445	documenting	_	
160-4	33446-33450	that	_	
160-5	33451-33462	individuals	_	
160-6	33463-33467	with	_	
160-7	33468-33469	a	_	
160-8	33470-33473	CUD	_	
160-9	33474-33480	showed	_	
160-10	33481-33488	reduced	_	
160-11	33489-33491	DA	_	
160-12	33492-33501	responses	_	
160-13	33502-33504	to	_	
160-14	33505-33507	MP	_	
160-15	33508-33512	when	_	
160-16	33513-33522	expecting	_	
160-17	33523-33525	it	_	
160-18	33526-33529	but	_	
160-19	33530-33538	enhanced	_	
160-20	33539-33548	responses	_	
160-21	33549-33553	when	_	
160-22	33554-33563	expecting	_	
160-23	33564-33566	PL	_	
160-24	33567-33568	(	_	
160-25	33568-33576	opposite	_	
160-26	33577-33579	to	_	
160-27	33580-33583	the	_	
160-28	33584-33593	responses	_	
160-29	33594-33596	in	_	
160-30	33597-33605	controls	_	
160-31	33605-33606	)	_	
160-32	33607-33614	support	_	
160-33	33615-33618	the	_	
160-34	33619-33624	model	_	
160-35	33625-33629	that	_	
160-36	33630-33642	dopaminergic	_	
160-37	33643-33652	responses	_	
160-38	33653-33660	reflect	_	
160-39	33661-33664	the	_	
160-40	33665-33674	predicted	_	
160-41	33675-33686	expectation	_	
160-42	33687-33689	of	_	
160-43	33690-33696	reward	_	
160-44	33697-33700	and	_	
160-45	33701-33709	document	_	
160-46	33710-33713	for	_	
160-47	33714-33717	the	_	
160-48	33718-33723	first	_	
160-49	33724-33728	time	_	
160-50	33729-33733	that	_	
160-51	33734-33739	these	_	
160-52	33740-33742	DA	_	
160-53	33743-33752	responses	_	
160-54	33753-33756	are	_	
160-55	33757-33764	altered	_	
160-56	33765-33767	in	_	
160-57	33768-33777	addiction	_	
160-58	33778-33782	when	_	
160-59	33783-33791	compared	_	
160-60	33792-33794	to	_	
160-61	33795-33803	controls	_	
160-62	33803-33804	.	_	

#Text=To the extent that therapeutic interventions can be developed to restore to normal the reward prediction error signals in addicted individuals, it might be possible to prevent the craving and the compulsive drive for drug intake in CUD.
161-1	33805-33807	To	_	
161-2	33808-33811	the	_	
161-3	33812-33818	extent	_	
161-4	33819-33823	that	_	
161-5	33824-33835	therapeutic	_	
161-6	33836-33849	interventions	_	
161-7	33850-33853	can	_	
161-8	33854-33856	be	_	
161-9	33857-33866	developed	_	
161-10	33867-33869	to	_	
161-11	33870-33877	restore	_	
161-12	33878-33880	to	_	
161-13	33881-33887	normal	_	
161-14	33888-33891	the	_	
161-15	33892-33898	reward	_	
161-16	33899-33909	prediction	_	
161-17	33910-33915	error	_	
161-18	33916-33923	signals	_	
161-19	33924-33926	in	_	
161-20	33927-33935	addicted	_	
161-21	33936-33947	individuals	_	
161-22	33947-33948	,	_	
161-23	33949-33951	it	_	
161-24	33952-33957	might	_	
161-25	33958-33960	be	_	
161-26	33961-33969	possible	_	
161-27	33970-33972	to	_	
161-28	33973-33980	prevent	_	
161-29	33981-33984	the	_	
161-30	33985-33992	craving	_	
161-31	33993-33996	and	_	
161-32	33997-34000	the	_	
161-33	34001-34011	compulsive	_	
161-34	34012-34017	drive	_	
161-35	34018-34021	for	_	
161-36	34022-34026	drug	_	
161-37	34027-34033	intake	_	
161-38	34034-34036	in	_	
161-39	34037-34040	CUD	_	
161-40	34040-34041	.	_	

#Text=Although PET [11C]raclopride measures of MP-induced DA changes in the striatum (including caudate) show good test–retest reliability, the reproducibility in midbrain has not been tested, which is a limitation to our study.
162-1	34042-34050	Although	_	
162-2	34051-34054	PET	_	
162-3	34055-34056	[	_	
162-4	34056-34059	11C	_	
162-5	34059-34060	]	_	
162-6	34060-34070	raclopride	_	
162-7	34071-34079	measures	_	
162-8	34080-34082	of	_	
162-9	34083-34093	MP-induced	_	
162-10	34094-34096	DA	_	
162-11	34097-34104	changes	_	
162-12	34105-34107	in	_	
162-13	34108-34111	the	_	
162-14	34112-34120	striatum	_	
162-15	34121-34122	(	_	
162-16	34122-34131	including	_	
162-17	34132-34139	caudate	_	
162-18	34139-34140	)	_	
162-19	34141-34145	show	_	
162-20	34146-34150	good	_	
162-21	34151-34162	test–retest	_	
162-22	34163-34174	reliability	_	
162-23	34174-34175	,	_	
162-24	34176-34179	the	_	
162-25	34180-34195	reproducibility	_	
162-26	34196-34198	in	_	
162-27	34199-34207	midbrain	_	
162-28	34208-34211	has	_	
162-29	34212-34215	not	_	
162-30	34216-34220	been	_	
162-31	34221-34227	tested	_	
162-32	34227-34228	,	_	
162-33	34229-34234	which	_	
162-34	34235-34237	is	_	
162-35	34238-34239	a	_	
162-36	34240-34250	limitation	_	
162-37	34251-34253	to	_	
162-38	34254-34257	our	_	
162-39	34258-34263	study	_	
162-40	34263-34264	.	_	

#Text=Also, while in caudate and putamen D2R availability predominantly reflects D2 receptors, in NAc and midbrain they reflect both D2 and D3 receptors.
163-1	34265-34269	Also	_	
163-2	34269-34270	,	_	
163-3	34271-34276	while	_	
163-4	34277-34279	in	_	
163-5	34280-34287	caudate	_	
163-6	34288-34291	and	_	
163-7	34292-34299	putamen	_	
163-8	34300-34303	D2R	_	
163-9	34304-34316	availability	_	
163-10	34317-34330	predominantly	_	
163-11	34331-34339	reflects	_	
163-12	34340-34342	D2	_	
163-13	34343-34352	receptors	_	
163-14	34352-34353	,	_	
163-15	34354-34356	in	_	
163-16	34357-34360	NAc	_	
163-17	34361-34364	and	_	
163-18	34365-34373	midbrain	_	
163-19	34374-34378	they	_	
163-20	34379-34386	reflect	_	
163-21	34387-34391	both	_	
163-22	34392-34394	D2	_	
163-23	34395-34398	and	_	
163-24	34399-34401	D3	_	
163-25	34402-34411	receptors	_	
163-26	34411-34412	.	_	

#Text=In CUD, there is evidence that D2R are downregulated, whereas D3 receptors might be upregulated, and this therefore confounds the interpretation of our findings.
164-1	34413-34415	In	_	
164-2	34416-34419	CUD	_	
164-3	34419-34420	,	_	
164-4	34421-34426	there	_	
164-5	34427-34429	is	_	
164-6	34430-34438	evidence	_	
164-7	34439-34443	that	_	
164-8	34444-34447	D2R	_	
164-9	34448-34451	are	_	
164-10	34452-34465	downregulated	_	
164-11	34465-34466	,	_	
164-12	34467-34474	whereas	_	
164-13	34475-34477	D3	_	
164-14	34478-34487	receptors	_	
164-15	34488-34493	might	_	
164-16	34494-34496	be	_	
164-17	34497-34508	upregulated	_	
164-18	34508-34509	,	_	
164-19	34510-34513	and	_	
164-20	34514-34518	this	_	
164-21	34519-34528	therefore	_	
164-22	34529-34538	confounds	_	
164-23	34539-34542	the	_	
164-24	34543-34557	interpretation	_	
164-25	34558-34560	of	_	
164-26	34561-34564	our	_	
164-27	34565-34573	findings	_	
164-28	34573-34574	.	_	

#Text=Another limitation of the study is that CUD consisted of more smokers (n = 20 current smokers) than the HC group (n = 3 current smokers), and group findings may be in part due to group differences in smoking.
165-1	34575-34582	Another	_	
165-2	34583-34593	limitation	_	
165-3	34594-34596	of	_	
165-4	34597-34600	the	_	
165-5	34601-34606	study	_	
165-6	34607-34609	is	_	
165-7	34610-34614	that	_	
165-8	34615-34618	CUD	_	
165-9	34619-34628	consisted	_	
165-10	34629-34631	of	_	
165-11	34632-34636	more	_	
165-12	34637-34644	smokers	_	
165-13	34645-34646	(	_	
165-14	34646-34647	n	_	
165-15	34648-34649	=	_	
165-16	34650-34652	20	_	
165-17	34653-34660	current	_	
165-18	34661-34668	smokers	_	
165-19	34668-34669	)	_	
165-20	34670-34674	than	_	
165-21	34675-34678	the	_	
165-22	34679-34681	HC	_	
165-23	34682-34687	group	_	
165-24	34688-34689	(	_	
165-25	34689-34690	n	_	
165-26	34691-34692	=	_	
165-27	34693-34694	3	_	
165-28	34695-34702	current	_	
165-29	34703-34710	smokers	_	
165-30	34710-34711	)	_	
165-31	34711-34712	,	_	
165-32	34713-34716	and	_	
165-33	34717-34722	group	_	
165-34	34723-34731	findings	_	
165-35	34732-34735	may	_	
165-36	34736-34738	be	_	
165-37	34739-34741	in	_	
165-38	34742-34746	part	_	
165-39	34747-34750	due	_	
165-40	34751-34753	to	_	
165-41	34754-34759	group	_	
165-42	34760-34771	differences	_	
165-43	34772-34774	in	_	
165-44	34775-34782	smoking	_	
165-45	34782-34783	.	_	

#Text=However, an exploratory analysis of main effects of Challenge in striatal areas (NAc, caudate, putamen), for which we hypothesized blunted DA release in smokers, did not reveal a significant effect of smoking status (p > 0.05; corrected for CUD Group).
166-1	34784-34791	However	_	
166-2	34791-34792	,	_	
166-3	34793-34795	an	_	
166-4	34796-34807	exploratory	_	
166-5	34808-34816	analysis	_	
166-6	34817-34819	of	_	
166-7	34820-34824	main	_	
166-8	34825-34832	effects	_	
166-9	34833-34835	of	_	
166-10	34836-34845	Challenge	_	
166-11	34846-34848	in	_	
166-12	34849-34857	striatal	_	
166-13	34858-34863	areas	_	
166-14	34864-34865	(	_	
166-15	34865-34868	NAc	_	
166-16	34868-34869	,	_	
166-17	34870-34877	caudate	_	
166-18	34877-34878	,	_	
166-19	34879-34886	putamen	_	
166-20	34886-34887	)	_	
166-21	34887-34888	,	_	
166-22	34889-34892	for	_	
166-23	34893-34898	which	_	
166-24	34899-34901	we	_	
166-25	34902-34914	hypothesized	_	
166-26	34915-34922	blunted	_	
166-27	34923-34925	DA	_	
166-28	34926-34933	release	_	
166-29	34934-34936	in	_	
166-30	34937-34944	smokers	_	
166-31	34944-34945	,	_	
166-32	34946-34949	did	_	
166-33	34950-34953	not	_	
166-34	34954-34960	reveal	_	
166-35	34961-34962	a	_	
166-36	34963-34974	significant	_	
166-37	34975-34981	effect	_	
166-38	34982-34984	of	_	
166-39	34985-34992	smoking	_	
166-40	34993-34999	status	_	
166-41	35000-35001	(	_	
166-42	35001-35002	p	_	
166-43	35003-35004	>	_	
166-44	35005-35009	0.05	_	
166-45	35009-35010	;	_	
166-46	35011-35020	corrected	_	
166-47	35021-35024	for	_	
166-48	35025-35028	CUD	_	
166-49	35029-35034	Group	_	
166-50	35034-35035	)	_	
166-51	35035-35036	.	_	

#Text=Effects of tobacco smoking on stimulant-induced DA release may not be as strong compared to that of CUD.
167-1	35037-35044	Effects	_	
167-2	35045-35047	of	_	
167-3	35048-35055	tobacco	_	
167-4	35056-35063	smoking	_	
167-5	35064-35066	on	_	
167-6	35067-35084	stimulant-induced	_	
167-7	35085-35087	DA	_	
167-8	35088-35095	release	_	
167-9	35096-35099	may	_	
167-10	35100-35103	not	_	
167-11	35104-35106	be	_	
167-12	35107-35109	as	_	
167-13	35110-35116	strong	_	
167-14	35117-35125	compared	_	
167-15	35126-35128	to	_	
167-16	35129-35133	that	_	
167-17	35134-35136	of	_	
167-18	35137-35140	CUD	_	
167-19	35140-35141	.	_	

#Text=Since CUD is more prevalent in males than in females, recruitment for females was harder than for males, and we matched four women CUD with four HC in our dataset.
168-1	35142-35147	Since	_	
168-2	35148-35151	CUD	_	
168-3	35152-35154	is	_	
168-4	35155-35159	more	_	
168-5	35160-35169	prevalent	_	
168-6	35170-35172	in	_	
168-7	35173-35178	males	_	
168-8	35179-35183	than	_	
168-9	35184-35186	in	_	
168-10	35187-35194	females	_	
168-11	35194-35195	,	_	
168-12	35196-35207	recruitment	_	
168-13	35208-35211	for	_	
168-14	35212-35219	females	_	
168-15	35220-35223	was	_	
168-16	35224-35230	harder	_	
168-17	35231-35235	than	_	
168-18	35236-35239	for	_	
168-19	35240-35245	males	_	
168-20	35245-35246	,	_	
168-21	35247-35250	and	_	
168-22	35251-35253	we	_	
168-23	35254-35261	matched	_	
168-24	35262-35266	four	_	
168-25	35267-35272	women	_	
168-26	35273-35276	CUD	_	
168-27	35277-35281	with	_	
168-28	35282-35286	four	_	
168-29	35287-35289	HC	_	
168-30	35290-35292	in	_	
168-31	35293-35296	our	_	
168-32	35297-35304	dataset	_	
168-33	35304-35305	.	_	

#Text=Haltia et al. found that iv PL with the expectation of receiving glucose lead to decreased ventral striatal D2R (and increased D2R binding in the dorsal striatum) in men but not in women, suggesting gender differences in DA function after pharmacological challenge.
169-1	35306-35312	Haltia	_	
169-2	35313-35315	et	_	
169-3	35316-35318	al	_	
169-4	35318-35319	.	_	
169-5	35320-35325	found	_	
169-6	35326-35330	that	_	
169-7	35331-35333	iv	_	
169-8	35334-35336	PL	_	
169-9	35337-35341	with	_	
169-10	35342-35345	the	_	
169-11	35346-35357	expectation	_	
169-12	35358-35360	of	_	
169-13	35361-35370	receiving	_	
169-14	35371-35378	glucose	_	
169-15	35379-35383	lead	_	
169-16	35384-35386	to	_	
169-17	35387-35396	decreased	_	
169-18	35397-35404	ventral	_	
169-19	35405-35413	striatal	_	
169-20	35414-35417	D2R	_	
169-21	35418-35419	(	_	
169-22	35419-35422	and	_	
169-23	35423-35432	increased	_	
169-24	35433-35436	D2R	_	
169-25	35437-35444	binding	_	
169-26	35445-35447	in	_	
169-27	35448-35451	the	_	
169-28	35452-35458	dorsal	_	
169-29	35459-35467	striatum	_	
169-30	35467-35468	)	_	
169-31	35469-35471	in	_	
169-32	35472-35475	men	_	
169-33	35476-35479	but	_	
169-34	35480-35483	not	_	
169-35	35484-35486	in	_	
169-36	35487-35492	women	_	
169-37	35492-35493	,	_	
169-38	35494-35504	suggesting	_	
169-39	35505-35511	gender	_	
169-40	35512-35523	differences	_	
169-41	35524-35526	in	_	
169-42	35527-35529	DA	_	
169-43	35530-35538	function	_	
169-44	35539-35544	after	_	
169-45	35545-35560	pharmacological	_	
169-46	35561-35570	challenge	_	
169-47	35570-35571	.	_	

#Text=An exploratory analysis revealed no gender effect on striatal DA release in NAc and caudate (p > 0.05; corrected for CUD Group).
170-1	35572-35574	An	_	
170-2	35575-35586	exploratory	_	
170-3	35587-35595	analysis	_	
170-4	35596-35604	revealed	_	
170-5	35605-35607	no	_	
170-6	35608-35614	gender	_	
170-7	35615-35621	effect	_	
170-8	35622-35624	on	_	
170-9	35625-35633	striatal	_	
170-10	35634-35636	DA	_	
170-11	35637-35644	release	_	
170-12	35645-35647	in	_	
170-13	35648-35651	NAc	_	
170-14	35652-35655	and	_	
170-15	35656-35663	caudate	_	
170-16	35664-35665	(	_	
170-17	35665-35666	p	_	
170-18	35667-35668	>	_	
170-19	35669-35673	0.05	_	
170-20	35673-35674	;	_	
170-21	35675-35684	corrected	_	
170-22	35685-35688	for	_	
170-23	35689-35692	CUD	_	
170-24	35693-35698	Group	_	
170-25	35698-35699	)	_	
170-26	35699-35700	.	_	

#Text=Additionally, although we used a full factorial design of Expectation (PL/MP) × Drug Challenge (PL/MP), which is the golden standard for a PL design, we have not systematically tested whether the deception was successful by asking participants after their scans how certain they were about their drug expectation.
171-1	35701-35713	Additionally	_	
171-2	35713-35714	,	_	
171-3	35715-35723	although	_	
171-4	35724-35726	we	_	
171-5	35727-35731	used	_	
171-6	35732-35733	a	_	
171-7	35734-35738	full	_	
171-8	35739-35748	factorial	_	
171-9	35749-35755	design	_	
171-10	35756-35758	of	_	
171-11	35759-35770	Expectation	_	
171-12	35771-35772	(	_	
171-13	35772-35774	PL	_	
171-14	35774-35775	/	_	
171-15	35775-35777	MP	_	
171-16	35777-35778	)	_	
171-17	35779-35780	×	_	
171-18	35781-35785	Drug	_	
171-19	35786-35795	Challenge	_	
171-20	35796-35797	(	_	
171-21	35797-35799	PL	_	
171-22	35799-35800	/	_	
171-23	35800-35802	MP	_	
171-24	35802-35803	)	_	
171-25	35803-35804	,	_	
171-26	35805-35810	which	_	
171-27	35811-35813	is	_	
171-28	35814-35817	the	_	
171-29	35818-35824	golden	_	
171-30	35825-35833	standard	_	
171-31	35834-35837	for	_	
171-32	35838-35839	a	_	
171-33	35840-35842	PL	_	
171-34	35843-35849	design	_	
171-35	35849-35850	,	_	
171-36	35851-35853	we	_	
171-37	35854-35858	have	_	
171-38	35859-35862	not	_	
171-39	35863-35877	systematically	_	
171-40	35878-35884	tested	_	
171-41	35885-35892	whether	_	
171-42	35893-35896	the	_	
171-43	35897-35906	deception	_	
171-44	35907-35910	was	_	
171-45	35911-35921	successful	_	
171-46	35922-35924	by	_	
171-47	35925-35931	asking	_	
171-48	35932-35944	participants	_	
171-49	35945-35950	after	_	
171-50	35951-35956	their	_	
171-51	35957-35962	scans	_	
171-52	35963-35966	how	_	
171-53	35967-35974	certain	_	
171-54	35975-35979	they	_	
171-55	35980-35984	were	_	
171-56	35985-35990	about	_	
171-57	35991-35996	their	_	
171-58	35997-36001	drug	_	
171-59	36002-36013	expectation	_	
171-60	36013-36014	.	_	

#Text=Therefore, group differences in sensitivity to deception may have played a role in the outcome.
172-1	36015-36024	Therefore	_	
172-2	36024-36025	,	_	
172-3	36026-36031	group	_	
172-4	36032-36043	differences	_	
172-5	36044-36046	in	_	
172-6	36047-36058	sensitivity	_	
172-7	36059-36061	to	_	
172-8	36062-36071	deception	_	
172-9	36072-36075	may	_	
172-10	36076-36080	have	_	
172-11	36081-36087	played	_	
172-12	36088-36089	a	_	
172-13	36090-36094	role	_	
172-14	36095-36097	in	_	
172-15	36098-36101	the	_	
172-16	36102-36109	outcome	_	
172-17	36109-36110	.	_	

#Text=Nevertheless, if a Group effect in deception was indeed present this would be an effect consistent over all four conditions and corrected by the factorial model.
173-1	36111-36123	Nevertheless	_	
173-2	36123-36124	,	_	
173-3	36125-36127	if	_	
173-4	36128-36129	a	_	
173-5	36130-36135	Group	_	
173-6	36136-36142	effect	_	
173-7	36143-36145	in	_	
173-8	36146-36155	deception	_	
173-9	36156-36159	was	_	
173-10	36160-36166	indeed	_	
173-11	36167-36174	present	_	
173-12	36175-36179	this	_	
173-13	36180-36185	would	_	
173-14	36186-36188	be	_	
173-15	36189-36191	an	_	
173-16	36192-36198	effect	_	
173-17	36199-36209	consistent	_	
173-18	36210-36214	over	_	
173-19	36215-36218	all	_	
173-20	36219-36223	four	_	
173-21	36224-36234	conditions	_	
173-22	36235-36238	and	_	
173-23	36239-36248	corrected	_	
173-24	36249-36251	by	_	
173-25	36252-36255	the	_	
173-26	36256-36265	factorial	_	
173-27	36266-36271	model	_	
173-28	36271-36272	.	_	

#Text=Last, we did not correct our analyses for potential sleep disturbances in CUD, whereas it has been previously found that cocaine abusers show shorter sleep durations than non-abusing volunteers and that sleep deprivation reduces striatal D2R in healthy volunteers.
174-1	36273-36277	Last	_	
174-2	36277-36278	,	_	
174-3	36279-36281	we	_	
174-4	36282-36285	did	_	
174-5	36286-36289	not	_	
174-6	36290-36297	correct	_	
174-7	36298-36301	our	_	
174-8	36302-36310	analyses	_	
174-9	36311-36314	for	_	
174-10	36315-36324	potential	_	
174-11	36325-36330	sleep	_	
174-12	36331-36343	disturbances	_	
174-13	36344-36346	in	_	
174-14	36347-36350	CUD	_	
174-15	36350-36351	,	_	
174-16	36352-36359	whereas	_	
174-17	36360-36362	it	_	
174-18	36363-36366	has	_	
174-19	36367-36371	been	_	
174-20	36372-36382	previously	_	
174-21	36383-36388	found	_	
174-22	36389-36393	that	_	
174-23	36394-36401	cocaine	_	
174-24	36402-36409	abusers	_	
174-25	36410-36414	show	_	
174-26	36415-36422	shorter	_	
174-27	36423-36428	sleep	_	
174-28	36429-36438	durations	_	
174-29	36439-36443	than	_	
174-30	36444-36455	non-abusing	_	
174-31	36456-36466	volunteers	_	
174-32	36467-36470	and	_	
174-33	36471-36475	that	_	
174-34	36476-36481	sleep	_	
174-35	36482-36493	deprivation	_	
174-36	36494-36501	reduces	_	
174-37	36502-36510	striatal	_	
174-38	36511-36514	D2R	_	
174-39	36515-36517	in	_	
174-40	36518-36525	healthy	_	
174-41	36526-36536	volunteers	_	
174-42	36536-36537	.	_	

#Text=In summary, these results in active CUD subjects expanded prior findings of decreased striatal DA responses in detoxified CUD.
175-1	36538-36540	In	_	
175-2	36541-36548	summary	_	
175-3	36548-36549	,	_	
175-4	36550-36555	these	_	
175-5	36556-36563	results	_	
175-6	36564-36566	in	_	
175-7	36567-36573	active	_	
175-8	36574-36577	CUD	_	
175-9	36578-36586	subjects	_	
175-10	36587-36595	expanded	_	
175-11	36596-36601	prior	_	
175-12	36602-36610	findings	_	
175-13	36611-36613	of	_	
175-14	36614-36623	decreased	_	
175-15	36624-36632	striatal	_	
175-16	36633-36635	DA	_	
175-17	36636-36645	responses	_	
175-18	36646-36648	in	_	
175-19	36649-36659	detoxified	_	
175-20	36660-36663	CUD	_	
175-21	36663-36664	.	_	

#Text=They also identify group differences in expectation responses in caudate and midbrain such that HC showed DA increases with expectation of receiving MP, whereas CUD did not, which is consistent with dysfunction of caudate and midbrain DA activity.
176-1	36665-36669	They	_	
176-2	36670-36674	also	_	
176-3	36675-36683	identify	_	
176-4	36684-36689	group	_	
176-5	36690-36701	differences	_	
176-6	36702-36704	in	_	
176-7	36705-36716	expectation	_	
176-8	36717-36726	responses	_	
176-9	36727-36729	in	_	
176-10	36730-36737	caudate	_	
176-11	36738-36741	and	_	
176-12	36742-36750	midbrain	_	
176-13	36751-36755	such	_	
176-14	36756-36760	that	_	
176-15	36761-36763	HC	_	
176-16	36764-36770	showed	_	
176-17	36771-36773	DA	_	
176-18	36774-36783	increases	_	
176-19	36784-36788	with	_	
176-20	36789-36800	expectation	_	
176-21	36801-36803	of	_	
176-22	36804-36813	receiving	_	
176-23	36814-36816	MP	_	
176-24	36816-36817	,	_	
176-25	36818-36825	whereas	_	
176-26	36826-36829	CUD	_	
176-27	36830-36833	did	_	
176-28	36834-36837	not	_	
176-29	36837-36838	,	_	
176-30	36839-36844	which	_	
176-31	36845-36847	is	_	
176-32	36848-36858	consistent	_	
176-33	36859-36863	with	_	
176-34	36864-36875	dysfunction	_	
176-35	36876-36878	of	_	
176-36	36879-36886	caudate	_	
176-37	36887-36890	and	_	
176-38	36891-36899	midbrain	_	
176-39	36900-36902	DA	_	
176-40	36903-36911	activity	_	
176-41	36911-36912	.	_	

#Text=Supplementary information
#Text=Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
177-1	36913-36926	Supplementary	_	
177-2	36927-36938	information	_	
177-3	36939-36948	Publisher	_	
177-4	36948-36949	’	_	
177-5	36949-36950	s	_	
177-6	36951-36955	note	_	
177-7	36955-36956	:	_	
177-8	36957-36965	Springer	_	
177-9	36966-36972	Nature	_	
177-10	36973-36980	remains	_	
177-11	36981-36988	neutral	_	
177-12	36989-36993	with	_	
177-13	36994-37000	regard	_	
177-14	37001-37003	to	_	
177-15	37004-37018	jurisdictional	_	
177-16	37019-37025	claims	_	
177-17	37026-37028	in	_	
177-18	37029-37038	published	_	
177-19	37039-37043	maps	_	
177-20	37044-37047	and	_	
177-21	37048-37061	institutional	_	
177-22	37062-37074	affiliations	_	
177-23	37074-37075	.	_	

#Text=Supplementary information
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-019-0421-x).
178-1	37076-37089	Supplementary	_	
178-2	37090-37101	information	_	
178-3	37102-37115	Supplementary	_	
178-4	37116-37127	Information	_	
178-5	37128-37139	accompanies	_	
178-6	37140-37144	this	_	
178-7	37145-37150	paper	_	
178-8	37151-37153	at	_	
178-9	37154-37155	(	_	
178-10	37155-37162	10.1038	_	
178-11	37162-37163	/	_	
178-12	37163-37169	s41398	_	
178-13	37169-37170	-	_	
178-14	37170-37173	019	_	
178-15	37173-37174	-	_	
178-16	37174-37178	0421	_	
178-17	37178-37179	-	_	
178-18	37179-37180	x	_	
178-19	37180-37181	)	_	
178-20	37181-37182	.	_	

#Text=Conflict of interest
#Text=The authors declare that they have no conflict of interest.
179-1	37183-37191	Conflict	_	
179-2	37192-37194	of	_	
179-3	37195-37203	interest	_	
179-4	37204-37207	The	_	
179-5	37208-37215	authors	_	
179-6	37216-37223	declare	_	
179-7	37224-37228	that	_	
179-8	37229-37233	they	_	
179-9	37234-37238	have	_	
179-10	37239-37241	no	_	
179-11	37242-37250	conflict	_	
179-12	37251-37253	of	_	
179-13	37254-37262	interest	_	
179-14	37262-37263	.	_	

#Text=References
#Text=Reciprocal responsiveness of nucleus accumbens shell and core dopamine to food- and drug-conditioned stimuli
#Text=Effects of cocaine context on NAcc dopamine and behavioral activity after repeated intravenous cocaine administration
#Text=Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat
#Text=Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers
#Text=Individual differences in reward responding explain placebo-induced expectations and effects
#Text=Effects of expectation on placebo-induced dopamine release in Parkinson disease
#Text=Therapeutic application of transcranial magnetic stimulation in Parkinson’s disease: the contribution of expectation
#Text=Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects
#Text=Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications
#Text=mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat
#Text=Belief about nicotine selectively modulates value and reward prediction error signals in smokers
#Text=Expectancy modulation of opioid neurotransmission
#Text=Enhanced striatal dopamine release to expectation of alcohol: a potential risk factor for alcohol use disorder
#Text=Beliefs modulate the effects of drugs on the human brain
#Text=The dopamine motive system: implications for drug and food addiction
#Text=Imaging endogenous dopamine competition with [11C]raclopride in the human brain
#Text=Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers
#Text=A demographically based index of premorbid intelligence test for the WAIS-R
#Text=Association of genetic ancestry with striatal dopamine D2/D3 receptor availability
#Text=Distribution volume ratios without blood sampling from graphical analysis of PET data
#Text=Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects
#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets
#Text=Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males
#Text=Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients
#Text=Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
#Text=Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine
#Text=Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues
#Text=Reward signaling by dopamine neurons
#Text=Dissociating motivation from reward in human striatal activity
#Text=High reward expectancy during methylphenidate depresses the dopaminergic response to gain and loss
#Text=Decoding the formation of reward predictions across learning
#Text=Identity prediction errors in the human midbrain update reward-identity expectations in the orbitofrontal cortex
#Text=Stalnaker, T.
180-1	37264-37274	References	_	
180-2	37275-37285	Reciprocal	_	
180-3	37286-37300	responsiveness	_	
180-4	37301-37303	of	_	
180-5	37304-37311	nucleus	_	
180-6	37312-37321	accumbens	_	
180-7	37322-37327	shell	_	
180-8	37328-37331	and	_	
180-9	37332-37336	core	_	
180-10	37337-37345	dopamine	_	
180-11	37346-37348	to	_	
180-12	37349-37353	food	_	
180-13	37353-37354	-	_	
180-14	37355-37358	and	_	
180-15	37359-37375	drug-conditioned	_	
180-16	37376-37383	stimuli	_	
180-17	37384-37391	Effects	_	
180-18	37392-37394	of	_	
180-19	37395-37402	cocaine	_	
180-20	37403-37410	context	_	
180-21	37411-37413	on	_	
180-22	37414-37418	NAcc	_	
180-23	37419-37427	dopamine	_	
180-24	37428-37431	and	_	
180-25	37432-37442	behavioral	_	
180-26	37443-37451	activity	_	
180-27	37452-37457	after	_	
180-28	37458-37466	repeated	_	
180-29	37467-37478	intravenous	_	
180-30	37479-37486	cocaine	_	
180-31	37487-37501	administration	_	
180-32	37502-37513	Differences	_	
180-33	37514-37516	in	_	
180-34	37517-37530	extracellular	_	
180-35	37531-37539	dopamine	_	
180-36	37540-37554	concentrations	_	
180-37	37555-37557	in	_	
180-38	37558-37561	the	_	
180-39	37562-37569	nucleus	_	
180-40	37570-37579	accumbens	_	
180-41	37580-37586	during	_	
180-42	37587-37605	response-dependent	_	
180-43	37606-37609	and	_	
180-44	37610-37630	response-independent	_	
180-45	37631-37638	cocaine	_	
180-46	37639-37653	administration	_	
180-47	37654-37656	in	_	
180-48	37657-37660	the	_	
180-49	37661-37664	rat	_	
180-50	37665-37676	Expectation	_	
180-51	37677-37685	enhances	_	
180-52	37686-37689	the	_	
180-53	37690-37698	regional	_	
180-54	37699-37704	brain	_	
180-55	37705-37714	metabolic	_	
180-56	37715-37718	and	_	
180-57	37719-37722	the	_	
180-58	37723-37734	reinforcing	_	
180-59	37735-37742	effects	_	
180-60	37743-37745	of	_	
180-61	37746-37756	stimulants	_	
180-62	37757-37759	in	_	
180-63	37760-37767	cocaine	_	
180-64	37768-37775	abusers	_	
180-65	37776-37786	Individual	_	
180-66	37787-37798	differences	_	
180-67	37799-37801	in	_	
180-68	37802-37808	reward	_	
180-69	37809-37819	responding	_	
180-70	37820-37827	explain	_	
180-71	37828-37843	placebo-induced	_	
180-72	37844-37856	expectations	_	
180-73	37857-37860	and	_	
180-74	37861-37868	effects	_	
180-75	37869-37876	Effects	_	
180-76	37877-37879	of	_	
180-77	37880-37891	expectation	_	
180-78	37892-37894	on	_	
180-79	37895-37910	placebo-induced	_	
180-80	37911-37919	dopamine	_	
180-81	37920-37927	release	_	
180-82	37928-37930	in	_	
180-83	37931-37940	Parkinson	_	
180-84	37941-37948	disease	_	
180-85	37949-37960	Therapeutic	_	
180-86	37961-37972	application	_	
180-87	37973-37975	of	_	
180-88	37976-37988	transcranial	_	
180-89	37989-37997	magnetic	_	
180-90	37998-38009	stimulation	_	
180-91	38010-38012	in	_	
180-92	38013-38022	Parkinson	_	
180-93	38022-38023	’	_	
180-94	38023-38024	s	_	
180-95	38025-38032	disease	_	
180-96	38032-38033	:	_	
180-97	38034-38037	the	_	
180-98	38038-38050	contribution	_	
180-99	38051-38053	of	_	
180-100	38054-38065	expectation	_	
180-101	38066-38073	Effects	_	
180-102	38074-38076	of	_	
180-103	38077-38088	expectation	_	
180-104	38089-38091	on	_	
180-105	38092-38095	the	_	
180-106	38096-38101	brain	_	
180-107	38102-38111	metabolic	_	
180-108	38112-38121	responses	_	
180-109	38122-38124	to	_	
180-110	38125-38140	methylphenidate	_	
180-111	38141-38144	and	_	
180-112	38145-38147	to	_	
180-113	38148-38151	its	_	
180-114	38152-38159	placebo	_	
180-115	38160-38162	in	_	
180-116	38163-38171	non-drug	_	
180-117	38172-38179	abusing	_	
180-118	38180-38188	subjects	_	
180-119	38189-38201	Relationship	_	
180-120	38202-38209	between	_	
180-121	38210-38218	blockade	_	
180-122	38219-38221	of	_	
180-123	38222-38230	dopamine	_	
180-124	38231-38243	transporters	_	
180-125	38244-38246	by	_	
180-126	38247-38251	oral	_	
180-127	38252-38267	methylphenidate	_	
180-128	38268-38271	and	_	
180-129	38272-38275	the	_	
180-130	38276-38285	increases	_	
180-131	38286-38288	in	_	
180-132	38289-38302	extracellular	_	
180-133	38303-38311	dopamine	_	
180-134	38311-38312	:	_	
180-135	38313-38324	therapeutic	_	
180-136	38325-38337	implications	_	
180-137	38338-38343	mGlu5	_	
180-138	38344-38352	receptor	_	
180-139	38353-38363	antagonist	_	
180-140	38364-38370	blocks	_	
180-141	38371-38392	bromocriptine-induced	_	
180-142	38393-38404	conditioned	_	
180-143	38405-38410	place	_	
180-144	38411-38421	preference	_	
180-145	38422-38424	in	_	
180-146	38425-38434	bilateral	_	
180-147	38435-38454	mesolimbic-lesioned	_	
180-148	38455-38458	rat	_	
180-149	38459-38465	Belief	_	
180-150	38466-38471	about	_	
180-151	38472-38480	nicotine	_	
180-152	38481-38492	selectively	_	
180-153	38493-38502	modulates	_	
180-154	38503-38508	value	_	
180-155	38509-38512	and	_	
180-156	38513-38519	reward	_	
180-157	38520-38530	prediction	_	
180-158	38531-38536	error	_	
180-159	38537-38544	signals	_	
180-160	38545-38547	in	_	
180-161	38548-38555	smokers	_	
180-162	38556-38566	Expectancy	_	
180-163	38567-38577	modulation	_	
180-164	38578-38580	of	_	
180-165	38581-38587	opioid	_	
180-166	38588-38605	neurotransmission	_	
180-167	38606-38614	Enhanced	_	
180-168	38615-38623	striatal	_	
180-169	38624-38632	dopamine	_	
180-170	38633-38640	release	_	
180-171	38641-38643	to	_	
180-172	38644-38655	expectation	_	
180-173	38656-38658	of	_	
180-174	38659-38666	alcohol	_	
180-175	38666-38667	:	_	
180-176	38668-38669	a	_	
180-177	38670-38679	potential	_	
180-178	38680-38684	risk	_	
180-179	38685-38691	factor	_	
180-180	38692-38695	for	_	
180-181	38696-38703	alcohol	_	
180-182	38704-38707	use	_	
180-183	38708-38716	disorder	_	
180-184	38717-38724	Beliefs	_	
180-185	38725-38733	modulate	_	
180-186	38734-38737	the	_	
180-187	38738-38745	effects	_	
180-188	38746-38748	of	_	
180-189	38749-38754	drugs	_	
180-190	38755-38757	on	_	
180-191	38758-38761	the	_	
180-192	38762-38767	human	_	
180-193	38768-38773	brain	_	
180-194	38774-38777	The	_	
180-195	38778-38786	dopamine	_	
180-196	38787-38793	motive	_	
180-197	38794-38800	system	_	
180-198	38800-38801	:	_	
180-199	38802-38814	implications	_	
180-200	38815-38818	for	_	
180-201	38819-38823	drug	_	
180-202	38824-38827	and	_	
180-203	38828-38832	food	_	
180-204	38833-38842	addiction	_	
180-205	38843-38850	Imaging	_	
180-206	38851-38861	endogenous	_	
180-207	38862-38870	dopamine	_	
180-208	38871-38882	competition	_	
180-209	38883-38887	with	_	
180-210	38888-38889	[	_	
180-211	38889-38892	11C	_	
180-212	38892-38893	]	_	
180-213	38893-38903	raclopride	_	
180-214	38904-38906	in	_	
180-215	38907-38910	the	_	
180-216	38911-38916	human	_	
180-217	38917-38922	brain	_	
180-218	38923-38940	Stimulant-induced	_	
180-219	38941-38949	dopamine	_	
180-220	38950-38959	increases	_	
180-221	38960-38963	are	_	
180-222	38964-38972	markedly	_	
180-223	38973-38980	blunted	_	
180-224	38981-38983	in	_	
180-225	38984-38990	active	_	
180-226	38991-38998	cocaine	_	
180-227	38999-39006	abusers	_	
180-228	39007-39008	A	_	
180-229	39009-39024	demographically	_	
180-230	39025-39030	based	_	
180-231	39031-39036	index	_	
180-232	39037-39039	of	_	
180-233	39040-39049	premorbid	_	
180-234	39050-39062	intelligence	_	
180-235	39063-39067	test	_	
180-236	39068-39071	for	_	
180-237	39072-39075	the	_	
180-238	39076-39082	WAIS-R	_	
180-239	39083-39094	Association	_	
180-240	39095-39097	of	_	
180-241	39098-39105	genetic	_	
180-242	39106-39114	ancestry	_	
180-243	39115-39119	with	_	
180-244	39120-39128	striatal	_	
180-245	39129-39137	dopamine	_	
180-246	39138-39140	D2	_	
180-247	39140-39141	/	_	
180-248	39141-39143	D3	_	
180-249	39144-39152	receptor	_	
180-250	39153-39165	availability	_	
180-251	39166-39178	Distribution	_	
180-252	39179-39185	volume	_	
180-253	39186-39192	ratios	_	
180-254	39193-39200	without	_	
180-255	39201-39206	blood	_	
180-256	39207-39215	sampling	_	
180-257	39216-39220	from	_	
180-258	39221-39230	graphical	_	
180-259	39231-39239	analysis	_	
180-260	39240-39242	of	_	
180-261	39243-39246	PET	_	
180-262	39247-39251	data	_	
180-263	39252-39261	Graphical	_	
180-264	39262-39270	analysis	_	
180-265	39271-39273	of	_	
180-266	39274-39284	reversible	_	
180-267	39285-39296	radioligand	_	
180-268	39297-39304	binding	_	
180-269	39305-39309	from	_	
180-270	39310-39323	time-activity	_	
180-271	39324-39336	measurements	_	
180-272	39337-39344	applied	_	
180-273	39345-39347	to	_	
180-274	39348-39349	[	_	
180-275	39349-39350	N	_	
180-276	39350-39351	-	_	
180-277	39351-39361	11C-methyl	_	
180-278	39361-39362	]	_	
180-279	39362-39363	-	_	
180-280	39363-39364	(	_	
180-281	39364-39365	-	_	
180-282	39365-39366	)	_	
180-283	39366-39367	-	_	
180-284	39367-39374	cocaine	_	
180-285	39375-39378	PET	_	
180-286	39379-39386	studies	_	
180-287	39387-39389	in	_	
180-288	39390-39395	human	_	
180-289	39396-39404	subjects	_	
180-290	39405-39407	An	_	
180-291	39408-39417	automated	_	
180-292	39418-39424	method	_	
180-293	39425-39428	for	_	
180-294	39429-39442	neuroanatomic	_	
180-295	39443-39446	and	_	
180-296	39447-39464	cytoarchitectonic	_	
180-297	39465-39476	atlas-based	_	
180-298	39477-39490	interrogation	_	
180-299	39491-39493	of	_	
180-300	39494-39498	fMRI	_	
180-301	39499-39503	data	_	
180-302	39504-39508	sets	_	
180-303	39509-39517	Cannabis	_	
180-304	39518-39525	abusers	_	
180-305	39526-39530	show	_	
180-306	39531-39545	hypofrontality	_	
180-307	39546-39549	and	_	
180-308	39550-39557	blunted	_	
180-309	39558-39563	brain	_	
180-310	39564-39573	responses	_	
180-311	39574-39576	to	_	
180-312	39577-39578	a	_	
180-313	39579-39588	stimulant	_	
180-314	39589-39598	challenge	_	
180-315	39599-39601	in	_	
180-316	39602-39609	females	_	
180-317	39610-39613	but	_	
180-318	39614-39617	not	_	
180-319	39618-39620	in	_	
180-320	39621-39626	males	_	
180-321	39627-39637	Biological	_	
180-322	39638-39645	markers	_	
180-323	39646-39648	of	_	
180-324	39649-39652	the	_	
180-325	39653-39660	effects	_	
180-326	39661-39663	of	_	
180-327	39664-39675	intravenous	_	
180-328	39676-39691	methylphenidate	_	
180-329	39692-39694	on	_	
180-330	39695-39704	improving	_	
180-331	39705-39715	inhibitory	_	
180-332	39716-39723	control	_	
180-333	39724-39726	in	_	
180-334	39727-39744	cocaine-dependent	_	
180-335	39745-39753	patients	_	
180-336	39754-39763	Decreased	_	
180-337	39764-39772	striatal	_	
180-338	39773-39785	dopaminergic	_	
180-339	39786-39800	responsiveness	_	
180-340	39801-39803	in	_	
180-341	39804-39814	detoxified	_	
180-342	39815-39832	cocaine-dependent	_	
180-343	39833-39841	subjects	_	
180-344	39842-39861	Amphetamine-induced	_	
180-345	39862-39870	dopamine	_	
180-346	39871-39878	release	_	
180-347	39878-39879	:	_	
180-348	39880-39888	markedly	_	
180-349	39889-39896	blunted	_	
180-350	39897-39899	in	_	
180-351	39900-39907	cocaine	_	
180-352	39908-39918	dependence	_	
180-353	39919-39922	and	_	
180-354	39923-39933	predictive	_	
180-355	39934-39936	of	_	
180-356	39937-39940	the	_	
180-357	39941-39947	choice	_	
180-358	39948-39950	to	_	
180-359	39951-39966	self-administer	_	
180-360	39967-39974	cocaine	_	
180-361	39975-39983	Dopamine	_	
180-362	39984-39993	increases	_	
180-363	39994-39996	in	_	
180-364	39997-40005	striatum	_	
180-365	40006-40008	do	_	
180-366	40009-40012	not	_	
180-367	40013-40019	elicit	_	
180-368	40020-40027	craving	_	
180-369	40028-40030	in	_	
180-370	40031-40038	cocaine	_	
180-371	40039-40046	abusers	_	
180-372	40047-40053	unless	_	
180-373	40054-40058	they	_	
180-374	40059-40062	are	_	
180-375	40063-40070	coupled	_	
180-376	40071-40075	with	_	
180-377	40076-40083	cocaine	_	
180-378	40084-40088	cues	_	
180-379	40089-40095	Reward	_	
180-380	40096-40105	signaling	_	
180-381	40106-40108	by	_	
180-382	40109-40117	dopamine	_	
180-383	40118-40125	neurons	_	
180-384	40126-40138	Dissociating	_	
180-385	40139-40149	motivation	_	
180-386	40150-40154	from	_	
180-387	40155-40161	reward	_	
180-388	40162-40164	in	_	
180-389	40165-40170	human	_	
180-390	40171-40179	striatal	_	
180-391	40180-40188	activity	_	
180-392	40189-40193	High	_	
180-393	40194-40200	reward	_	
180-394	40201-40211	expectancy	_	
180-395	40212-40218	during	_	
180-396	40219-40234	methylphenidate	_	
180-397	40235-40244	depresses	_	
180-398	40245-40248	the	_	
180-399	40249-40261	dopaminergic	_	
180-400	40262-40270	response	_	
180-401	40271-40273	to	_	
180-402	40274-40278	gain	_	
180-403	40279-40282	and	_	
180-404	40283-40287	loss	_	
180-405	40288-40296	Decoding	_	
180-406	40297-40300	the	_	
180-407	40301-40310	formation	_	
180-408	40311-40313	of	_	
180-409	40314-40320	reward	_	
180-410	40321-40332	predictions	_	
180-411	40333-40339	across	_	
180-412	40340-40348	learning	_	
180-413	40349-40357	Identity	_	
180-414	40358-40368	prediction	_	
180-415	40369-40375	errors	_	
180-416	40376-40378	in	_	
180-417	40379-40382	the	_	
180-418	40383-40388	human	_	
180-419	40389-40397	midbrain	_	
180-420	40398-40404	update	_	
180-421	40405-40420	reward-identity	_	
180-422	40421-40433	expectations	_	
180-423	40434-40436	in	_	
180-424	40437-40440	the	_	
180-425	40441-40454	orbitofrontal	_	
180-426	40455-40461	cortex	_	
180-427	40462-40471	Stalnaker	_	
180-428	40471-40472	,	_	
180-429	40473-40474	T	_	
180-430	40474-40475	.	_	

#Text=A., Liu, T.
181-1	40476-40477	A	_	
181-2	40477-40478	.	_	
181-3	40478-40479	,	_	
181-4	40480-40483	Liu	_	
181-5	40483-40484	,	_	
181-6	40485-40486	T	_	
181-7	40486-40487	.	_	

#Text=L., Takahashi, Y.
182-1	40488-40489	L	_	
182-2	40489-40490	.	_	
182-3	40490-40491	,	_	
182-4	40492-40501	Takahashi	_	
182-5	40501-40502	,	_	
182-6	40503-40504	Y	_	
182-7	40504-40505	.	_	

#Text=K. & Schoenbaum, G.
183-1	40506-40507	K	_	
183-2	40507-40508	.	_	
183-3	40509-40510	&	_	
183-4	40511-40521	Schoenbaum	_	
183-5	40521-40522	,	_	
183-6	40523-40524	G	_	
183-7	40524-40525	.	_	

#Text=Orbitofrontal neurons signal reward predictions, not reward prediction errors.
184-1	40526-40539	Orbitofrontal	_	
184-2	40540-40547	neurons	_	
184-3	40548-40554	signal	_	
184-4	40555-40561	reward	_	
184-5	40562-40573	predictions	_	
184-6	40573-40574	,	_	
184-7	40575-40578	not	_	
184-8	40579-40585	reward	_	
184-9	40586-40596	prediction	_	
184-10	40597-40603	errors	_	
184-11	40603-40604	.	_	

#Text=Neurobiol.
185-1	40605-40614	Neurobiol	_	
185-2	40614-40615	.	_	

#Text=Learn.
186-1	40616-40621	Learn	_	
186-2	40621-40622	.	_	

#Text=Mem. 153, 137–143 (2018).
187-1	40623-40626	Mem	_	
187-2	40626-40627	.	_	
187-3	40628-40631	153	_	
187-4	40631-40632	,	_	
187-5	40633-40636	137	_	
187-6	40636-40637	–	_	
187-7	40637-40640	143	_	
187-8	40641-40642	(	_	
187-9	40642-40646	2018	_	
187-10	40646-40647	)	_	
187-11	40647-40648	.	_	

#Text=Caudate nucleus signals for breaches of expectation in a movement observation paradigm
#Text=Basal ganglia circuits for reward value-guided behavior
#Text=Information content and reward processing in the human striatum during performance of a declarative memory task
#Text=A neural substrate of prediction and reward
#Text=The effects of methylphenidate on resting-state functional connectivity of the basal nucleus of meynert, locus coeruleus, and ventral tegmental area in healthy adults
#Text=The effects of methylphenidate on cerebral activations to salient stimuli in healthy adults
#Text=Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine
#Text=Expectation of caffeine induces dopaminergic responses in humans
#Text=Placebo analgesia: self-report measures and preliminary evidence of cortical dopamine release associated with placebo response
#Text=Molecular mechanisms of placebo responses in humans
#Text=Dopaminergic response to drug words in cocaine addiction
#Text=Prelude to passion: limbic activation by “unseen” drug and sexual cues
#Text=Imaging dopamine’s role in drug abuse and addiction
#Text=Dopamine reward prediction error coding
#Text=Reproducibility of repeated measures of endogenous dopamine competition with [11C]raclopride in the human brain in response to methylphenidate
#Text=Dopamine D(3) receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO
#Text=Striatal dopamine D2/D3 receptor availability varies across smoking status
#Text=Dopaminergic activity in depressed smokers: a positron emission tomography study
#Text=Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015
#Text=Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function
#Text=Effects of intravenous glucose on dopaminergic function in the human brain in vivo
#Text=Reduced sleep duration mediates decreases in striatal D2/D3 receptor availability in cocaine abusers
#Text=Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review
#Text=Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain
#Text=Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain
188-1	40649-40656	Caudate	_	
188-2	40657-40664	nucleus	_	
188-3	40665-40672	signals	_	
188-4	40673-40676	for	_	
188-5	40677-40685	breaches	_	
188-6	40686-40688	of	_	
188-7	40689-40700	expectation	_	
188-8	40701-40703	in	_	
188-9	40704-40705	a	_	
188-10	40706-40714	movement	_	
188-11	40715-40726	observation	_	
188-12	40727-40735	paradigm	_	
188-13	40736-40741	Basal	_	
188-14	40742-40749	ganglia	_	
188-15	40750-40758	circuits	_	
188-16	40759-40762	for	_	
188-17	40763-40769	reward	_	
188-18	40770-40782	value-guided	_	
188-19	40783-40791	behavior	_	
188-20	40792-40803	Information	_	
188-21	40804-40811	content	_	
188-22	40812-40815	and	_	
188-23	40816-40822	reward	_	
188-24	40823-40833	processing	_	
188-25	40834-40836	in	_	
188-26	40837-40840	the	_	
188-27	40841-40846	human	_	
188-28	40847-40855	striatum	_	
188-29	40856-40862	during	_	
188-30	40863-40874	performance	_	
188-31	40875-40877	of	_	
188-32	40878-40879	a	_	
188-33	40880-40891	declarative	_	
188-34	40892-40898	memory	_	
188-35	40899-40903	task	_	
188-36	40904-40905	A	_	
188-37	40906-40912	neural	_	
188-38	40913-40922	substrate	_	
188-39	40923-40925	of	_	
188-40	40926-40936	prediction	_	
188-41	40937-40940	and	_	
188-42	40941-40947	reward	_	
188-43	40948-40951	The	_	
188-44	40952-40959	effects	_	
188-45	40960-40962	of	_	
188-46	40963-40978	methylphenidate	_	
188-47	40979-40981	on	_	
188-48	40982-40995	resting-state	_	
188-49	40996-41006	functional	_	
188-50	41007-41019	connectivity	_	
188-51	41020-41022	of	_	
188-52	41023-41026	the	_	
188-53	41027-41032	basal	_	
188-54	41033-41040	nucleus	_	
188-55	41041-41043	of	_	
188-56	41044-41051	meynert	_	
188-57	41051-41052	,	_	
188-58	41053-41058	locus	_	
188-59	41059-41068	coeruleus	_	
188-60	41068-41069	,	_	
188-61	41070-41073	and	_	
188-62	41074-41081	ventral	_	
188-63	41082-41091	tegmental	_	
188-64	41092-41096	area	_	
188-65	41097-41099	in	_	
188-66	41100-41107	healthy	_	
188-67	41108-41114	adults	_	
188-68	41115-41118	The	_	
188-69	41119-41126	effects	_	
188-70	41127-41129	of	_	
188-71	41130-41145	methylphenidate	_	
188-72	41146-41148	on	_	
188-73	41149-41157	cerebral	_	
188-74	41158-41169	activations	_	
188-75	41170-41172	to	_	
188-76	41173-41180	salient	_	
188-77	41181-41188	stimuli	_	
188-78	41189-41191	in	_	
188-79	41192-41199	healthy	_	
188-80	41200-41206	adults	_	
188-81	41207-41218	Conditioned	_	
188-82	41219-41227	dopamine	_	
188-83	41228-41235	release	_	
188-84	41236-41238	in	_	
188-85	41239-41245	humans	_	
188-86	41245-41246	:	_	
188-87	41247-41248	a	_	
188-88	41249-41257	positron	_	
188-89	41258-41266	emission	_	
188-90	41267-41277	tomography	_	
188-91	41278-41279	[	_	
188-92	41279-41282	11C	_	
188-93	41282-41283	]	_	
188-94	41283-41293	raclopride	_	
188-95	41294-41299	study	_	
188-96	41300-41304	with	_	
188-97	41305-41316	amphetamine	_	
188-98	41317-41328	Expectation	_	
188-99	41329-41331	of	_	
188-100	41332-41340	caffeine	_	
188-101	41341-41348	induces	_	
188-102	41349-41361	dopaminergic	_	
188-103	41362-41371	responses	_	
188-104	41372-41374	in	_	
188-105	41375-41381	humans	_	
188-106	41382-41389	Placebo	_	
188-107	41390-41399	analgesia	_	
188-108	41399-41400	:	_	
188-109	41401-41412	self-report	_	
188-110	41413-41421	measures	_	
188-111	41422-41425	and	_	
188-112	41426-41437	preliminary	_	
188-113	41438-41446	evidence	_	
188-114	41447-41449	of	_	
188-115	41450-41458	cortical	_	
188-116	41459-41467	dopamine	_	
188-117	41468-41475	release	_	
188-118	41476-41486	associated	_	
188-119	41487-41491	with	_	
188-120	41492-41499	placebo	_	
188-121	41500-41508	response	_	
188-122	41509-41518	Molecular	_	
188-123	41519-41529	mechanisms	_	
188-124	41530-41532	of	_	
188-125	41533-41540	placebo	_	
188-126	41541-41550	responses	_	
188-127	41551-41553	in	_	
188-128	41554-41560	humans	_	
188-129	41561-41573	Dopaminergic	_	
188-130	41574-41582	response	_	
188-131	41583-41585	to	_	
188-132	41586-41590	drug	_	
188-133	41591-41596	words	_	
188-134	41597-41599	in	_	
188-135	41600-41607	cocaine	_	
188-136	41608-41617	addiction	_	
188-137	41618-41625	Prelude	_	
188-138	41626-41628	to	_	
188-139	41629-41636	passion	_	
188-140	41636-41637	:	_	
188-141	41638-41644	limbic	_	
188-142	41645-41655	activation	_	
188-143	41656-41658	by	_	
188-144	41659-41660	“	_	
188-145	41660-41666	unseen	_	
188-146	41666-41667	”	_	
188-147	41668-41672	drug	_	
188-148	41673-41676	and	_	
188-149	41677-41683	sexual	_	
188-150	41684-41688	cues	_	
188-151	41689-41696	Imaging	_	
188-152	41697-41705	dopamine	_	
188-153	41705-41706	’	_	
188-154	41706-41707	s	_	
188-155	41708-41712	role	_	
188-156	41713-41715	in	_	
188-157	41716-41720	drug	_	
188-158	41721-41726	abuse	_	
188-159	41727-41730	and	_	
188-160	41731-41740	addiction	_	
188-161	41741-41749	Dopamine	_	
188-162	41750-41756	reward	_	
188-163	41757-41767	prediction	_	
188-164	41768-41773	error	_	
188-165	41774-41780	coding	_	
188-166	41781-41796	Reproducibility	_	
188-167	41797-41799	of	_	
188-168	41800-41808	repeated	_	
188-169	41809-41817	measures	_	
188-170	41818-41820	of	_	
188-171	41821-41831	endogenous	_	
188-172	41832-41840	dopamine	_	
188-173	41841-41852	competition	_	
188-174	41853-41857	with	_	
188-175	41858-41859	[	_	
188-176	41859-41862	11C	_	
188-177	41862-41863	]	_	
188-178	41863-41873	raclopride	_	
188-179	41874-41876	in	_	
188-180	41877-41880	the	_	
188-181	41881-41886	human	_	
188-182	41887-41892	brain	_	
188-183	41893-41895	in	_	
188-184	41896-41904	response	_	
188-185	41905-41907	to	_	
188-186	41908-41923	methylphenidate	_	
188-187	41924-41932	Dopamine	_	
188-188	41933-41934	D	_	
188-189	41934-41935	(	_	
188-190	41935-41936	3	_	
188-191	41936-41937	)	_	
188-192	41938-41946	receptor	_	
188-193	41947-41958	alterations	_	
188-194	41959-41961	in	_	
188-195	41962-41979	cocaine-dependent	_	
188-196	41980-41986	humans	_	
188-197	41987-41993	imaged	_	
188-198	41994-41998	with	_	
188-199	41999-42000	[	_	
188-200	42000-42003	11C	_	
188-201	42003-42004	]	_	
188-202	42004-42005	(	_	
188-203	42005-42006	+	_	
188-204	42006-42007	)	_	
188-205	42007-42011	PHNO	_	
188-206	42012-42020	Striatal	_	
188-207	42021-42029	dopamine	_	
188-208	42030-42032	D2	_	
188-209	42032-42033	/	_	
188-210	42033-42035	D3	_	
188-211	42036-42044	receptor	_	
188-212	42045-42057	availability	_	
188-213	42058-42064	varies	_	
188-214	42065-42071	across	_	
188-215	42072-42079	smoking	_	
188-216	42080-42086	status	_	
188-217	42087-42099	Dopaminergic	_	
188-218	42100-42108	activity	_	
188-219	42109-42111	in	_	
188-220	42112-42121	depressed	_	
188-221	42122-42129	smokers	_	
188-222	42129-42130	:	_	
188-223	42131-42132	a	_	
188-224	42133-42141	positron	_	
188-225	42142-42150	emission	_	
188-226	42151-42161	tomography	_	
188-227	42162-42167	study	_	
188-228	42168-42174	Trends	_	
188-229	42175-42178	and	_	
188-230	42179-42189	correlates	_	
188-231	42190-42192	of	_	
188-232	42193-42200	cocaine	_	
188-233	42201-42204	use	_	
188-234	42205-42208	and	_	
188-235	42209-42216	cocaine	_	
188-236	42217-42220	use	_	
188-237	42221-42229	disorder	_	
188-238	42230-42232	in	_	
188-239	42233-42236	the	_	
188-240	42237-42243	United	_	
188-241	42244-42250	States	_	
188-242	42251-42255	from	_	
188-243	42256-42260	2011	_	
188-244	42261-42263	to	_	
188-245	42264-42268	2015	_	
188-246	42269-42276	Effects	_	
188-247	42277-42279	of	_	
188-248	42280-42291	intravenous	_	
188-249	42292-42299	placebo	_	
188-250	42300-42304	with	_	
188-251	42305-42312	glucose	_	
188-252	42313-42324	expectation	_	
188-253	42325-42327	on	_	
188-254	42328-42333	human	_	
188-255	42334-42339	basal	_	
188-256	42340-42347	ganglia	_	
188-257	42348-42360	dopaminergic	_	
188-258	42361-42369	function	_	
188-259	42370-42377	Effects	_	
188-260	42378-42380	of	_	
188-261	42381-42392	intravenous	_	
188-262	42393-42400	glucose	_	
188-263	42401-42403	on	_	
188-264	42404-42416	dopaminergic	_	
188-265	42417-42425	function	_	
188-266	42426-42428	in	_	
188-267	42429-42432	the	_	
188-268	42433-42438	human	_	
188-269	42439-42444	brain	_	
188-270	42445-42447	in	_	
188-271	42448-42452	vivo	_	
188-272	42453-42460	Reduced	_	
188-273	42461-42466	sleep	_	
188-274	42467-42475	duration	_	
188-275	42476-42484	mediates	_	
188-276	42485-42494	decreases	_	
188-277	42495-42497	in	_	
188-278	42498-42506	striatal	_	
188-279	42507-42509	D2	_	
188-280	42509-42510	/	_	
188-281	42510-42512	D3	_	
188-282	42513-42521	receptor	_	
188-283	42522-42534	availability	_	
188-284	42535-42537	in	_	
188-285	42538-42545	cocaine	_	
188-286	42546-42553	abusers	_	
188-287	42554-42559	Sleep	_	
188-288	42560-42573	abnormalities	_	
188-289	42574-42584	associated	_	
188-290	42585-42589	with	_	
188-291	42590-42597	alcohol	_	
188-292	42597-42598	,	_	
188-293	42599-42607	cannabis	_	
188-294	42607-42608	,	_	
188-295	42609-42616	cocaine	_	
188-296	42616-42617	,	_	
188-297	42618-42621	and	_	
188-298	42622-42628	opiate	_	
188-299	42629-42632	use	_	
188-300	42632-42633	:	_	
188-301	42634-42635	a	_	
188-302	42636-42649	comprehensive	_	
188-303	42650-42656	review	_	
188-304	42657-42665	Evidence	_	
188-305	42666-42670	that	_	
188-306	42671-42676	sleep	_	
188-307	42677-42688	deprivation	_	
188-308	42689-42702	downregulates	_	
188-309	42703-42711	dopamine	_	
188-310	42712-42715	D2R	_	
188-311	42716-42718	in	_	
188-312	42719-42726	ventral	_	
188-313	42727-42735	striatum	_	
188-314	42736-42738	in	_	
188-315	42739-42742	the	_	
188-316	42743-42748	human	_	
188-317	42749-42754	brain	_	
188-318	42755-42760	Sleep	_	
188-319	42761-42772	deprivation	_	
188-320	42773-42782	decreases	_	
188-321	42783-42790	binding	_	
188-322	42791-42793	of	_	
188-323	42794-42795	[	_	
188-324	42795-42798	11C	_	
188-325	42798-42799	]	_	
188-326	42799-42809	raclopride	_	
188-327	42810-42812	to	_	
188-328	42813-42821	dopamine	_	
188-329	42822-42824	D2	_	
188-330	42824-42825	/	_	
188-331	42825-42827	D3	_	
188-332	42828-42837	receptors	_	
188-333	42838-42840	in	_	
188-334	42841-42844	the	_	
188-335	42845-42850	human	_	
188-336	42851-42856	brain	_	
